Patent Grant
11241218
Several embodiments of the invention relate to energy-based noninvasive treatments for obtaining aesthetically and/or cosmetically enhancing effects on skin and/or tissue near the skin of a human face, head, neck, and/or body.
Some cosmetic procedures involve invasive procedures that may require invasive surgery. Patients not only have to endure weeks of recovery time, but also are frequently required to undergo risky anesthetic procedures. Non-invasive energy-based therapeutic devices and methods are available, but may have various shortcomings with respect to efficiency and effectiveness. Some cosmetic procedures create a sequential series of treatment points or lines. In those procedures, the period of time for treatment is the sum of the sequential treatments.
In several embodiments, provided are systems and methods that successfully achieve an aesthetic effect using targeted and precise ultrasound to cause a visible and effective cosmetic result via a thermal pathway by splitting an ultrasound therapy beam to two, three, four, or more simultaneous focal zones for performing various treatment and/or imaging procedures. In various embodiments, an ultrasound system is configured for focusing ultrasound to produce localized, mechanical motion within tissues and cells for the purpose of producing either localized heating for tissue coagulation or for mechanical cellular membrane disruption intended for non-invasive aesthetic use. In various embodiments, an ultrasound system is configured for lifting a brow (e.g., an eyebrow). In various embodiments, an ultrasound system is configured for lifting lift lax tissue, such as submental (beneath the chin) and neck tissue. In various embodiments, an ultrasound system is configured for improving lines and wrinkles of the décolleté. In various embodiments, an ultrasound system is configured for reducing fat. In various embodiments, an ultrasound system is configured for reducing the appearance of cellulite.
In various embodiments, an ultrasound system is configured for imaging to visualize tissue (e.g., dermal and subdermal layers of tissue) to ensure proper coupling of the transducer to the skin. In various embodiments, an ultrasound system is configured for imaging to visualize tissue (e.g., dermal and subdermal layers of tissue) to confirm appropriate depth of treatment such as to avoid certain tissues (e.g., bone).
In various embodiments, treating tissue, such as skin tissue, with multiple beams provides one or more advantages, such as, for example, reducing treatment time, creating unique heating patterns, leveraging multiple channels for greater power, the option to treat skin at two or more depths with the same or different power levels, (e.g., a thermal coagulation point in the superficial muscular aponeurotic system (“SMAS”) and another defocused energy at the surface of the skin, or other combinations), optional simultaneous treatment at different depths (e.g., such as at depths below a skin surface of 3 mm and 4.5 mm thermal coagulation points simultaneously or in an overlapping time period); and/or treatment with one, two, or more simultaneous linear or line focuses, such as at different depths below the skin surface or spaced apart. In some embodiments simultaneous multi-focus therapy uses dithering.
In several embodiments, provided are systems and methods that successfully improve the effectiveness and/or efficiency of an aesthetic effect using targeted and precise ultrasound to cause a visible and effective cosmetic result via a thermal pathway. In some embodiments, a single focal zone targeted. In some embodiments an ultrasound therapy beam is split into two, three, four, or more simultaneous focal zones for performing various treatment and/or imaging procedures. In particular, embodiments of the invention improve effectiveness and/or efficiency in confirming the proper coupling between the treatment device and tissue for treatment in a treatment zone.
In several embodiments, provided are systems and methods that successfully improve the effectiveness and/or efficiency of an aesthetic effect using targeted and precise ultrasound to cause a visible and effective cosmetic result via a thermal pathway by splitting an ultrasound therapy beam to two, three, four, or more simultaneous focal zones for performing various treatment and/or imaging procedures.
According to one embodiment, an ultrasound treatment system creates two or more simultaneous therapeutic treatment points and/or focal zones under the skin surface for a cosmetic treatment, wherein the treatment points are enlarged by dithering the ultrasound beams. In one embodiment, a focal zone is a point. In one embodiment, a focal zone is a line. In one embodiment, a focal zone is a plane. In one embodiment, a focal zone is a three-dimensional volume or shape. The dithering of the ultrasound beam focus points enlarges the treatment area by shaking, blurring, or splattering the focus point or focus zone (e.g., a focus point, line, plane, or volume) like paint through an air brush by mechanically and/or electronically scattering the location of the focus points by varying the frequency, and therefore focal point, of the ultrasound treatment beams. In some embodiments, dithering increases efficacy by making a larger treatment points and/or focal zones. In some embodiments, dithering reduces pain since the temperature of the hot spot is spread over a larger volume of tissue, allowing a potential reduction in dose. In some embodiments, mechanical dithering is one method of spreading the acoustic energy from the ultrasound beam so there is less reliance on tissue thermal conduction away from the focus. In one embodiment of mechanical dithering, the therapy transducer is moved locally around the intended center of the thermal coagulation point (TCP). The acoustic beam movement can be side-to-side, up-down, and/or angular. In one embodiment of mechanical dithering, the movement of the motion mechanism is sufficiently fast enough to create a flatter temperature profile around the intended TCP which either allows a reduction of total acoustic energy for the same effected tissue volume or the same total acoustic energy for a larger effected tissue volume or any combination thereof.
In accordance with various embodiments, frequency modulation modifies the location of a focal zone and/or spacing between the focal zones, such that electronic dithering of beam via modulation of the frequency precisely alters and/or moves the position of the beam focus point(s). For example, in one embodiment, a spacing of 1.5 mm can be dithered with +/−0.1 mm using a small frequency swing. In various embodiments, any one or more spacings of 0.5, 0.75, 1.0, 1.2, 1.5, 2.0 mm can be dithered with +/−0.01, 0.05, 0.1, 0.12, 0.15, 0.20, 0.25, 0.30 mm using a frequency swing. In various embodiments, a frequency is modulated by 1-200% (e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%. 100%, 120%, 150%, 180%, 200% and any range therein).
Several embodiments relate to devices, systems and methods for providing one or more (e.g., a plurality or multiple) focus zones and/or ultrasound treatment points in performing various ultrasound treatment and/or imaging procedures quickly, safely, efficiently, and effectively. In some embodiments, no imaging is used. Some embodiments relate to splitting an ultrasound therapy beam to two, three, four, or more focal zones from a single ultrasound transducer and/or single ultrasound transduction element. In some embodiments, multiple ultrasound beams are electronically manipulated with frequency modulation. In some embodiments, dithering (e.g., electronic dithering) of multiple and/or split ultrasound beam apertures using frequency modulation provide treatment zones or points in multiple locations. In some embodiments, dithering relates to intentional movement of the position/location of a focal point of an energy beam. For example, in one embodiment, dithering involves shaking, moving, vibrating, altering the location and/or position of a single focal zone, and/or a relative spacing between two or more focal zones. In various embodiments, the relative position of a focal zones is dithered by 1-50% (e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% and any range therein, such as a percentage of a mean location by a certain percentage). In various embodiments, spacing between focal zones is dithered by a range of between 1-50% (e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% and any range therein). In some embodiments, dithering may be achieved through mechanical, electronic, or combinations of mechanical and electronic means depending on the system design. In one embodiment of mechanical dithering, the ultrasound beam is moved locally around the intended TCP center through a mechanical translation or tilt of the therapy transducer or patient or any combination thereof. The mechanical translation and/or tilt enable(s) the spread of the acoustic energy such that thermal conduction limitations of tissue are overcome. This creates a flatter temperature profile in tissue to either reduce the total acoustic energy to create the same effected tissue volume or have the same total acoustic energy to increase the effected tissue volume when compared to a stationary ultrasound therapy device. In various embodiments of electronic dithering, frequency, phase, amplitude modulations or time based techniques are used to in combination with a uniquely defined transducer to move the ultrasound beam in tissue without any mechanical movement. In one embodiment, electronic movement of the ultrasound beam occurs significantly faster than mechanical movement to overcome the thermal conductivity limitation of tissue. In various embodiments, a ratio of relative focal zone positioning via dithering is 1:1000, 1:500, 1:200; 1:100, 1:50, 1:25, 1:10, 1:2 or any ratio between 1:1000 and 1:1. In various embodiments, a ratio of spacing between relative focal zone positioning via dithering is 1:1000, 1:500, 1:200; 1:100, 1:50, 1:25, 1:10, 1:2 or any ratio between 1:1000 and 1:1. For example, in some embodiments, a focal zone is activated at “1” and an open spacing ratio of untreated tissue is provided in the second number of the ratio. For example, in one embodiment, a dithering spacing is e.g., 1 mm, and a dithering distance is 0.1 mm, so a ratio is 1:10. In various embodiments, a ratio of spacing between focal zones via dithering is 1:1000, 1:500, 1:200; 1:100, 1:50, 1:25, 1:10, 1:2 or any ratio between 1:1000 and 1:1. In some embodiments, the spacing of simultaneous focal zones is dithered. In some embodiments, the treatment points and/or zones are formed simultaneously in tissue. In various embodiments, dithering for performing various treatment and/or imaging procedures is with modulated and/or multiphased with controlled variance in frequency. Some embodiments relate to splitting an ultrasound therapy beam to two, three, four, or more focal zones for performing various treatment with, for example, dithering, poling, phasing, and/or modulation techniques and/or imaging procedures.
In several embodiments disclosed herein, non-invasive ultrasound systems are adapted to be used in achieving one or more of the following beneficial aesthetic and/or cosmetic improvement effects: a face lift, a brow lift, a chin lift, an eye treatment (e.g., malar bags, treat infraorbital laxity), a wrinkle reduction, fat reduction (e.g., treatment of adipose and/or cellulite), cellulite (which may be called gynoid lipodystrophy) treatment (e.g., dimple or non-dimple type female gynoid lipodystrophy), décolletage improvement (e.g., upper chest), a buttock lift (e.g., buttock tightening), skin tightening (for example, treating laxity to cause tightening on the face or body, such as the face, neck, chest, arms, thighs, abdomen, buttocks, etc.), a scar reduction, a burn treatment, a tattoo removal, a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, a sun spot removal, an acne treatment, a pimple reduction. Several embodiments of the invention are particularly advantageous because they include one, several or all of the following benefits: faster treatment time, (ii) less pain during treatment, (iii) less pain after treatment, (iv) shorter recovery time, (v) more efficient treatment, (vi) higher customer satisfaction, (vii) less energy to complete a treatment, and/or (viii) larger treatment area by dithered focal regions.
In accordance with various embodiments, a cosmetic ultrasound treatment system and/or method can non-invasively produce single or multiple dithered cosmetic treatment zones and/or thermal coagulation points where ultrasound is focused in one or more locations in a region of treatment in tissue under a skin surface, and moved via changes in frequency (e.g., via frequency modulation). Some systems and methods provide cosmetic treatment at different locations in tissue, such as at different depths, heights, widths, and/or positions. In one embodiment, a method and system comprise a multiple depth/height/width transducer system configured for providing ultrasound treatment to one or more region of interest, such as between at least one depth of treatment region of interest, a superficial region of interest, and/or a subcutaneous region of interest. In one embodiment, a method and system comprise a transducer system configured for providing ultrasound treatment to more than one region of interest, such as between at least two points in various locations (e.g. at a fixed or variable depth, height, width, and/or orientation, etc.) in a region of interest in tissue. Some embodiments can split a beam to focus at two, three, four, or more focal points (e.g., multiple focal points, multi-focal points) for cosmetic treatment zones and/or for imaging in a region of interest in tissue. Position and/or dithering of the focal points can be positioned axially, laterally, or otherwise within the tissue. Some embodiments can be configured for spatial control, such as by the location and/or dithering of a focus point, changing the distance from a transducer to a reflecting surface, and/or changing the angles of energy focused or unfocused to the region of interest, and/or configured for temporal control, such as by controlling changes in the frequency, drive amplitude and timing of the transducer. In some embodiments the position and/or dithering of multiple treatment zones or focal points is achieved with poling, phasic poling, biphasic poling, and/or multi-phasic poling. In some embodiments the position of multiple treatment zones or focal points with phasing, such as in one embodiment, electrical phasing. As a result, changes in the location of the treatment region, the number, shape, size and/or volume of treatment zones or lesions in a region of interest, as well as the thermal conditions, can be dynamically controlled over time.
In accordance with various embodiments, a cosmetic ultrasound treatment system and/or method can create multiple cosmetic treatment zones using one or more of frequency modulation, phase modulation, poling, nonlinear acoustics, and/or Fourier transforms to create any spatial periodic pattern with one or multiple ultrasound portions. In one embodiment, a system simultaneously or sequentially delivers single or multiple treatment zones using poling at a ceramic level. In one embodiment, a poling pattern is function of focal depth and frequency, and the use of odd or even functions. In one embodiment, a poling pattern, which can be a combination of odd or even functions, is applied, and based on focal depth and/or frequency. In one embodiment, a process can be used in two or more dimensions to create any spatial periodic pattern. In one embodiment, an ultrasound beam is split axially and laterally to significantly reduce treatment time through the use of nonlinear acoustics and Fourier transforms. In one embodiment, modulation from a system and amplitude modulation from a ceramic or a transducer can be used to place multiple treatments zones in tissue, either sequentially or simultaneously.
In one embodiment, an aesthetic imaging and treatment system includes an ultrasonic probe that includes an ultrasound transducer configured to apply ultrasonic therapy to tissue at a plurality of locations at a focal depth with electronic dithering of multiple energy beam apertures with frequency modulation. In one embodiment, the system includes a control module coupled to the ultrasonic probe for controlling the ultrasound transducer.
In one embodiment, the system includes dithering configured to provide variable spacing between a plurality of individual cosmetic treatment zones. In one embodiment, a sequence of individual cosmetic treatment zones has a treatment spacing in a range from about 0.01 mm to about 25 mm (e.g., 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 5 mm, 10 mm, 20 mm and any value ranges therein), with a dithering alteration of the spacing by 1-50% (e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% and any range therein). In one embodiment, a sequence of individual cosmetic treatment zones has a treatment spacing in a range from about 0.01 mm to about 100 mm (e.g., 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 5 mm, 10 mm, 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, 45, mm, 50 mm, 60 mm, 70 mm, 80 mm, 90 mm, and 100 mm, and any value ranges therein), with a dithering alteration of the spacing by 1-50% (e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% and any range therein).
In one embodiment, the system further includes a movement mechanism configured to be programmed to provide constant or variable spacing between the plurality of individual cosmetic treatment zones. In one embodiment, a sequence of individual cosmetic treatment zones has a treatment spacing in a range from about 0.01 mm to about 25 mm (e.g., 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 19 mm or any range or value therein). In one embodiment, a sequence of individual cosmetic treatment zones has a treatment spacing in a range from about 0.01 mm to about 100 mm (e.g., 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 50, 100 mm or any range or value therein). In one embodiment, treatment zones are provided along a distance of about 25 mm. In one embodiment, treatment zones are provided along a distance of about 50 mm. In various embodiments, treatment zones are provided along a distance of 5 mm to 100 mm (e.g., 10 mm, 20 mm, 25 mm, 35 mm, 50 mm, 75 mm, 100 mm, and any amounts or ranges therein. In various embodiments, treatment zones are provided along a linear and/or curved distance.
For example, in some non-limiting embodiments transducers can be configured for a tissue depth of 0.5 mm, 1.0 mm, 1.5 mm, 2 mm, 3 mm, 4.5 mm, 6 mm, less than 3 mm, between 0.5 mm and 5 mm, between 1.5 mm and 4.5 mm, more than more than 4.5 mm, more than 6 mm, and anywhere in the ranges of 0.1 mm-3 mm, 0.1 mm-4.5 mm, 0.1 mm-25 mm, 0.1 mm-100 mm, and any depths therein (e.g., 6 mm, 10 mm, 13 mm, 15 mm). In several embodiments, tissue is treated at a depth below a skin surface and the skin surface is not impaired. Instead, the therapeutic effect achieved at the depth below the skin surface results in a favorable cosmetic appearance of the skin surface. In other embodiments, the skin surface is treated with ultrasound (e.g., at a depth less than 0.5 mm).
One benefit of a motion mechanism is that it can provide for a more efficient, accurate and precise use of an ultrasound transducer, for imaging and/or therapy purposes. One advantage this type of motion mechanism has over conventional fixed arrays of multiple transducers fixed in space in a housing is that the fixed arrays are a fixed distance apart. In one embodiment, the transducer module is configured to provide an acoustic power of the ultrasonic therapy in a range of between about 1 W to about 100 W (e.g., 3-30 W, 7-30 W, 21-33 W) and a frequency of about 1 MHz to about 10 MHz to thermally heat the tissue to cause coagulation. In one embodiment, the transducer module is configured to provide an acoustic power of the ultrasonic therapy in a range of between about 1 W to about 500 W for peak or average energy, (e.g., 3-30 W, 7-30 W, 21-33 W, 100 W, 220 W, or more) and a frequency of about 1 MHz to about 10 MHz to thermally heat the tissue to cause coagulation. In some embodiments, an instantaneous energy is delivered. In some embodiments, an average energy is delivered. In one embodiment, the acoustic power can be from a range of 1 W to about 100 W in a frequency range from about 1 MHz to about 12 MHz (e.g., 1 MHz, 3 MHz, 4 MHz, 4.5 MHz, 7 MHz, 10 MHz, 2-12 MHz), or from about 10 W to about 50 W at a frequency range from about 3 MHz to about 8 MHz (e.g., 3 MHz, 4 MHz, 4.5 MHz, 7 MHz). In one embodiment, the acoustic power can be from a range of 1 W to about 500 W in a frequency range from about 1 MHz to about 12 MHz (e.g., 1 MHz, 4 MHz, 7 MHz, 10 MHz, 2-12 MHz), or from about 10 W to about 220 W at a frequency range from about 3 MHz to about 8 MHz, or 3 MHz to 10 MHz. In one embodiment, the acoustic power and frequencies are about 40 W at about 4.3 MHz and about 30 W at about 7.5 MHz. An acoustic energy produced by this acoustic power can be between about 0.01 joule (“J”) to about 10 J or about 2 J to about 5 J. An acoustic energy produced by this acoustic power can be between about 0.01 J to about 60,000 J (e.g., via bulk heating, for body shaping, submental fat, abdomen and/or flanks, arms, inner thigh, outer thigh, buttocks, abdominal laxity, cellulite), about 10 J or about 2 J to about 5 J. In one embodiment, the acoustic energy is in a range less than about 3 J. In various embodiments, a treatment power is 1 kW/cm2 to 100 kW/cm2, 15 kW/cm2 to 75 kW/cm2, 1 kW/cm2 to 5 kW/cm2, 500 W/cm2 to 10 kW/cm2, 3 kW/cm2 to 10 kW/cm2, 15 kW/cm2 to 50 kW/cm2, 20 kW/cm2 to 40 kW/cm2, and/or 15 kW/cm2 to 35 kW/cm2.
In various embodiments, an ultrasound treatment system for dithering multiple simultaneous focus points from an ultrasound transducer includes an ultrasonic probe and a control module coupled to the ultrasonic probe for controlling the ultrasound transducer. The ultrasonic probe includes an ultrasound transducer with a single transduction element adapted to simultaneously apply ultrasonic therapy to tissue at a plurality of spaced locations at a focal depth. The ultrasound transducer is poled with at least a first poling configuration and a second poling configuration. The control module modifies the spacing between the spaced locations via dithering of a first focal zone and a second focal zone, such that dithering via modulation of a frequency precisely moves a position of a beam focus point at the spaced locations.
In one embodiment, the plurality of locations are positioned in a linear sequence within a cosmetic treatment zone, wherein the spaced locations are separated with a spacing dithered via a frequency swing. In one embodiment, a first set of locations is positioned within a first cosmetic treatment zone and a second set of locations is positioned within a second cosmetic treatment zone, the first zone being different from the second zone. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In one embodiment, at least one portion of the ultrasonic transducer is adapted to emit ultrasonic therapy at two or more amplitudes of acoustic intensity, and wherein the amplitude of ultrasonic therapy emitted by the at least one portion of the piezoelectric varies over time. In one embodiment, the ultrasound transducer comprises piezoelectric material and the plurality of portions of the ultrasound transducer are adapted to create a plurality of corresponding piezoelectric material variations in response to an electric field applied to the ultrasound transducer. In one embodiment, the plurality of piezoelectric material variations comprise at least one of expansion of the piezoelectric material and contraction of the piezoelectric material. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy via phase shifting whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In one embodiment, the plurality of phases comprises discrete phase values. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude, and apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In various embodiments, the ultrasonic treatment is at least one of: a face lift, a brow lift, a chin lift, an eye treatment (e.g., malar bags, treat infraorbital laxity), a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a skin tightening (e.g., abdominal laxity treatment or treating laxity in other locations), a blood vessel reduction, a treatment of a sweat gland, a sun spot removal, a fat treatment, and a cellulite treatment. Skin tightening by reducing skin laxity is accomplished in some embodiments to treat subject with excess or loose skin post weight loss, whether such weight loss occurs naturally or is performed surgically.
In various embodiments, an ultrasound treatment system for use in cosmetic treatment for dithering multiple simultaneous focal points from an ultrasound transducer includes an ultrasonic probe including a control module adapted to modify a spacing between a first focal zone and a second focal zone via dithering, a switch operably controlling an ultrasonic treatment function for providing an ultrasonic treatment, and a movement mechanism adapted to direct ultrasonic treatment in at least one pair of simultaneous sequences of individual thermal cosmetic treatment zones, and a transducer module adapted to apply ultrasonic therapy. The transducer module is adapted for both ultrasonic imaging and ultrasonic treatment. The transducer module is adapted for coupling to the ultrasonic probe. The transducer module includes an ultrasound transducer adapted to apply ultrasonic therapy to tissue at a plurality of locations at a focal depth. The transducer module is adapted to be operably coupled to at least one of the switch and the movement mechanism. The control module includes a processor and a display for controlling the transducer module.
In one embodiment, the transducer module is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the transducer module are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In one embodiment, the transducer module is adapted to apply ultrasonic therapy whereby a plurality of portions of the transducer module are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase.
In various embodiments, an ultrasound treatment system for dithering multi-focus treatment includes a module comprising an ultrasound transducer. The ultrasound transducer is adapted to simultaneously apply ultrasonic therapy to tissue at a plurality of spaced locations in tissue, wherein the module modifies a spacing between the plurality of spaced locations via dithering of a first focal zone and a second focal zone, such that dithering via modulation of a frequency precisely moves a position of a beam focus point at the plurality of spaced locations, wherein the module further comprises an interface guide designed to for removable coupling to a hand wand to provide electronic communication and power between the module and the hand wand.
In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In one embodiment, the ultrasound transducer comprises piezoelectric material and the plurality of portions of the ultrasound transducer are adapted to create a plurality of corresponding piezoelectric material variations in response to an electric field applied to the ultrasound transducer. In one embodiment, at least one portion of the ultrasonic transducer is adapted to emit ultrasonic therapy at two or more amplitudes of acoustic intensity, and wherein the amplitude of ultrasonic therapy emitted by the at least one portion of the ultrasonic transducer remains constant over time. In one embodiment, the ultrasonic treatment is at least one of a face lift, a brow lift, a chin lift, an eye treatment (e.g., malar bags, treat infraorbital laxity), a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a tattoo removal, a skin tightening (e.g., abdominal laxity treatment or tightening of the skin on other areas of the body and face, such as any excess skin or tissue, such as during or after weight loss, such as, for example, the abdomen, buttocks, thighs, arms, and other areas), a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, a sun spot removal, a fat treatment, a vaginal rejuvenation, and an acne treatment.
In various embodiments, a method of dithering simultaneous focused ultrasound treatment beams includes providing an ultrasonic probe comprising an ultrasound transducer comprising a single transduction element adapted to simultaneously apply ultrasonic therapy to tissue at a plurality of spaced locations at a focal depth and a control module coupled to the ultrasonic probe for controlling the ultrasound transducer, and dithering the spacing between the spaced locations of a first focal zone and a second focal zone via modulation of a frequency to move a position of an ultrasound focus point at the spaced locations.
In one embodiment, the method includes imaging the first focal zone with an ultrasound imaging element. In one embodiment, the method includes imaging the second focal zone with an ultrasound imaging element. In one embodiment, the spacing between the first focal zone and the second focal zone is dithered in a range of between 1-50%. In one embodiment, the spacing between the first focal zone and the second focal zone is 1.5 mm and is by 0.1 mm. In one embodiment, the modulation of frequency is in a range of between 1-50%. In one embodiment, the ultrasound treatment is at least one of a face lift, a brow lift, a chin lift, an eye treatment (e.g., malar bags, treat infraorbital laxity), a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a tattoo removal, a skin tightening (e.g., treating laxity on the face and body, such as abdominal laxity treatment, tightening of the skin on other areas of the body and face, such as any excess skin or tissue, such as during or after weight loss, such as, for example, the abdomen, buttocks, thighs, arms, and other areas), a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, a sun spot removal, a fat treatment, a vaginal rejuvenation, and an acne treatment.
In various embodiments, a method of dithering a focused ultrasound beam includes providing an ultrasonic probe comprising a single transduction element and a control module, wherein the single transduction element is adapted to apply ultrasonic therapy to tissue at a focal zone at a focal depth, wherein the control module is coupled to the ultrasonic probe for controlling the single transduction element, and dithering the focal zone via modulation of a frequency to alter a size of the focal zone at the tissue.
In one embodiment, the relative position of the focal zone is dithered in a range of between 1-50%. In one embodiment, a second focal zone is emitted simultaneously from the single transduction element. In one embodiment, the method includes imaging the focal zone with an ultrasound imaging element. In one embodiment, the modulation of the frequency is in a range of between 1-50%.
In several of the embodiments described herein, the procedure is entirely cosmetic and not a medical act. For example, in one embodiment, the methods described herein need not be performed by a doctor, but at a spa or other aesthetic institute. In some embodiments, a system can be used for the non-invasive cosmetic treatment of skin.
In some embodiments simultaneous multi-focus therapy using multi-channel signal mixing. In several embodiments, a treatment system utilizes multiple therapy channels to enable electronic focusing and/or steering. For example, a treatment system that utilizes multiple therapy channels to enable electronic focusing and/or steering allows for faster electronic dithering to either create more thermal coagulation using the same amount of energy as other treatment devices or equal thermal coagulation using electronic dithering with less energy than other treatment devices.
In various embodiments, an ultrasound treatment system configured for generating multiple simultaneous focus points from an ultrasound transducer includes an ultrasonic probe comprising an ultrasound transducer with a multiple transduction elements adapted to simultaneously apply ultrasonic therapy to tissue at a plurality of spaced locations, wherein each transduction element comprises a channel wherein the ultrasonic probe has a geometric focus; wherein the ultrasonic probe has a first electronic focus; and wherein the ultrasonic probe has a second electronic focus; a control module coupled to the ultrasonic probe for controlling the ultrasound transducer, wherein the control module modifies the spacing between the spaced locations via dithering of a first focal zone and a second focal zone, such that dithering via an excitation function that moves a position of a beam focus point at the spaced locations.
In one embodiment, the plurality of locations are positioned in a linear sequence within a cosmetic treatment zone, wherein the spaced locations are separated. In one embodiment, a first set of locations is positioned within a first cosmetic treatment zone and a second set of locations is positioned within a second cosmetic treatment zone, the first zone being different from the second zone. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In one embodiment, at least one portion of the ultrasonic transducer is adapted to emit ultrasonic therapy at two or more amplitudes of acoustic intensity, and wherein the amplitude of ultrasonic therapy emitted by the at least one portion of the piezoelectric varies over time. In one embodiment, the ultrasound transducer comprises piezoelectric material and the plurality of portions of the ultrasound transducer are adapted to create a plurality of corresponding piezoelectric material variations in response to an electric field applied to the ultrasound transducer. In one embodiment, the plurality of piezoelectric material variations comprise at least one of expansion of the piezoelectric material and contraction of the piezoelectric material. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy via phase shifting whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In one embodiment, the plurality of phases comprises discrete phase values. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude; and apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase.
In various embodiments, the ultrasonic treatment is at least one of: a face lift, a brow lift, a chin lift, an eye (e.g., malar bags, treat infraorbital laxity) treatment, a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a skin tightening (e.g., abdominal, thigh, buttock, arm, neck or other laxity treatment), a blood vessel reduction, a treatment of a sweat gland, a sun spot removal, a fat treatment, and a cellulite treatment.
In various embodiments, an ultrasound treatment system for use in cosmetic treatment for forming multiple simultaneous focal zones from an ultrasound transducer, the system includes an ultrasonic probe including a control module adapted to modify a spacing between a first focal zone and a second focal zone, a switch operably controlling an ultrasonic treatment function for providing an ultrasonic treatment; and a movement mechanism adapted to direct ultrasonic treatment in at least one pair of simultaneous sequences of individual thermal cosmetic treatment zones; and a transducer module adapted to apply ultrasonic therapy, wherein the transducer module is adapted for ultrasonic imaging and/or ultrasonic treatment, wherein the transducer module is adapted for coupling to the ultrasonic probe, wherein the transducer module comprises an ultrasound transducer adapted to simultaneously apply ultrasonic therapy to tissue at a plurality of locations, wherein the transducer module is adapted to be operably coupled to at least one of the switch and the movement mechanism; and wherein the control module comprises a processor and a display for controlling the transducer module.
In one embodiment, the transducer module is adapted to apply ultrasonic therapy whereby a plurality of portions of the transducer module are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In one embodiment, the transducer module is adapted to apply ultrasonic therapy whereby a plurality of portions of the transducer module are adapted to emit ultrasonic therapy at a plurality of acoustic intensities. In various embodiments, an ultrasound treatment system for generating a multi-focus treatment using multi-channel signal mixing including a module comprising an ultrasound transducer, wherein the ultrasound transducer is adapted to simultaneously apply ultrasonic therapy to tissue at a plurality of spaced locations in tissue, wherein the module modifies a spacing between the plurality of spaced locations between a first focal zone and a second focal zone, such that multi-channel signal mixing precisely moves a position of a beam focus point at the plurality of spaced locations, wherein the module further comprises an interface guide designed to for removable coupling to a hand wand to provide electronic communication and power between the module and the hand wand. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In one embodiment, the ultrasound transducer comprises piezoelectric material and the plurality of portions of the ultrasound transducer are adapted to create a plurality of corresponding piezoelectric material variations in response to an electric field applied to the ultrasound transducer. In one embodiment, at least one portion of the ultrasonic transducer is adapted to emit ultrasonic therapy at two or more amplitudes of acoustic intensity, and wherein the amplitude of ultrasonic therapy emitted by the at least one portion of the ultrasonic transducer remains constant over time. In one embodiment, the ultrasonic treatment is at least one of a face lift, a brow lift, a chin lift, an eye treatment (e.g., malar bags, treat infraorbital laxity), a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a tattoo removal, a skin tightening (e.g., a laxity treatment, a tissue laxity treatment, an abdominal laxity treatment, and any tightening of the skin on other areas of the body and face, such as any excess skin or tissue, such as during or after weight loss, such as, for example, the abdomen, buttocks, thighs, arms, and other areas) a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, a sun spot removal, a fat treatment, a vaginal rejuvenation, and an acne treatment. In various embodiments, a method of generating simultaneous focused ultrasound treatment beams using multi-channel signal mixing includes providing an ultrasonic probe comprising an ultrasound transducer comprising a plurality of transduction elements adapted to simultaneously apply ultrasonic therapy to tissue at a plurality of spaced locations at a plurality of focal depths and a control module coupled to the ultrasonic probe for controlling the ultrasound transducer, and modifying the spacing between the spaced locations of a first focal zone and a second focal zone via multi-channel signal mixing to move a position of an ultrasound focus point at the spaced locations. In one embodiment, the method includes imaging the first focal zone with an ultrasound imaging element. In one embodiment, the method includes imaging the second focal zone with an ultrasound imaging element. In one embodiment, the spacing between the first focal zone and the second focal zone is varied in a range of between 1-50%. In one embodiment, the spacing between the first focal zone and the second focal zone is 1.5 mm and is by 0.1 mm. In one embodiment, the spacing between electrical foci ranges of between 10-50% of the nominal distance between the electrical foci. In one embodiment, the ultrasound treatment is at least one of a face lift, a brow lift, a chin lift, an eye treatment, a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a tattoo removal, a skin tightening (e.g., tightening of tissue on a human or an abdominal laxity treatment), a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, a sun spot removal, a fat treatment, a vaginal rejuvenation, and an acne treatment.
In various embodiments, a method of generating simultaneous focused ultrasound beams includes providing an ultrasonic probe comprising an array of transduction elements and a control module, wherein the array of transduction elements is adapted to apply ultrasonic therapy to tissue at a focal zone at a plurality of foci, wherein the control module is coupled to the ultrasonic probe for controlling the array of transduction elements, and moving the focal zone.
In one embodiment, the relative position of the focal zone is moved in a range of between 10-50%. In one embodiment, a second focal zone is emitted simultaneously from the single transduction element. In one embodiment, the method includes imaging the focal zone with an ultrasound imaging element. In one embodiment, the system is designed to work non-invasively to treat tissue. In one embodiment, the method functions in a non-invasive manner to treat tissue.
In various embodiments, ultrasound imaging is employed to ensure sufficient acoustic coupling during delivery of an ultrasound therapy treatment. In various embodiments, ultrasound imaging is employed to prevent treatment at an undesired area in a body, such as a bone or an implant. Sound, unlike light, needs a medium for propagation. In an embodiment, an ultrasound treatment system acoustically couples ultrasound energy from the transducer to the body through an acoustic window using gel. In this embodiment, the gel is the medium which mimics the acoustic impedance properties of tissue so there is efficient transfer of energy from the device into tissue. Unfortunately, any pockets of air between the transducer and tissue prevent proper coupling and can therefore cause an inadequate transfer of the ultrasound therapy energy. The ultrasound imaging checks this coupling. Inadequate coupling may show up as shadows or vertical stripes in the ultrasound images or a completely dark image. Even if there is sufficient coupling, tissues or objects, such as bone or an implant can cause challenges since these objects can have a different acoustic impedance and absorption characteristics than soft tissue (e.g. skin, muscle). Because of this, objects (such as bone or an implant) in between the device and intended therapy focus may cause significant reflection and the appearance heating at a shallower depth than intended. Objects (e.g., bone, etc.) slightly beyond the focus may also cause issues since the object reflects and readily absorbs the ultrasound from the soft tissue. The reflected energy may inadvertently add to the energy already at the therapy focus causing a higher temperature rise than intended. The absorbed energy at the bone may cause heating or discomfort in the bone.
In various embodiments, advantages of the present invention include using image to assess coupling of an ultrasound therapy beam to the intended treatment tissue. In various embodiments, higher resolution imaging is advantageous to provide more detail in an image of the tissue in and near the target tissue for treatment. In various embodiments, the invention improves safety characteristics, improves efficacy performance, provides a component of safety and efficacy for bulk heating devices (such as a band treatment, a linear focal treatment zone, a cylindrical focal line, a plane and/or a volume, etc.) for body shaping, submental fat, abdomen and/or flanks, arms, inner thigh, outer thigh, buttocks, laxity, abdominal laxity, etc., provides qualitative and/or quantitative assessment of coupling, provides for blending of high resolution image(s) with coupling image(s), is employed for assessing out-of-plane impediments post-focally (e.g. bone, intestine, implants), and/or can be used to reduce the need for sonographer equivalent skills.
In various embodiments, an ultrasound treatment and imaging system includes an ultrasonic probe comprising an ultrasound therapy transducer adapted to apply ultrasonic therapy to tissue, an ultrasound imaging transducer adapted for imaging the tissue, and an acoustic window, wherein the ultrasound imaging transducer comprises an annular imaging array; wherein the ultrasound imaging transducer comprises a plurality of transmit channels; wherein the ultrasound imaging transducer comprises a plurality of receive channels; wherein the ultrasound imaging transducer is configured for focusing at a location proximate the ultrasound imaging transducer with respect to a distance between the ultrasound imaging transducer and the acoustic window; and a control module coupled to the ultrasonic probe for controlling the ultrasound imaging transducer, wherein the ultrasound imaging transducer is configured to interrogate more than 40% of the acoustic window.
In various embodiments, an ultrasound treatment and imaging system includes an ultrasonic probe comprising an ultrasound therapy transducer adapted to apply ultrasonic therapy to tissue, an ultrasound imaging transducer adapted for imaging the tissue, and an acoustic window, wherein the ultrasound imaging transducer comprises an annular imaging array; wherein the ultrasound imaging transducer comprises a plurality of transmit channels; wherein the ultrasound imaging transducer comprises a plurality of receive channels; wherein the wherein the ultrasound imaging transducer operates at an imaging frequency of between 8 MHz to 50 MHz, wherein the ultrasound imaging transducer is configured to image tissue at a depth of up to 25 mm (e.g., 5 mm, 8 mm, 10 mm, 12 mm, 15 mm, 20 mm) below a skin surface; wherein the ultrasound imaging transducer is configured for focusing at a location behind the ultrasound imaging transducer with respect to the acoustic window; and a control module coupled to the ultrasonic probe for controlling the ultrasound imaging transducer, wherein the ultrasound imaging transducer is configured to interrogate more than 10% of the acoustic window.
In various embodiments, an ultrasound treatment and imaging system includes an ultrasonic probe comprising an ultrasound therapy transducer adapted to apply ultrasonic therapy to tissue, an ultrasound imaging transducer adapted for imaging the tissue, and an acoustic window, wherein the ultrasound imaging transducer comprises an annular or a linear imaging array; wherein the ultrasound imaging transducer comprises a plurality of transmit channels; wherein the ultrasound imaging transducer comprises a plurality of receive channels; wherein the wherein the ultrasound imaging transducer operates at an imaging frequency of between 8 MHz to 50 MHz, wherein the ultrasound imaging transducer is configured to image tissue at a depth of up to 25 mm below a skin surface; wherein the ultrasound imaging transducer is configured for focusing at a location proximate the ultrasound imaging transducer with respect to a distance between the ultrasound imaging transducer and the acoustic window; and a control module coupled to the ultrasonic probe for controlling the ultrasound imaging transducer, wherein the ultrasound imaging transducer is configured to interrogate more than 15% of the acoustic window.
In one embodiment, an imaging beam width from the ultrasound imaging transducer is at least 20% the cross-sectional size of a therapy beam width from the ultrasound therapy transducer. In one embodiment, an imaging beam width from the ultrasound imaging transducer is at least 30% the cross-sectional size of a therapy beam width from the ultrasound therapy transducer. In one embodiment, an imaging beam width from the ultrasound imaging transducer is at least 40% the cross-sectional size of a therapy beam width from the ultrasound therapy transducer. In one embodiment, an imaging beam width from the ultrasound imaging transducer is at least 50% the cross-sectional size of a therapy beam width from the ultrasound therapy transducer. In one embodiment, an imaging beam width from the ultrasound imaging transducer is at least 80% the cross-sectional size of a therapy beam width from the ultrasound therapy transducer.
In one embodiment, a coupling of the imaging of the ultrasound imaging transducer provides an indication of the coupling for the treatment by the ultrasound therapy transducer. In one embodiment, the ultrasound imaging transducer is configured to interrogate more than 80% of the acoustic window. In one embodiment, the ultrasound imaging transducer is configured to interrogate more than 90% of the acoustic window. In one embodiment, the annular imaging array is positioned in the ultrasound therapy transducer.
In one embodiment, the control module controls the ultrasound imaging transducer for vector imaging. In one embodiment, the control module controls the ultrasound imaging transducer for defocused vector imaging.
In one embodiment, the ultrasound therapy transducer is configured for treatment of tissue at a first set of locations that is positioned within a first cosmetic treatment zone and a second set of locations that is positioned within a second cosmetic treatment zone, the first zone being different from the second zone. In one embodiment, the ultrasound therapy transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In one embodiment, at least one portion of the ultrasonic transducer is adapted to emit ultrasonic therapy at two or more amplitudes of acoustic intensity, and wherein the amplitude of ultrasonic therapy emitted by the at least one portion of the piezoelectric varies over time. In one embodiment, the ultrasound transducer comprises piezoelectric material and the plurality of portions of the ultrasound transducer are adapted to create a plurality of corresponding piezoelectric material variations in response to an electric field applied to the ultrasound transducer. In one embodiment, plurality of piezoelectric material variations comprise at least one of expansion of the piezoelectric material and contraction of the piezoelectric material. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy via phase shifting whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In one embodiment, the plurality of phases comprises discrete phase values. In one embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude; and apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase.
In various embodiments, the ultrasonic treatment is at least one of a face lift, a brow lift, a chin lift, an eye treatment, a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a skin tightening (e.g., an abdominal laxity treatment), a blood vessel reduction, a treatment of a sweat gland, a sun spot removal, a fat treatment, and a cellulite treatment.
In various embodiments, a method of confirming coupling between an ultrasound probe and tissue for treatment includes providing an ultrasonic probe comprising an acoustic window, an ultrasound transducer comprising an ultrasound therapy transduction element adapted to apply ultrasonic therapy to a tissue, a plurality of imaging transduction elements in an array for imaging the tissue, and a control module coupled to the ultrasonic probe for controlling the ultrasound transducer, and interrogating at least 20% of the acoustic window with an imaging beam from the plurality of imaging transduction elements.
In one embodiment, the plurality of imaging transduction elements interrogates at least 30% of the acoustic window. In one embodiment, the plurality of imaging transduction elements interrogates at least 40% of the acoustic window. In one embodiment, the plurality of imaging transduction elements interrogates at least 50% of the acoustic window.
In one embodiment, the plurality of imaging transduction elements interrogates at least 60% of the acoustic window. In one embodiment, the plurality of imaging transduction elements interrogates at least 70% of the acoustic window. In one embodiment, the method further includes vector imaging. In one embodiment, the method further includes defocused vector imaging. In one embodiment, the method further includes imaging a first focal zone in the tissue with the plurality of imaging transduction elements. In one embodiment, the method further includes imaging a second focal zone in the tissue with the plurality of imaging transduction elements. In various embodiments, the ultrasound treatment is at least one of a face lift, a brow lift, a chin lift, an eye treatment, a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a tattoo removal, a skin tightening, (e.g., a laxity treatment), a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, a sun spot removal, a fat treatment, a vaginal rejuvenation, and an acne treatment.
In several of the embodiments described herein, the procedure is entirely cosmetic and not a medical act. For example, in one embodiment, the methods described herein need not be performed by a doctor, but at a spa or other aesthetic institute. In some embodiments, a system can be used for the non-invasive cosmetic treatment of skin.
In several embodiments, provided are systems and methods that successfully improve the ultrasound imaging of tissue while moving, such as when an imaging transducer is on a motion mechanism. In various embodiments, higher resolution is achieved. In various embodiments, better imaging signal quality is obtained. In various embodiments, ultrasound imaging is used with a therapeutic tissue treatment.
In various embodiments, an ultrasound treatment and imaging system configured for reducing imaging misalignment, including an ultrasonic probe comprising an ultrasound therapy transducer adapted to apply ultrasonic therapy to tissue, an ultrasound imaging transducer adapted for imaging the tissue, and a motion mechanism for moving the ultrasound imaging transducer in a first direction and a second direction. In an embodiment, the ultrasound imaging transducer is mechanically attached to the motion mechanism. In an embodiment, the first direction is linear. In an embodiment, the second direction is linear. In an embodiment, the first direction is parallel to the second direction. In an embodiment, the first direction is opposite the second direction. In an embodiment, the ultrasound imaging transducer images with a first focal zone sequence order (f1, f2) when travelling in the first direction, the ultrasound imaging transducer images with a second focal zone sequence order (f2, f1) when travelling in the second direction, and a spatial registration between the first direction imaging and the second direction imaging is improved by staggering a triggering location. In an embodiment, a control module is coupled to the ultrasonic probe for controlling the ultrasound imaging transducer.
In various embodiments, an ultrasound treatment and imaging system configured for reducing imaging misalignment, includes an ultrasonic probe comprising an ultrasound therapy transducer adapted to apply ultrasonic therapy to tissue, an ultrasound imaging transducer adapted for imaging the tissue, and a motion mechanism for moving the ultrasound imaging transducer in a first direction and a second direction. In an embodiment, the ultrasound imaging transducer is mechanically attached to the motion mechanism, wherein the first direction is linear, wherein the second direction is linear, wherein the first direction is parallel to the second direction, wherein the first direction is opposite the second direction, wherein the ultrasound imaging transducer images with a first focal zone sequence order (f1, f2, f3, f4) when travelling in the first direction, wherein the ultrasound imaging transducer images with a second focal zone sequence order (f4, f3, f2, f1) when travelling in the second direction, wherein a spatial registration between the first direction imaging and the second direction imaging is improved by staggering a triggering location, wherein the imaging system employs a sequence of two consecutive A-lines following progression of (line 1: f1, f2, f3, f4; line2: f4, f3, f2, f1) continuously; and a control module coupled to the ultrasonic probe for controlling the ultrasound imaging transducer.
In various embodiments, an ultrasound treatment and imaging system configured for reducing imaging misalignment, includes an ultrasonic probe comprising an ultrasound therapy transducer adapted to apply ultrasonic therapy to tissue, an ultrasound imaging transducer adapted for imaging the tissue, and a motion mechanism for moving the ultrasound imaging transducer in a first direction and a second direction. In an embodiment, the ultrasound imaging transducer is mechanically attached to the motion mechanism. In an embodiment, the first direction is opposite the second direction. In an embodiment, the ultrasound imaging transducer images with a focal zone sequence order (f1, . . . , fN), where N>1 when travelling in the first direction. In an embodiment, the ultrasound imaging transducer images with a second focal zone sequence order (fN, . . . , f1) when travelling in the second direction. In an embodiment, a spatial registration between the first direction imaging and the second direction imaging is improved by staggering a triggering location. In an embodiment, the imaging system employs a directionally dependent focal zone sequencing with alternating between (f1- . . . -fN) and (fN- . . . -f1) on consecutive A-lines; and a control module coupled to the ultrasonic probe for controlling the ultrasound imaging transducer.
In an embodiment, the first direction of motion of the transducer is any one or more of the group consisting of: linear, rotational, and curved. In an embodiment, the second direction is the reversed path of the first direction. In an embodiment, the first direction of motion occurs in multiple dimensions and the second direction is the reversed path of the first direction. In an embodiment, the ultrasound imaging transducer images with a first focal zone sequence order is specified as (f1, . . . , fN), where N>1. In an embodiment, the ultrasound therapy transducer is configured for treatment of tissue at a first set of locations that is positioned within a first cosmetic treatment zone and a second set of locations that is positioned within a second cosmetic treatment zone, the first zone being different from the second zone. In an embodiment, the ultrasound therapy transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude. In an embodiment, at least one portion of the ultrasonic transducer is adapted to emit ultrasonic therapy at two or more amplitudes of acoustic intensity, and wherein the amplitude of ultrasonic therapy emitted by the at least one portion of the piezoelectric varies over time. In an embodiment, the ultrasound transducer comprises piezoelectric material and the plurality of portions of the ultrasound transducer are adapted to create a plurality of corresponding piezoelectric material variations in response to an electric field applied to the ultrasound transducer. In an embodiment, the plurality of piezoelectric material variations comprise at least one of expansion of the piezoelectric material and contraction of the piezoelectric material. In an embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy via phase shifting whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In an embodiment, the plurality of phases comprises discrete phase values. In an embodiment, the ultrasound transducer is adapted to apply ultrasonic therapy using amplitude modulation whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of amplitudes of acoustic intensity, wherein a first amplitude is different than a second amplitude; and apply ultrasonic therapy whereby a plurality of portions of the ultrasound transducer are adapted to emit ultrasonic therapy at a plurality of phases of acoustic intensity, wherein a first phase is different than a second phase. In various embodiments, the ultrasonic treatment is at least one of: a face lift, a brow lift, a chin lift, an eye treatment, a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a skin tightening (e.g., a laxity treatment), a blood vessel reduction, a treatment of a sweat gland, a sun spot removal, a fat treatment, a cellulite treatment, a vaginal rejuvenation, and an acne treatment.
In various embodiments, a method of reducing imaging misalignment in a moving ultrasound probe, including staggering a triggering location of a spatial registration between a first direction imaging and a second direction imaging with an ultrasonic probe, the ultrasound probe comprising an ultrasound therapy transducer adapted to apply ultrasonic therapy to tissue, an ultrasound imaging transducer adapted for imaging the tissue, and a motion mechanism for moving the ultrasound imaging transducer in a first direction and a second direction, wherein the ultrasound imaging transducer is mechanically attached to the motion mechanism, wherein the first direction is opposite the second direction, wherein the ultrasound imaging transducer images with a focal zone sequence order (f1, . . . , fN), with N>1, wherein the ultrasound imaging transducer images with a first focal zone sequence order (f1, . . . , fN) when travelling in the first direction, wherein the ultrasound imaging transducer images with a second focal zone sequence order (fN, . . . , f1) when travelling in the second direction.
In an embodiment, N=any one of the group consisting of: 2, 3, 4, 5, 6, 7, 8, 9, and 10. In an embodiment, N=4. In various embodiments, the ultrasound treatment is at least one of a face lift, a brow lift, a chin lift, an eye treatment, a wrinkle reduction, a décolletage improvement, a buttock lift, a scar reduction, a burn treatment, a tattoo removal, a skin tightening (e.g., an abdominal laxity treatment), a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, a sun spot removal, a fat treatment, a vaginal rejuvenation, and an acne treatment.
The methods summarized above and set forth in further detail below describe certain actions taken by a practitioner; however, it should be understood that they can also include the instruction of those actions by another party. Thus, actions such as “dithering an energy beam” include “instructing the dithering of an energy beam.”
In some embodiments, the system comprises various features that are present as single features (as opposed to multiple features). For example, in one embodiment, the system includes a single transduction element that produces two simultaneous treatment focus points that are dithered. Multiple features or components are provided in alternate embodiments. In various embodiments, the system comprises, consists essentially of, or consists of one, two, three, or more embodiments of any features or components disclosed herein. In some embodiments, a feature or component is not included and can be negatively disclaimed from a specific claim, such that the system is without such feature or component.
Further, areas of applicability will become apparent from the description provided herein. It should be understood that the description and specific examples are intended for purposes of illustration only and are not intended to limit the scope of the embodiments disclosed herein.
The drawings described herein are for illustration purposes only and are not intended to limit the scope of the present disclosure in any way. Embodiments of the present invention will become more fully understood from the detailed description and the accompanying drawings wherein:
The following description sets forth examples of embodiments, and is not intended to limit the present invention or its teachings, applications, or uses thereof. It should be understood that throughout the drawings, corresponding reference numerals indicate like or corresponding parts and features. The description of specific examples indicated in various embodiments of the present invention are intended for purposes of illustration only and are not intended to limit the scope of the invention disclosed herein. Moreover, recitation of multiple embodiments having stated features is not intended to exclude other embodiments having additional features or other embodiments incorporating different combinations of the stated features. Further, features in one embodiment (such as in one figure) may be combined with descriptions (and figures) of other embodiments.
In various embodiments, systems and methods for ultrasound treatment of tissue are adapted for and/or configured to provide cosmetic treatment. In some embodiments, devices and methods of directing ultrasound therapy to a single focus point or multiple, simultaneous focus points, employing ultrasound imaging to confirm sufficient acoustic coupling to a treatment area for improving performance or providing improved correlation between movement in a first and second direction when forming images in cosmetic and/or medical procedures are provided in several embodiments. In some embodiments, devices and methods of employing ultrasound imaging to confirm sufficient acoustic coupling to a treatment area for improving performance and safety when directing ultrasound therapy to a single focus point or multiple, simultaneous focus points in cosmetic and/or medical procedures are provided in several embodiments. In some embodiments, devices and methods of improved ultrasound imaging provide better correlation between movement in a first and second direction when forming images. Embodiments of the invention provide better imaging correlation between a first moving direction and a second moving direction, (e.g., better correlation between left-traveling & right-traveling formed images). Devices and methods of improved ultrasound imaging improve effect B-mode imaging faster (e.g., 1.5×, 2×, 3×, 5× times the scanning rate). In various embodiments, tissue below or even at a skin surface such as epidermis, dermis, fascia, muscle, fat, and superficial muscular aponeurotic system (“SMAS”), are treated non-invasively with ultrasound energy. The ultrasound energy can be focused at one or more treatment points and/or zones, can be unfocused and/or defocused, and can be applied to a region of interest containing at least one of epidermis, dermis, hypodermis, fascia, muscle, fat, cellulite, and SMAS to achieve a cosmetic and/or therapeutic effect. In various embodiments, systems and/or methods provide non-invasive dermatological treatment to tissue through thermal treatment, coagulation, ablation, and/or tightening. In several embodiments disclosed herein, non-invasive ultrasound is used to achieve one or more of the following effects: a face lift, a brow lift, a chin lift, an eye treatment (e.g., malar bags, treat infraorbital laxity), a wrinkle reduction, fat reduction (e.g., treatment of adipose and/or cellulite), cellulite treatment (e.g., dimple or non-dimple type female gynoid lipodystrophy), décolletage improvement (e.g., upper chest), a buttock lift (e.g., buttock tightening), a skin laxity treatment (e.g., treatment of tissue for tightening or an abdominal laxity treatment), a scar reduction, a burn treatment, a tattoo removal, a vein removal, a vein reduction, a treatment on a sweat gland, a treatment of hyperhidrosis, sun spot removal, an acne treatment, and a pimple removal. In one embodiment, fat reduction is achieved. In various embodiments, cellulite (e.g., dimple or non-dimple type gynoid lipodystrophy) reduction or amelioration of one or more characteristics (such as dimples, nodularity, “orange peel” appearance, etc., is achieved by about 10-20%, 20-40%, 40-60%, 60-80% or higher (as well as overlapping ranging therein) as compared to, for example, untreated tissue. In one embodiment, décolletage is treated. In some embodiments, two, three or more beneficial effects are achieved during the same treatment session, and may be achieved simultaneously.
Various embodiments of the present invention relate to devices or methods of controlling the delivery of energy to tissue. In various embodiments, various forms of energy can include acoustic, ultrasound, light, laser, radio-frequency (RF), microwave, electromagnetic, radiation, thermal, cryogenic, electron beam, photon-based, magnetic, magnetic resonance, and/or other energy forms. Various embodiments of the present invention relate to devices or methods of splitting an ultrasonic energy beam into multiple beams. In various embodiments, devices or methods can be used to alter the delivery of ultrasound acoustic energy in any procedures such as, but not limited to, therapeutic ultrasound, diagnostic ultrasound, ultrasonic welding, any application that involves coupling mechanical waves to an object, and other procedures. Generally, with therapeutic ultrasound, a tissue effect is achieved by concentrating the acoustic energy using focusing techniques from the aperture. In some instances, high intensity focused ultrasound (HIFU) is used for therapeutic purposes in this manner. In one embodiment, a tissue effect created by application of therapeutic ultrasound at a particular depth to can be referred to as creation of a thermal coagulation point (TCP). In some embodiments, a zone can include a point. In some embodiments, a zone is a line, plane, spherical, elliptical, cubical, or other one-, two-, or three-dimensional shape. It is through creation of TCPs at particular positions that thermal and/or mechanical ablation of tissue can occur non-invasively or remotely. In some embodiments, an ultrasound treatment does not include cavitation and/or shock waves. In some embodiments, an ultrasound treatment includes cavitation and/or shock waves.
In one embodiment, TCPs can be created in a linear or substantially linear, curved or substantially curved, zone or sequence, with each individual TCP separated from neighboring TCPs by a treatment spacing. In one embodiment, multiple sequences of TCPs can be created in a treatment region. For example, TCPs can be formed along a first sequence and a second sequence separated by a treatment distance from the first sequence. Although treatment with therapeutic ultrasound can be administered through creation of individual TCPs in a sequence and sequences of individual TCPs, it may be desirable to reduce treatment time and corresponding risk of pain and/or discomfort experienced by a patient. Therapy time can be reduced by forming multiple TCPs simultaneously, nearly simultaneously, or sequentially. In some embodiments, a treatment time can be reduced 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or more by creating multiple TCPs.
Various embodiments of the present invention address potential challenges posed by administration of ultrasound therapy. In various embodiments, time for effecting the formation of TCPs for a desired cosmetic and/or therapeutic treatment for a desired clinical approach at a target tissue is reduced. In various embodiments, target tissue is, but is not limited to, any of skin, eyelids, eye lash, eye brow, caruncula lacrimalis, crow's feet, wrinkles, eye, nose, mouth (e.g., nasolabial fold, perioral wrinkles), tongue, teeth, gums, ears, brain, heart, lungs, ribs, abdomen (e.g., for abdominal laxity), stomach, liver, kidneys, uterus, breast, vagina, prostrate, testicles, glands, thyroid glands, internal organs, hair, muscle, bone, ligaments, cartilage, fat, fat labuli, adipose tissue, subcutaneous tissue, implanted tissue, an implanted organ, lymphoid, a tumor, a cyst, an abscess, or a portion of a nerve, or any combination thereof.
Various embodiments of ultrasound treatment and/or imaging devices are described in U.S. application Ser. No. 12/996,616, which published as U.S. Publication No. 2011-0112405 A1 on May 12, 2011, which is a U.S. National Phase under 35 U.S.C. § 371 of International Application No. PCT/US2009/046475, filed on Jun. 5, 2009 and published in English on Dec. 10, 2009, which claims the benefit of priority from U.S. Provisional No. 61/059,477 filed Jun. 6, 2008, each of which is incorporated in its entirety by reference, herein. Various embodiments of ultrasound treatment and/or imaging devices are described in U.S. application Ser. No. 14/193,234, which published as U.S. Publication No. 2014/0257145 on Sep. 11, 2014, which is incorporated in its entirety by reference, herein. Various embodiments of ultrasound treatment and/or imaging devices are described in International App. PCT/US15/25581, which published as WO 2015/160708 on Oct. 22, 2015 with a national phase U.S. application Ser. No. 15/302,436, which published as U.S. Publication No. 2017/0028227 on Feb. 2, 2017, each of which is incorporated in its entirety by reference, herein.
System Overview
With reference to the illustration in
In various embodiments, the controller 300 can be adapted to and/or configured for operation with the hand wand 100 and the module 200, as well as the overall ultrasound system 20 functionality. In various embodiments, multiple controllers 300, 300′, 300″, etc. can be adapted to and/or configured for operation with multiple hand wands 100, 100′, 100″, etc. and or multiple modules 200, 200′, 200″, etc. The controller 300 can include connectivity to one or more interactive graphical display 310, which can include a touchscreen monitor and Graphic User Interface (GUI) that allows the user to interact with the ultrasound system 20. In one embodiment, a second smaller, more mobile display that allows the user to more easily position and view the treatment screen. In one embodiment, a second display that allows the system user to view a treatment screen (e.g., on a wall, on a mobile device, large screen, remote screen). In one embodiment the graphical display 310 includes a touchscreen interface 315 (not shown). In various embodiments, the display 310 sets and displays the operating conditions, including equipment activation status, treatment parameters, system messages and prompts, and ultrasound images. In various embodiments, the controller 300 can be adapted to and/or configured to include, for example, a microprocessor with software and input/output devices, systems and devices for controlling electronic and/or mechanical scanning and/or multiplexing of transducers and/or multiplexing of transducer modules, a system for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or transducers and/or multiplexing of transducer modules, and/or systems for handling user input and recording treatment results, among others. In various embodiments, the controller 300 can include a system processor and various analog and/or digital control logic, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays, computer boards, and associated components, including firmware and control software, which may be capable of interfacing with user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software running on the system process may be adapted to and/or configured to control all initialization, timing, level setting, monitoring, safety monitoring, and all other ultrasound system functions for accomplishing user-defined treatment objectives. Further, the controller 300 can include various input/output modules, such as switches, buttons, etc., that may also be suitably adapted to and/or configured to control operation of the ultrasound system 20.
In one embodiment, the hand wand 100 includes one or more finger activated controllers or switches, such as 150 and 160. In various embodiments, one or more thermal treatment controllers 160 (e.g., switch, button) activates and/or stops treatment. In various embodiments, one or more imaging controllers 150 (e.g., switch, button) activates and/or stops imaging. In one embodiment, the hand wand 100 can include a removable module 200. In other embodiments, the module 200 may be non-removable. In various embodiments, the module 200 can be mechanically coupled to the hand wand 100 using a latch or coupler 140. In various embodiments, an interface guide 235 or multiple interface guides 235 can be used for assisting the coupling of the module 200 to the hand wand 100. The module 200 can include one or more ultrasound transducers 280. In some embodiments, an ultrasound transducer 280 includes one or more ultrasound elements. The module 200 can include one or more ultrasound elements. The hand wand 100 can include imaging-only modules, treatment-only modules, imaging-and-treatment modules, and the like. In various embodiments, the ultrasound transducer 280 is movable in one or more directions 290 within the module 200. The transducer 280 is connected to a motion mechanism 400. In various embodiments, the motion mechanism comprises zero, one, or more bearings, shafts, rods, screws, lead screws 401, encoders 402 (e.g., optical encoder to measure position of the transducer 280), motors 403 (e.g., a step motor) to help ensure accurate and repeatable movement of the transducer 280 within the module 200. In various embodiments, module 200 can include a transducer 280 which can emit energy through an acoustically transparent member 230. In one embodiment, the control module 300 can be coupled to the hand wand 100 via the interface 130, and the graphic user interface 310 can be adapted to and/or configured for controlling the module 200. In one embodiment, the control module 300 can provide power to the hand wand 100. In one embodiment, the hand wand 100 can include a power source. In one embodiment, the switch 150 can be adapted to and/or configured for controlling a tissue imaging function and the switch 160 can be adapted to and/or configured for controlling a tissue treatment function. In various embodiments, delivery of emitted energy 50 at a suitable focal depth, distribution, timing, and energy level is provided by the module 200 through controlled operation by the control system 300 of the transducer 280 to achieve the desired therapeutic effect with a thermal coagulation zone 550.
In one embodiment, the module 200 can be coupled to the hand wand 100. The module 200 can emit and receive energy, such as ultrasonic energy. The module 200 can be electronically coupled to the hand wand 100 and such coupling may include an interface which is in communication with the controller 300. In one embodiment, the interface guide 235 can be adapted to and/or configured to provide electronic communication between the module 200 and the hand wand 100. The module 200 can comprise various probe and/or transducer configurations. For example, the module 200 can be adapted to and/or configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, separate therapy and imaging probes, and the like. In one embodiment, when the module 200 is inserted into or connected to the hand wand 100, the controller 300 automatically detects it and updates the interactive graphical display 310.
In some embodiments, an access key 320 (e.g., a secure USB drive, key) is removably connected to a system 20 to permit the system 20 to function. In various embodiments, the access key is programmed to be customer specific, and serves multiple functions, including system security, country/region specific access to treatment guidelines and functionality, software upgrades, support log transfers and/or credit transfer and/or storage. In various embodiments, the system 20 has internet and/or data connectivity. In an embodiment, connectivity provides a method by which data is transferred between the system 20 provider and the customer. In various embodiments, data includes credits, software updates and support logs. Connectivity is divided into different model embodiments, based on how a user's console is connected to the internet. In one embodiment, Disconnected Model connectivity comprises a console that is disconnected from the internet and customer doesn't have internet access. Credit transfers and software upgrades are conducted by shipping access key(s), (e.g., USB drives) to the customer. In one embodiment, Semi-Connected Model connectivity comprises a console that is disconnected from the internet but customer has internet access. Credit transfers, software upgrades and support log transfers are conducted using the customer's personal computer, smart phone, or other computing device in conjunction with the system access key to transfer data. In one embodiment, Fully-Connected Model connectivity comprises a console that is wirelessly connected to the internet using wifi, cellular modem, Bluetooth, or other protocol. Credit transfers, software upgrades and support log transfers are made directly between the console and the cloud. In various embodiments, the system 20 connects to an online portal, for streamlined inventory management, on-demand treatment purchases and business analytics insights to drive customer aesthetic treatment business to the next level.
In various embodiments, tissue below or even at a skin surface such as epidermis, dermis, hypodermis, fascia, and superficial muscular aponeurotic system (“SMAS”), and/or muscle are treated non-invasively with ultrasound energy. Tissue may also include blood vessels and/or nerves. The ultrasound energy can be focused, unfocused or defocused and applied to a region of interest containing at least one of epidermis, dermis, hypodermis, fascia, and SMAS to achieve a therapeutic effect.
With reference to the illustration in
With reference to the illustration in
Coupling components can comprise various substances, materials, and/or devices to facilitate coupling of the transducer 280 or module 200 to a region of interest. For example, coupling components can comprise an acoustic coupling system adapted to and/or configured for acoustic coupling of ultrasound energy and signals. Acoustic coupling system with possible connections such as manifolds may be utilized to couple sound into the region of interest, provide liquid- or fluid-filled lens focusing. The coupling system may facilitate such coupling through use of one or more coupling media, including air, gases, water, liquids, fluids, gels, solids, non-gels, and/or any combination thereof, or any other medium that allows for signals to be transmitted between the transducer 280 and a region of interest. In one embodiment one or more coupling media is provided inside a transducer. In one embodiment a fluid-filled module 200 contains one or more coupling media inside a housing. In one embodiment a fluid-filled module 200 contains one or more coupling media inside a sealed housing, which is separable from a dry portion of an ultrasonic device. In various embodiments, a coupling medium is used to transmit ultrasound energy between one or more devices and tissue with a transmission efficiency of 100%, 99% or more, 98% or more, 95% or more, 90% or more, 80% or more, 75% or more, 60% or more, 50% or more, 40% or more, 30% or more, 25% or more, 20% or more, 10% or more, and/or 5% or more.
In various embodiments, the transducer 280 can image and treat a region of interest at any suitable tissue depths 279. In one embodiment, the transducer module 280 can provide an acoustic power in a range of about 1 W or less, between about 1 W to about 100 W, and more than about 100 W, e.g., 200 W, 300 W, 400 W, 500 W. In one embodiment, the transducer module 280 can provide an acoustic power at a frequency of about 1 MHz or less, between about 1 MHz to about 10 MHz (e.g., 3 MHz, 4 MHz, 4.5 MHz, 7 MHz, 10 MHz), and more than about 10 MHz. In one embodiment, the module 200 has a focal depth 278 for a treatment at a tissue depth 279 of about 4.5 mm below the skin surface 501. In one embodiment, the module 200 has a focal depth 278 for a treatment at a tissue depth 279 of about 3 mm below the skin surface 501. In one embodiment, the module 200 has a focal depth 278 for a treatment at a tissue depth 279 of about 1.5 mm below the skin surface 501. Some non-limiting embodiments of transducers 280 or modules 200 can be adapted to and/or configured for delivering ultrasonic energy at a tissue depth of 1.5 mm, 3 mm, 4.5 mm, 6 mm, 7 mm, less than 3 mm, between 3 mm and 4.5 mm, between 4.5 mm and 6 mm, more than more than 4.5 mm, more than 6 mm, etc., and anywhere in the ranges of 0-3 mm, 0-4.5 mm, 0-6 mm, 0-25 mm, 0-100 mm, etc. and any depths therein. In one embodiment, the ultrasound system 20 is provided with two or more transducer modules 280. For example, a first transducer module can apply treatment at a first tissue depth (e.g., about 4.5 mm) and a second transducer module can apply treatment at a second tissue depth (e.g., of about 3 mm), and a third transducer module can apply treatment at a third tissue depth (e.g., of about 1.5-2 mm). In one embodiment, at least some or all transducer modules can be adapted to and/or configured to apply treatment at substantially same depths.
In various embodiments, changing the number of focus point locations (e.g., such as with a tissue depth 279) for an ultrasonic procedure can be advantageous because it permits treatment of a patient at varied tissue depths even if the focal depth 278 of a transducer 270 is fixed. This can provide synergistic results and maximizing the clinical results of a single treatment session. For example, treatment at multiple depths under a single surface region permits a larger overall volume of tissue treatment, which results in enhanced collagen formation and tightening. Additionally, treatment at different depths affects different types of tissue, thereby producing different clinical effects that together provide an enhanced overall cosmetic result. For example, superficial treatment may reduce the visibility of wrinkles and deeper treatment may induce formation of more collagen growth. Likewise, treatment at various locations at the same or different depths can improve a treatment.
Although treatment of a subject at different locations in one session may be advantageous in some embodiments, sequential treatment over time may be beneficial in other embodiments. For example, a subject may be treated under the same surface region at one depth in time one, a second depth in time two, etc. In various embodiments, the time can be on the order of nanoseconds, microseconds, milliseconds, seconds, minutes, hours, days, weeks, months, or other time periods. The new collagen produced by the first treatment may be more sensitive to subsequent treatments, which may be desired for some indications. Alternatively, multiple depth treatment under the same surface region in a single session may be advantageous because treatment at one depth may synergistically enhance or supplement treatment at another depth (due to, for example, enhanced blood flow, stimulation of growth factors, hormonal stimulation, etc.). In several embodiments, different transducer modules provide treatment at different depths. In one embodiment, a single transducer module can be adjusted or controlled for varied depths. Safety features to minimize the risk that an incorrect depth will be selected can be used in conjunction with the single module system.
In several embodiments, a method of treating the lower face and neck area (e.g., the submental area) is provided. In several embodiments, a method of treating (e.g., softening) mentolabial folds is provided. In other embodiments, a method of treating the eye region (e.g., malar bags, treat infraorbital laxity) is provided. Upper lid laxity improvement and periorbital lines and texture improvement will be achieved by several embodiments by treating at variable depths. By treating at varied locations in a single treatment session, optimal clinical effects (e.g., softening, tightening) can be achieved. In several embodiments, the treatment methods described herein are non-invasive cosmetic procedures. In some embodiments, the methods can be used in conjunction with invasive procedures, such as surgical facelifts or liposuction, where skin tightening is desired. In various embodiments, the methods can be applied to any part of the body.
In one embodiment, a transducer module 200 permits a treatment sequence at a fixed depth at or below the skin surface. In one embodiment, a transducer module permits a treatment sequence at one, two, or more variable or fixed depths below the dermal layer. In several embodiments, the transducer module comprises a movement mechanism adapted to and/or configured to direct ultrasonic treatment in a sequence of individual thermal lesions (hereinafter “thermal coagulation points” or “TCPs”) at a fixed focal depth. In one embodiment, the sequence of individual TCPs has a treatment spacing in a range from about 0.01 mm to about 25 mm (e.g., 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 5 mm, 10 mm, 20 mm and any value ranges therein), with a dithering alteration of the spacing by 1-50% (e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% and any range therein). For example, the spacing can be 1.1 mm or less, 1.5 mm or more, between about 1.1 mm and about 1.5 mm, etc. In one embodiment, the individual TCPs are discrete. In one embodiment, the individual TCPs are overlapping. In one embodiment, the movement mechanism is adapted to and/or configured to be programmed to provide variable spacing between the individual TCPs. In one embodiment, the dithering can be adapted to and/or configured to provide variable spacing between the individual TCPs. In several embodiments, a transducer module comprises a movement mechanism adapted to and/or configured to direct ultrasonic treatment in a sequence so that TCPs are formed in linear or substantially linear sequences separated by a treatment distance. For example, a transducer module can be adapted to and/or configured to form TCPs along a first linear sequence and a second linear sequence separated by a treatment distance from the first linear sequence. In one embodiment, treatment distance between adjacent linear sequences of individual TCPs is in a range from about 0.01 mm to about 25 mm. In one embodiment, treatment distance between adjacent linear sequences of individual TCPs is in a range from about 0.01 mm to about 50 mm. For example, the treatment distance can be 2 mm or less, 3 mm or more, between about 2 mm and about 3 mm, etc. In several embodiments, a transducer module can comprise one or more movement mechanisms 400 adapted to and/or configured to direct ultrasonic treatment in a sequence so that TCPs are formed in linear or substantially linear sequences of individual thermal lesions separated by a treatment distance from other linear sequences. In one embodiment a treatment is applied in a first direction 290 (e.g., push). In one embodiment, a treatment is applied opposite the first direction 290 (e.g., pull). In one embodiment, treatment is applied in both a first direction 290 and opposite the first direction (e.g., push and pull). In one embodiment, the treatment distance separating linear or substantially linear TCPs sequences is the same or substantially the same. In one embodiment, the treatment distance separating linear or substantially linear TCPs sequences is different or substantially different for various adjacent pairs of linear TCPs sequences.
In one embodiment, first and second removable transducer modules are provided. In one embodiment, each of the first and second transducer modules are adapted to and/or configured for both ultrasonic imaging and ultrasonic treatment. In one embodiment, a transducer module is adapted to and/or configured for treatment only. In one embodiment, an imaging transducer may be attached to a handle of a probe or a hand wand. The first and second transducer modules are adapted to and/or configured for interchangeable coupling to a hand wand. The first transducer module is adapted to and/or configured to apply ultrasonic therapy to a first layer of tissue, while the second transducer module is adapted to and/or configured to apply ultrasonic therapy to a second layer of tissue. The second layer of tissue is at a different depth than the first layer of tissue.
As illustrated in
In one embodiment, an ultrasound system 20 generates ultrasound energy which is directed to and focused below the surface 501. This controlled and focused ultrasound energy 50 creates the thermal coagulation point or zone (TCP) 550. In one embodiment, the ultrasound energy 50 creates a void in subcutaneous tissue 510. In various embodiments, the emitted energy 50 targets the tissue below the surface 501 which cuts, ablates, coagulates, micro-ablates, manipulates, and/or causes a TCP 550 in the tissue portion 10 below the surface 501 at a specified focal depth 278. In one embodiment, during the treatment sequence, the transducer 280 moves in a direction denoted by the arrow marked 290 at specified intervals 295 to create a series of treatment zones 254 each of which receives an emitted energy 50 to create one or more TCPs 550. In one embodiment, an arrow marked 291 illustrates an axis or direction that is orthogonal to arrow 290, and a spacing of TCP's 550 show TCP's can be spaced orthogonally to the motion direction of the transducer 280. In some embodiments, an orientation of the spaced TCP's can be set at any angle 0-180 degrees from arrow 290. In some embodiments, an orientation of the spaced TCP's can be set at any angle 0-180 degrees based on the orientation of poled areas on the transducer 280.
In various embodiments, transducer modules can comprise one or more transduction elements. The transduction elements can comprise a piezoelectrically active material, such as lead zirconante titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In various embodiments, in addition to, or instead of, a piezoelectrically active material, transducer modules can comprise any other materials adapted to and/or configured for generating radiation and/or acoustical energy. In various embodiments, transducer modules can be adapted to and/or configured to operate at different frequencies and treatment depths. Transducer properties can be defined by an outer diameter (“OD”) and focal length (FL). In one embodiment, a transducer can be adapted to and/or configured to have OD=19 mm and FL=15 mm. In other embodiments, other suitable values of OD and FL can be used, such as OD of less than about 19 mm, greater than about 19 mm, etc. and FL of less than about 15 mm, greater than about 15 mm, etc. Transducer modules can be adapted to and/or configured to apply ultrasonic energy at different target tissue depths. As described above, in several embodiments, transducer modules comprise movement mechanisms adapted to and/or configured to direct ultrasonic treatment in a linear or substantial liner sequence of individual TCPs with a treatment spacing between individual TCPs. For example, treatment spacing can be about 1.1 mm, 1.5 mm, etc. In several embodiments, transducer modules can further comprise movement mechanisms adapted to and/or configured to direct ultrasonic treatment in a sequence so that TCPs are formed in linear or substantially linear sequences separated by a treatment spacing. For example, a transducer module can be adapted to and/or configured to form TCPs along a first linear sequence and a second linear sequence separated by treatment spacing between about 2 mm and 3 mm from the first linear sequence. In one embodiment, a user can manually move the transducer modules across the surface of a treatment area so that adjacent linear sequences of TCPs are created. In one embodiment, a movement mechanism can automatically move the transducer modules across the surface of a treatment area so that adjacent linear sequences of TCPs are created.
Aperture Spatial Frequency Analysis and Fourier Transform
In various embodiments, spatial frequency analysis techniques based on Fourier analysis and Fourier optics can be used to increase efficiency of therapeutic treatment. When a system that has an impulse response h(t) is excited by a stimulus x(t), the relationship between the input x(t) and output y(t) is related by the convolution function as follows:
y(t)=x(t)*h(t)=∫−∞∞x(τ)h(t−τ)dτ (1)
In various embodiments, Fourier transform can be applied to compute the convolution of equation (1). Continuous one-dimensional Fourier transform can be defined at:
y(f)=F(y(t)=∫−∞∞y(t)e−j2πftdt (2)
Here f is frequency, t is time. It can be shown that convolution in the time domain is equivalent to multiplication in the frequency domain:
F(x(t)*h(t))=X(f)H(f)=Y(f) (3)
In various embodiments, the Fraunhofer approximation can be used for deriving a relationship between a transducer opening or aperture and a resulting ultrasonic beam response. Derivation of the Fraunhofer approximation is described in Joseph Goodman, Introduction to Fourier Optics (3d ed. 2004), which is incorporated in its entirety by reference, herein. According to the Fraunhofer approximation, a far-field complex amplitude pattern produced by a complex aperture is equal to a two-dimensional Fourier transform of the aperture amplitude and phase. In several embodiments, this relationship in optics can be extended to ultrasound since linear wave equations can be used to represent both light propagation and sound propagation. In the case of optics and/or ultrasound, the two-dimensional Fourier transform can determine a sound wave pressure amplitude distribution at the focus of a transducer.
For a focused system, the variable z which represents depth can be replaced with zf which represents a focal distance.
In various embodiments, Fourier optics and Fourier transform identities (some of which are listed in Table 1, below) can be used for ultrasound transducers in order to determine the intensity distribution corresponding to a transducer design. For example, Fourier transform of a rectangle rect(ax) is a sinc function. As another example, Fourier transform of a two dimensional circle of uniform amplitude is a first order Bessel function which can be represented as J1.
In several embodiments, an ultrasound transducer can have a rectangular aperture of suitable dimensions and focal length. In several embodiments, an ultrasound transducer can have a circular aperture with suitable dimensions and focal length. In one embodiment, a transducer can have a circular aperture with an outer radius of approximately 9.5 mm, an inner diameter of approximately 2 mm, and focal length of approximately 15 mm. The aperture of a circular transducer may be described as:
For example, in one embodiment, the variable ‘a’ can be approximately 9.5 mm and the variable ‘b’ in equation (5a) can be approximately 2 mm. Applying Fourier transform to equation (5a) can provide an estimate of the sound wave pressure distribution at the focus.
where ξx and ξy are same as fx and fy of equations (4a) and (4b). Equation (6) demonstrates that the sound wave pressure distribution of a transducer with a circular aperture is a first order Bessel function. In one embodiment, a substantial majority of the energy is concentrated at the focus (e.g., 15 mm away from the aperture). The width of a main ultrasonic beam and the distribution of energy away from the main beam can be expressed as a function of the operating frequency as is expressed in equations (4a) and (4b).
In various embodiments, two identical or nearly identical beams could be created at the focus if the aperture was modulated (e.g., multiplied) by a correct function. In one embodiment, a cosine function can be applied to a circular aperture as follows:
An energy distribution or beam response at the focus of the modulated aperture of equation (7) is the convolution of the Fourier transform of the two functions of the aperture:
Equation (8) can be simplified into the summation of two separate functions applying the Fourier Transform identity for a Dirac delta function (e.g., identity 2 in Table 2):
Equation (9) shows that two beams appearing at the focus are spatially shifted by
compared to the original, non-modulated beam. In several embodiments, one or more other modulation functions, such as sine function, can be used to achieve a desired beam response. In several embodiments, aperture can be modulated such that more than two foci are created. For example, three, four, five, etc. foci can be created. In several embodiments, aperture can be modulated such that foci are created sequentially or substantially sequentially rather than simultaneously.
In several embodiments, therapy transducer modules comprise movement mechanisms configured to direct ultrasonic treatment in a linear or substantial liner sequence of individual TCPs with a treatment spacing between individual TCPs. For example, treatment spacing can be about 1.1 mm, 1.5 mm, etc. In several embodiments, transducer modules can further comprise movement mechanisms configured to direct ultrasonic treatment in a sequence so that TCPs are formed in linear or substantially linear sequences separated by a treatment spacing. For example, a transducer module can be configured to form TCPs along a first linear sequence and a second linear sequence separated by treatment spacing between about 2 mm and 3 mm from the first linear sequence. According to equation (9), a simultaneous or substantially simultaneous split in the ultrasonic beam may be achieved at the focus (or before the focus) if the aperture is modulated by a cosine and/or sine function of a desired spatial frequency. In one embodiment, two simultaneous or nearly simultaneous focused beams separated by about 1.1 mm treatment spacing can be created in a linear or substantially linear sequence. At 7 MHz frequency of ultrasound, the wavelength λ of ultrasound wave in water is approximately 0.220 mm. Accordingly, spatial frequencies ξx and ξy at the focus are represented as:
In order to place two foci separated by about 1.1 mm, then the spatial frequency for modulating the aperture is calculated as follows. Using identities 3 and 4 in Table 2, the Fourier transformation of a sine or cosine function is a Dirac delta function with the argument:
In one embodiment, equation (11a) can solved for kx when argument is 0:
Further, xo can be replaced by half of the separation distance (e.g., 1.1 mm):
In several embodiments, a transducer with circular aperture emitting ultrasonic energy at various operating frequencies can be modulated by a sine and/or cosine functions at spatial frequencies listed in Table 2. Modulated aperture of the transducer can produce a simultaneously or substantially simultaneously split beam with two foci having different separation distances, as is indicated in Table 2. In one embodiment, the transducer can have OD of about 19 mm and a focal length of about 15 mm.
As is shown in Table 2, in several embodiments, a spatial frequency of an aperture modulation function increases as the ultrasonic operating frequency increases for a given foci separation distance. In addition, the spatial frequency increases as the desired foci separation distance increases.
In one embodiment, higher spatial frequency can result in amplitude transitions in the aperture occurring more rapidly. Due to transducer processing limitations, rapid amplitude variations in the aperture can make the aperture less efficient as there may be a variance in an amount of sound pressure produced by different parts of the aperture. In one embodiment, using spatial frequencies to simultaneously or nearly simultaneously split the beam can reduce the overall focal gain of each beam. As is shown in equation (9), a field pressure at the focus of each beam is reduced by a factor of two in comparison with an unmodulated beam. In one embodiment, the sound pressure or ultrasound intensity from the aperture can be increased to obtain similar or substantially similar intensities at the focal plane. However, in one embodiment, increasing the pressure at the aperture may not be limited by system and/or transducer processing limitations. In one embodiment, an increase in the pressure at the aperture can increase the overall intensity in the near field, which may increase the possibility of excessively heating treatment area tissue(s) that is located before focus. In one embodiment, the possibility of additional heating of the pre-focal tissue(s) may be limited or eliminated by using a lower ultrasound treatment frequency.
In one embodiment, applying aperture modulation function as is shown in equation (7) results in two simultaneous or substantially simultaneous ultrasound beams at the focus. In various embodiments, ultrasound beam can be split multiple times, such as three, four, five, etc. times, such that multiple simultaneous or nearly simultaneous beams are created. In one embodiment, four equally spaced beams along one dimension can be generated by modulating or multiplying the aperture by two separate spatial frequencies:
As is shown in equation (12b), unmodulated beam at the focus can be created at four different locations along the x-axis. In one embodiment, a constant or DC term, Cl, may be added to the amplitude modulation function to maintain placement of energy at the original focal location:
In one embodiment, aperture modulation of equations (12) and (13), whereby the beam can be placed at multiple locations simultaneously or nearly simultaneously, may be have limited applicability due to system, material, and/or tissue limitations. In one embodiment, due to the possibility of heating treatment area tissue(s) located before focus, the frequency of ultrasound therapy may be adjusted, such as lowered, in order to limit and/or eliminate such possibility. In one embodiment, nonlinear techniques can be applied at the focus in order to limit and/or eliminate the possibility of heating of the pre-focal tissue(s). In one embodiment, the sound pressure or ultrasound intensity from the aperture can be increased to obtain similar or substantially similar intensities at the focal plane.
In various embodiments, if the amplitude and phase functions at the aperture are separable, the two-dimensional Fourier transform of a sound pressure function U(x1, y1) can be expressed as a product of a one-dimensional Fourier transform of two functions in x and y. In various embodiments, it may be advantageous to create multiple TCPs in a linear or substantially linear sequence as well as to create multiple linear sequences simultaneously or nearly simultaneously.
Electronic Dithering of Multiple Beam Splitting Apertures Using Frequency Modulation
In various embodiments, Table 2 illustrates aperture spatial frequency for achieving a specific distance between two simultaneous foci for a given operational frequency (e.g. in various embodiments, 4 MHz, 7 MHz, 10 MHz). Equation (11c) shows that the separation distance between the foci is also a function operational frequency. For example, in one embodiment the spatial frequency of the aperture (kx) is fixed to 1.0 mm−1 and the operational frequency is allowed to vary. Equation 11c can be rewritten to show how the foci separation distance can be modulated through operation frequency.
s=(kxzfvc)/(πfop) (14)
where kx is the spatial frequency in mm−1, zf is the focal depth of the aperture in mm, vc is the velocity of ultrasound in the propagating medium (e.g. water) in mm/μsec and fop is the operational frequency of the aperture in MHz. In one embodiment, the following substitution is made in equation 11c:
λ=vc/fop (15)
As Equation (14) shows, the separation distance of the foci is a function of the operational frequency. Further, the rate in change of the separation distance to the operational frequency is:
ds/dfop=−(kxZfVc)/(πfop2) (16)
Equation (16) shows that the separation distance decreases as the operational frequency increases. Table 3 (below) shows the rate in change of separation distance as a function of operational frequency for the different spatial frequencies (e.g., in various embodiments, 4 MHz, 7 MHz, 10 MHz).
As shown in Table 3, as the operational frequency increases, the foci get closer together and as the operational frequency decreases the foci get farther apart without the need to change the phase or mechanically move the transducer. This is a unique method of electronically moving the beam to spread the energy without relying on thermal conduction in tissue. The benefits include a reduction or a minimization of the maximum temperature and an increase in the thermal coagulation volume of the lesion without the need for additional system channels.
The amount of movement from a main operational frequency can be determined by using equation (14). In one embodiment, the main operational frequency of an aperture is 5 MHz and the focal length is 15 mm. In some embodiments, the operational frequency is called the aperture center frequency. In one embodiment, the operational frequency is 5 MHz. In one embodiment, Table 4 at
In one embodiment, the separation distance is relative to a frequency 5 MHz. In one embodiment, one way to estimate the electronic dithering from frequency modulation can be determined by referencing all movement to the initial separation at 5 MHz. As
In various embodiments, the range of possible operational frequencies from one aperture can be described in terms of the transducer bandwidth. In one embodiment, a larger transducer bandwidth results in an aperture that has a wider range of operational frequencies. Transducer bandwidth can be described as a percent fraction of the aperture center frequency by locating the frequency where the transmit intensity decreases to −3 dB of the peak transmit intensity. In one embodiment the −3 dB high frequency is designated as f−3 db,H and the −3 dB low frequency is designated as f−3 dB,L for the transmit response of a transducer aperture. The −3 dB center frequency in [MHz] is described as:
f−3 dB,center=(f−3 dB,H+f−3 dB,L)/2 (17)
The −3 dB percent bandwidth is described as:
BW−3 dB=100%*(f−3 dB,H+f−3 dB,L)/((f−3 dB,H+f−3 dB,L)/2) (18)
In some embodiments, increasing the range of operational frequencies possible within one aperture may be achieved (but not limited to) by the use of backing layers, matching layers, multiple piezoelectric layers, electrical matching, piezoelectric composites, and/or a single crystal piezoceramic. In one embodiment, as the transducer bandwidth increases, the range of possible separation distance increases. Table 5 (below) shows how based on percent bandwidth the foci spread can vary if the aperture center frequency is 5 MHz. The foci separation distance for 5 MHz is 0.72 mm, 1.43 mm, 2.15 mm and 2.86 mm respectively for spatial frequencies of 0.5 mm−1, 1.00 mm−1, 1.50 mm−1, 2.00 mm−1. If the spatial frequency at the aperture is 1.50 mm−1 and the transducer bandwidth is 60%, then the separation distance between the foci varies by 1.42 mm which is a distance greater than the lateral resolution of the beam at 5 MHz.
In one embodiment, as the frequency is changed, the depth-of-field will also change as well as lateral resolution and focal gain. In one embodiment, as the frequency is changed, the depth-of-field, lateral resolution and focal gain will also change. Therefore, in one embodiment, the intensity at the aperture may change depending in the heating rate goals. Also, in some embodiments, it may be advantageous to send multiple operational frequencies at the same time to spread the energy immediately or near-immediately. For example, transmit excitation of the aperture may include excitation at 4 MHz, 5 MHz and 6 MHz all at the same time.
Multiple Foci by Changing the Aperture Spatial Frequency
As Equation 11c shows, the higher the aperture spatial frequency, the greater the separation distance between the foci. In one embodiment, an aperture is poled with a spatial frequency of kx. The spatial frequency can be easily doubled or decreased to zero by connecting individual electrical excitation channels that have the ability to modify the phase to 0 degrees or 180 degrees, as shown in the embodiments in
In one embodiment, a poled ceramic has a spatial frequency of 2kx, as shown in
Multiple Foci Using Multi-Channel Signal Mixing
In several embodiments, a treatment system utilizes multiple therapy channels to enable electronic focusing and/or steering. For example, a treatment system that utilizes multiple therapy channels to enable electronic focusing and/or steering allows for faster electronic dithering to either create more thermal coagulation using the same amount of energy as other treatment devices or equal thermal coagulation using electronic dithering with less energy than other treatment devices. This technique broadens the efficacy and comfort continuum that the device offers. In addition to electronic dithering, the multiple therapy channels also offer the possibility to move the beam to different depth locations such that two conventional transducers such as the DS7-4.5 (7 MHz at 4.5 mm depth) and DS7-3.0 (7 MHz at 3.0 mm depth) could be replaced by one single device that moves between the two different depths.
In one embodiment, a transducer 280 with multiple therapy channels 281 connected to move the beam axially (e.g. annular array) would typically create a TCP 550 at a deep depth first and then move to the shallower depth. In another embodiment, a TCP 550 is created at a shallow depth and then at a deeper depth below the skin surface. This creates the TCP 550 sequentially and would cause the treatment time to be extended. For example, in one embodiment, if the time for the deep TCP 550 is tdeep and the time for the shallow TCP 550 is tshallow, then the total treatment time for the two TCPs 550 is the sum of the two treatment times, tdeep plus tshallow. In one embodiment, total treatment time is reduced by forming multiple (two, or more) TCP's 550 simultaneously using signal mixing techniques which uses both signal apodization (shading) and phase control at each channel. In one embodiment, the total treatment time is the maximum of tdeep and tshallow:
Treatment time, conventional approach: ttreatment=tdeep+tshallow
Treatment time, signal mixing: ttreatment=max(tdeep, tshallow)
In an embodiment, an annular array design 280 enables the electronic movement of the therapy beam in depth (e.g., by changing depth of the TCP 550 below the skin surface). In one embodiment, a transducer 280 includes an eight therapy channel annular transducers elements 281 with a fixed mechanical focus.
In one embodiment, there is a unique amplitude ‘A’ and phase ‘8’ applied to each therapy channel and corresponding annular ring 281 for each focus at a given therapy frequency ‘w’. The excitation function for a channel can be generalized to the following form:
fn,m(t)=An,m sin(ωt+θn,m) (19)
where n is the ring or channel number and m is the focus number.
In the case of creating a TCP at the geometric focus, the phase is zero and equation (19) can be rewritten as:
fn,1(t)=An,1 sin(ωt) (20)
where the ‘1’ in the subscript signifies the geometric focus.
In the case of creating a TCP 550 at electronic focus #2, the phase of the rings must be adjusted to focus the ultrasound at the spatial point using bowl geometry and time delay estimates. The excitation function can be written as:
fn,2(t)=An,2 sin(ωt+θn,2) (21)
where the ‘2’ in the subscript signifies the electronic focus #2 and the angle is the required phasing for the ring.
Now, in the conventional case, the two TCP's would be created sequentially with typically the deeper TCP generated first and then the shallow TCP. However, signal mixing allows the two excitation signals to be represented as one signal such that both TCPs could be generated simultaneously.
fn,total(t)=fn,1(t)+fn,2(t)=An,1 sin(ωt)+An,2 sin(ωt+θn,2)
fn,total(t)=c sin(ωt+ϕ) (22a)
where c=sqrt(An,12+An,22+2An,1An,2 cos(θn,2)) and
ϕ=a tan 2(An,2 sin(θn,2),An,1+An,2 cos(θn,2)) (22b)
The amplitude and phase at each ring is modified to support the focusing at two locations simultaneously.
In some embodiments, the time to deliver the dose for one focus will be slightly different than the second focus. In one embodiment, the excitation may start or end on the focus with the longer dosing time with excitation modified to support the dosing at two foci simultaneously using Equation (22b) during the other times. For example, in one embodiment, for fn,1 a total dosing time of 30 msec is required whereas for fn,2 a total dosing time of 60 msec is required. In order to satisfy this, many different excitations scenarios could be used:
fn,2(t) for 30 msec and then fn,total(t) for 30 msec (23a)
fn,total(t) for 30 msec and then fn,2(t) for 30 msec (23b)
fn,2(t) for 15 msec and then fn,total(t) for 30 msec and fn,2(t) for 15 msec (23c)
In one embodiment, this concept can be further generalized to more than two simultaneous foci. Suppose the excitation on one ring is the following:
where n is the ring number and m is the number of simultaneous foci. This generalization to more than two foci enables the geometric focus, shallow electronic focus and deep electronic focus to be delivered at the same time.
In one embodiment, an experiment was conducted using simulations of two simultaneous foci were completed to show that when this theory is applied that two foci appear. The simulations attempted to place a therapy focus at 15 mm and 17 mm simultaneously.
Ultrasound Imaging for Improving Ultrasound Therapy Treatments
In an embodiment, the imaging resolution is improved via electronic focusing on the beam axis in transmit and receive signals. In various embodiments, imaging resolution is improved by 10%, 20%, 40%, or 50%, 10%-50%, or any values therein. In an embodiment, increasing imaging resolution may not interrogate as well the coupling between the therapy transducer and the skin since the cross-section of the therapy beam is much wider than the imaging beam at this tissue interface.
In an embodiment, an imaging beam 286 is extended to a larger (e.g., 10%, 15%. 25%, 50%, 75%, 90%, 100%) entire image frame to cover more, or all, of the therapy beam 281 cross section. In an embodiment, an image has a width of 25 mm. If the areas are calculated and compared (e.g. slice thickness and width), then the imaging plane only interrogates approximately 2.5% of the total therapy area cross-section at the acoustic window. Although this is improved over the initial calculation, it is still significantly below 100% coverage. In various embodiments, imaging provides for properly interrogate more (e.g., 10%, 15%. 25%, 50%, 75%, 90%, 100%) the coupling using an imaging system with an annular array. In some embodiments, image processing enables proper interpretation by the operator.
Linear Imaging Array
In various embodiments, an ultrasound treatment system comprises an imaging module and an imaging array 285. In various embodiments, the imaging array 285 is a linear array, such as shown in the embodiment at
Annular Imaging Array
In various embodiments, an ultrasound treatment system comprises an imaging module and an imaging array 285. In various embodiment, the imaging module has multiple (e.g., 2, 4, 8) transmit channels and multiple (e.g., 2, 4, 8) receive channels that operate from between 8 MHz to 50 MHz (e.g., 8, 9, 10, 12, 15, 20, 22, 25, 28, 30, 40 or 50 MHz and any ranges therein) for purposes of imaging the skin to approximately 25 mm in depth. In one embodiment, the imaging module has eight transmit channels and eight receive channels that operate from 8 MHz to 50 MHz for purposes of imaging the skin to approximately 25 mm in depth. The eight channels enable unique imaging aperture designs with elements that offer electronic steering and focusing in transmit and receive. One of these types of apertures is an annular array (
In some embodiments, the annular array 285 contains rings of equal element areas that permit electronic focusing along the beam axis. In one embodiment, a mechanically scanned annular array 285 offers superior imaging performance over a more technically advanced, electronically controlled linear array 285′. This is because an annular array 285 focuses the beam along the beam axis in azimuth and elevation. The radial symmetry produces a high resolution beam with equivalent beamwidth. The linear array 285′ uses electronic focusing in azimuth and mechanical focusing in elevation which is equivalent to a compound lens. The resolution of the beam in azimuth can match the performance of the annular array 285; however, the resolution of the beam in elevation underperforms the annular array 285 due to the mechanical lens having only one focal depth.
In one embodiment, the annular array 285 is superior to standard imaging transducers because it can focus on the beam axis in transmit and receive. Just as the annular array 285 can focus in tissue, it can also effectively focus behind the transducer 285. This focus behind the imaging array 285 defocuses the acoustic energy propagating toward the tissue such that it is possible to better interrogate the coupling of the therapy behind at the acoustic window as well as the possibility of obstructions (e.g., bone) behind the therapy focus.
Vector Imaging
In some embodiments, defocusing the beam at the acoustic window and behind the therapy focus is advantageous to test for coupling and potential tissue impediments (e.g., bone, intestines) or implants. The processing and display of this information can be used by the system operator to make appropriate decisions without interfering with normal imaging. In one embodiment, in order to provide the information in a timely manner, the transmit-receive events with the defocused beam are be interwoven with standard imaging. This form of imaging enables the frame rates for regular B-mode imaging and the coupling pulses.
The vector imaging is similar in
In embodiments where there is sufficient transmit sensitivity and receive signal-to-noise ratio, synthetic transmit and receive aperture imaging may be utilized to achieve optimal resolution in the ultrasound image and permit ample means to determine if there is sufficient coupling for the therapy transducer.
Image Processing
In one embodiment, an advantage of using the defocused beam are to help the operator assess coupling and the tissue behind the acoustic focus. In one embodiment, a method to display the information includes calculating a brightness variance across the top of the image. A significant brightness variance off of the dermis strongly suggests insufficient coupling whereas uniform brightness suggests uniform coupling across the majority of the therapy beam. A brightness variance calculation would be the second moment of the speckle brightness over a specific depth such as 1 mm to 2 mm from the acoustic window.
In one embodiment, a two-dimensional (2D) filtering function is used to reduce the brightness variation that naturally occurs from the speckle. In one embodiment, a quantitative or qualitative variable is presented to the user along with the high resolution image to suggest the quality of coupling at the acoustic window or tissue behind the focus.
In one embodiment, the coupling assessment image is combined with the high resolution image. For example, the two images could be multiplied together. This will provide one image to the operator without removing any of the information from the high resolution image. The 2D multiplication (pixel-by-pixel) will show the shadowing from poor coupling on top of the high resolution image. The operator can then decide whether treatment is appropriate based on the amount of brightness shadowing. In one embodiment, the two images are blended together like an overlay which permits greater emphasis on either the high resolution image or the coupling assessment image. In one embodiment, overlapping images can be configured in a manner like images presented to radiologists when combining registered images from different systems (e.g. MRI and ultrasound).
Multifocal Zone Sequencing
In various embodiments, ultrasound imaging is used with a therapeutic tissue treatment. According to various embodiments, an ultrasound treatment system creates one, two or more simultaneous therapeutic treatment points and/or focal zones under the skin surface for a cosmetic treatment. In one embodiment, a treatment comprises mechanical dithering in which the therapy transducer is moved locally around the intended center of the thermal coagulation point (TCP). The acoustic beam movement can be side-to-side, up-down, and/or angular. In one embodiment of mechanical dithering, the movement of the motion mechanism is sufficiently fast enough to create a flatter temperature profile around the intended TCP which either allows a reduction of total acoustic energy for the same effected tissue volume or the same total acoustic energy for a larger effected tissue volume or any combination thereof. In accordance with various embodiments, frequency modulation modifies the location of a focal zone and/or spacing between the focal zones, such that electronic dithering of beam via modulation of the frequency precisely alters and/or moves the position of the beam focus point(s). For example, in one embodiment, a spacing of 1.5 mm can be dithered with +/−0.1 mm using a small frequency swing. In various embodiments, any one or more spacings of 0.5, 0.75, 1.0, 1.2, 1.5, 2.0 mm can be dithered with +/−0.01, 0.05, 0.1, 0.12, 0.15, 0.20, 0.25, 0.30 mm using a frequency swing. In various embodiments, a frequency is modulated by 1-200% (e.g., 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%. 100%, 120%, 150%, 180%, 200% and any range therein).
In various embodiments for improved ultrasound imaging, multiple focal zones are employed to obtain better signal quality and resolution through depth. For traditional, conventional diagnostic ultrasound scanners (linear, curvilinear, phased arrays, etc.), where the 2-D ultrasound images are formed without having to move the transducer, the sequence of acquiring these multiple focal zones are relatively inconsequential as precise placement of these focal zones can be controlled electronically.
However, for moving imaging transducers (e.g., mechanically translated or steered arrays), this becomes problematic, due to the positional differences of the transducer as it scans through the multiple focal zones. This positional mis-registration is particularly magnified when forming imaging bidirectionally (forming both left-to-right and right-to-left images), as the region of interrogation between the two images will be different. This principle is demonstrated in
Embodiments of the imaging system disclosed herein address these misalignments.
In one embodiment, an alternative sequence is proposed such that the first direction-traveling (outbound) sequence shall proceed in order (f1, f2, f3, f4), but the second direction-traveling (returning) sequence is reversed (f4, f3, f2, f1), thereby allowing better registration of two images. In one embodiment, an alternative sequence is proposed such that the right-traveling (outbound) sequence shall proceed in order (f1, f2, f3, f4), but the left-traveling (returning) sequence is reversed (f4, f3, f2, f1), thereby allowing better registration of two images (
In an embodiment, an imaging system employs a novel sequence of two consecutive A-lines following progression of (line 1: f1, f2, f3, f4; line2: f4, f3, f2, f1) continuously. This sequence can be repeated across the entire field of view, and assuming an even number of vectors within the field of view, the returning sequence can have the exact same alternating pattern focal zone sequence, and the two images would be registered (
In various embodiments, the multifocal zone imaging provides advantages for better correlation between first direction-traveling and second direction-traveling formed images.
In various embodiments, the multifocal zone imaging provides advantages for improved effectiveness of B-mode imaging at faster (e.g., 2×, 3×, 4×) the scanning rate.
In various embodiments, multifocal zone imaging is applied to any number of focal zones greater than one. In various embodiments, the number of focal zones is two, three, four, five, six, seven, eight, nine, ten, or more.
Transducers
In various embodiments, transducer 280 comprises a convex side 282 and a concave side 283. In various embodiments, a transducer 280 comprises a convex side 282 and a concave side 283 with features that provide for any one or more of variable depth, variable spacing, variable focus positioning, with one, two, three, four, or more simultaneous focus zones.
Some embodiments and the examples described herein are examples and not intended to be limiting in describing the full scope of compositions and methods of these invention. Equivalent changes, modifications and variations of some embodiments, materials, compositions and methods can be made within the scope of the present invention, with substantially similar results.
While the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “coupling a transducer module with an ultrasonic probe” include “instructing the coupling of a transducer module with an ultrasonic probe.” The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 25 mm” includes “25 mm.”
This application is a U.S. National Phase of PCT Application No. PCT/US2017/046703, filed Aug. 14, 2017, which claims the benefit of priority from U.S. Provisional Application No. 62/375,607 filed Aug. 16, 2016, U.S. Provisional Application No. 62/482,476 filed Apr. 6, 2017, U.S. Provisional Application No. 62/482,440 filed Apr. 6, 2017, and U.S. Provisional Application No. 62/520,055 filed Jun. 15, 2017, each of which is incorporated in its entirety by reference, herein. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2017/046703 | 8/14/2017 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2018/035012 | 2/22/2018 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 2427348 | Bond et al. | Sep 1947 | A |
| 2792829 | Calosi | Feb 1952 | A |
| 3913386 | Saglio | Oct 1975 | A |
| 3965455 | Hurwitz | Jun 1976 | A |
| 3992925 | Perilhou | Nov 1976 | A |
| 4039312 | Patru | Aug 1977 | A |
| 4059098 | Murdock | Nov 1977 | A |
| 4101795 | Fukumoto | Jul 1978 | A |
| 4151834 | Sato et al. | May 1979 | A |
| 4166967 | Benes et al. | Sep 1979 | A |
| 4211948 | Smith et al. | Jul 1980 | A |
| 4211949 | Brisken et al. | Jul 1980 | A |
| 4213344 | Rose | Jul 1980 | A |
| 4276491 | Daniel | Jun 1981 | A |
| 4315514 | Drewes et al. | Feb 1982 | A |
| 4325381 | Glenn | Apr 1982 | A |
| 4343301 | Indech | Aug 1982 | A |
| 4372296 | Fahim | Feb 1983 | A |
| 4379145 | Masuho et al. | Apr 1983 | A |
| 4381007 | Doss | Apr 1983 | A |
| 4381787 | Hottinger | May 1983 | A |
| 4397314 | Vaguine | Aug 1983 | A |
| 4409839 | Taenzer | Oct 1983 | A |
| 4417170 | Benisncasa | Nov 1983 | A |
| 4431008 | Wanner et al. | Feb 1984 | A |
| 4441486 | Pounds | Apr 1984 | A |
| 4452084 | Taenzer | Jun 1984 | A |
| 4484569 | Driller | Nov 1984 | A |
| 4507582 | Glenn | Mar 1985 | A |
| 4513749 | Kino | Apr 1985 | A |
| 4513750 | Heyman et al. | Apr 1985 | A |
| 4527550 | Ruggera et al. | Jul 1985 | A |
| 4528979 | Marchenko | Jul 1985 | A |
| 4534221 | Fife et al. | Aug 1985 | A |
| 4566459 | Umemura et al. | Jan 1986 | A |
| 4567895 | Putzke | Feb 1986 | A |
| 4586512 | Do-Huu | May 1986 | A |
| 4587971 | Stolfi | May 1986 | A |
| 4601296 | Yerushalmi | Jul 1986 | A |
| 4620546 | Aida et al. | Nov 1986 | A |
| 4637256 | Sugiyama et al. | Jan 1987 | A |
| 4646756 | Watmough | Mar 1987 | A |
| 4663358 | Hyon | May 1987 | A |
| 4668516 | Duraffourd et al. | May 1987 | A |
| 4672591 | Breimesser et al. | Jun 1987 | A |
| 4680499 | Umemura et al. | Jul 1987 | A |
| 4697588 | Reichenberger | Oct 1987 | A |
| 4754760 | Fukukita et al. | Jul 1988 | A |
| 4757820 | Itoh | Jul 1988 | A |
| 4771205 | Mequio | Sep 1988 | A |
| 4801459 | Liburdy | Jan 1989 | A |
| 4803625 | Fu et al. | Feb 1989 | A |
| 4807633 | Fry | Feb 1989 | A |
| 4817615 | Fukukita et al. | Apr 1989 | A |
| 4858613 | Fry | Aug 1989 | A |
| 4860732 | Hasegawa et al. | Aug 1989 | A |
| 4865041 | Hassler | Sep 1989 | A |
| 4865042 | Umemura | Sep 1989 | A |
| 4867169 | Machida | Sep 1989 | A |
| 4874562 | Hyon | Oct 1989 | A |
| 4875487 | Seppi | Oct 1989 | A |
| 4881212 | Takeuchi | Nov 1989 | A |
| 4891043 | Zeimer et al. | Jan 1990 | A |
| 4893624 | Lele | Jan 1990 | A |
| 4896673 | Rose | Jan 1990 | A |
| 4900540 | Ryan et al. | Feb 1990 | A |
| 4901729 | Saitoh | Feb 1990 | A |
| 4917096 | Englehart | Apr 1990 | A |
| 4932414 | Coleman et al. | Jun 1990 | A |
| 4938216 | Lele | Jul 1990 | A |
| 4938217 | Lele | Jul 1990 | A |
| 4947046 | Kawabata et al. | Aug 1990 | A |
| 4951653 | Fry | Aug 1990 | A |
| 4955365 | Fry | Sep 1990 | A |
| 4958626 | Nambu | Sep 1990 | A |
| 4976709 | Sand | Dec 1990 | A |
| 4979501 | Valchanov | Dec 1990 | A |
| 4992989 | Watanabe et al. | Feb 1991 | A |
| 5012797 | Liang | May 1991 | A |
| 5018508 | Fry et al. | May 1991 | A |
| 5030874 | Saito et al. | Jul 1991 | A |
| 5036855 | Fry | Aug 1991 | A |
| 5040537 | Katakura | Aug 1991 | A |
| 5054310 | Flynn | Oct 1991 | A |
| 5054470 | Fry | Oct 1991 | A |
| 5054491 | Saito et al. | Oct 1991 | A |
| 5070879 | Herres | Dec 1991 | A |
| 5088495 | Miyagawa | Feb 1992 | A |
| 5115814 | Griffith | May 1992 | A |
| 5117832 | Sanghvi | Jun 1992 | A |
| 5123418 | Saurel | Jun 1992 | A |
| 5142511 | Kanai et al. | Aug 1992 | A |
| 5143063 | Fellner | Sep 1992 | A |
| 5143074 | Dory | Sep 1992 | A |
| 5149319 | Unger | Sep 1992 | A |
| 5150711 | Dory | Sep 1992 | A |
| 5150714 | Green | Sep 1992 | A |
| 5152294 | Mochizuki et al. | Oct 1992 | A |
| 5156144 | Iwasaki | Oct 1992 | A |
| 5158536 | Sekins | Oct 1992 | A |
| 5159931 | Pini | Nov 1992 | A |
| 5163421 | Bernstein | Nov 1992 | A |
| 5163436 | Saitoh et al. | Nov 1992 | A |
| 5178135 | Uchiyama et al. | Jan 1993 | A |
| 5190518 | Takasu | Mar 1993 | A |
| 5190766 | Ishihara | Mar 1993 | A |
| 5191880 | McLeod | Mar 1993 | A |
| 5205287 | Erbel et al. | Apr 1993 | A |
| 5209720 | Unger | May 1993 | A |
| 5212671 | Fujii et al. | May 1993 | A |
| 5215680 | D'Arrigo | Jun 1993 | A |
| 5224467 | Oku | Jul 1993 | A |
| 5230334 | Klopotek | Jul 1993 | A |
| 5230338 | Allen et al. | Jul 1993 | A |
| 5247924 | Suzuki et al. | Sep 1993 | A |
| 5255681 | Ishimura et al. | Oct 1993 | A |
| 5257970 | Dougherty | Nov 1993 | A |
| 5265614 | Hayakawa | Nov 1993 | A |
| 5267985 | Shimada | Dec 1993 | A |
| 5269297 | Weng | Dec 1993 | A |
| 5282797 | Chess | Feb 1994 | A |
| 5295484 | Marcus | Mar 1994 | A |
| 5295486 | Wollschlager et al. | Mar 1994 | A |
| 5304169 | Sand | Apr 1994 | A |
| 5305756 | Entrekin et al. | Apr 1994 | A |
| 5321520 | Inga et al. | Jun 1994 | A |
| 5323779 | Hardy et al. | Jun 1994 | A |
| 5327895 | Hashimoto et al. | Jul 1994 | A |
| 5329202 | Garlick et al. | Jul 1994 | A |
| 5348016 | Unger et al. | Sep 1994 | A |
| 5358466 | Aida et al. | Oct 1994 | A |
| 5360268 | Hayashi | Nov 1994 | A |
| 5370121 | Reichenberger | Dec 1994 | A |
| 5370122 | Kunig | Dec 1994 | A |
| 5371483 | Bhardwaj | Dec 1994 | A |
| 5375602 | Lancee et al. | Dec 1994 | A |
| 5379773 | Hornsby | Jan 1995 | A |
| 5380280 | Peterson | Jan 1995 | A |
| 5380519 | Schneider et al. | Jan 1995 | A |
| 5383917 | Desai et al. | Jan 1995 | A |
| 5391140 | Schaetzle et al. | Feb 1995 | A |
| 5391197 | Burdette et al. | Feb 1995 | A |
| 5392259 | Bolorforosh | Feb 1995 | A |
| 5396143 | Seyed-Bolorforosh et al. | Mar 1995 | A |
| 5398689 | Connor et al. | Mar 1995 | A |
| 5406503 | Williams | Apr 1995 | A |
| 5413550 | Castel | May 1995 | A |
| 5417216 | Tanaka | May 1995 | A |
| 5423220 | Finsterwald et al. | Jun 1995 | A |
| 5435311 | Umemura | Jul 1995 | A |
| 5438998 | Hanafy | Aug 1995 | A |
| 5443068 | Cline et al. | Aug 1995 | A |
| 5445611 | Eppstein et al. | Aug 1995 | A |
| 5458596 | Lax | Oct 1995 | A |
| 5460179 | Okunuki et al. | Oct 1995 | A |
| 5460595 | Hall et al. | Oct 1995 | A |
| 5419327 | Rohwedder | Nov 1995 | A |
| 5469854 | Unger et al. | Nov 1995 | A |
| 5471488 | Fujio | Dec 1995 | A |
| 5472405 | Buchholtz et al. | Dec 1995 | A |
| 5487388 | Rello et al. | Jan 1996 | A |
| 5492126 | Hennige | Feb 1996 | A |
| 5496256 | Bock | Mar 1996 | A |
| 5501655 | Rolt | Mar 1996 | A |
| 5503152 | Oakley et al. | Apr 1996 | A |
| 5503320 | Webster et al. | Apr 1996 | A |
| 5507790 | Weiss | Apr 1996 | A |
| 5511296 | Dias et al. | Apr 1996 | A |
| 5520188 | Hennige | May 1996 | A |
| 5522869 | Burdette | Jun 1996 | A |
| 5523058 | Umemura et al. | Jun 1996 | A |
| 5524620 | Rosenchein | Jun 1996 | A |
| 5524624 | Tepper | Jun 1996 | A |
| 5524625 | Okazaki | Jun 1996 | A |
| 5526624 | Berg | Jun 1996 | A |
| 5526812 | Dumoulin et al. | Jun 1996 | A |
| 5526814 | Cline et al. | Jun 1996 | A |
| 5526815 | Granz | Jun 1996 | A |
| 5529070 | Augustine et al. | Jun 1996 | A |
| 5540235 | Wilson | Jul 1996 | A |
| 5558092 | Unger | Sep 1996 | A |
| 5560362 | Sliwa et al. | Oct 1996 | A |
| 5573497 | Chapelon | Nov 1996 | A |
| 5575291 | Hayakawa | Nov 1996 | A |
| 5575807 | Faller | Nov 1996 | A |
| 5577502 | Darrow et al. | Nov 1996 | A |
| 5577507 | Snyder et al. | Nov 1996 | A |
| 5577991 | Akui et al. | Nov 1996 | A |
| 5580575 | Unger et al. | Dec 1996 | A |
| 5643179 | Fujimoto | Jan 1997 | A |
| 5601526 | Chapelon | Feb 1997 | A |
| 5603323 | Pflugrath et al. | Feb 1997 | A |
| 5605154 | Ries et al. | Feb 1997 | A |
| 5609562 | Kaali | Mar 1997 | A |
| 5615091 | Palatnik | Mar 1997 | A |
| 5618275 | Bock | Apr 1997 | A |
| 5620479 | Diederich | Apr 1997 | A |
| 5622175 | Sudol et al. | Apr 1997 | A |
| 5617858 | Taverna et al. | May 1997 | A |
| 5638819 | Manwaring et al. | Jun 1997 | A |
| 5644085 | Lorraine et al. | Jul 1997 | A |
| 5647373 | Paltieli | Jul 1997 | A |
| 5655535 | Frlemel et al. | Aug 1997 | A |
| 5655538 | Lorraine | Aug 1997 | A |
| 5657760 | Ying | Aug 1997 | A |
| 5658328 | Johnson | Aug 1997 | A |
| 5660836 | Knowlton | Aug 1997 | A |
| 5662116 | Kondo | Sep 1997 | A |
| 5665053 | Jacobs | Sep 1997 | A |
| 5665141 | Vago | Sep 1997 | A |
| 5671746 | Dreschel et al. | Sep 1997 | A |
| 5673699 | Trahey et al. | Oct 1997 | A |
| 5676692 | Sanghvi | Oct 1997 | A |
| 5677491 | Ishrak | Oct 1997 | A |
| 5685820 | Riek et al. | Nov 1997 | A |
| 5690608 | Watanabe | Nov 1997 | A |
| 5694936 | Fujimoto | Dec 1997 | A |
| 5697897 | Buchholtz | Dec 1997 | A |
| 5701900 | Shehada et al. | Dec 1997 | A |
| 5704361 | Seward et al. | Jan 1998 | A |
| 5706252 | Le Verrier et al. | Jan 1998 | A |
| 5706564 | Rhyne | Jan 1998 | A |
| 5715823 | Wood et al. | Feb 1998 | A |
| 5720287 | Chapelon et al. | Feb 1998 | A |
| 5722411 | Suzuki | Mar 1998 | A |
| 5727554 | Kalend et al. | Mar 1998 | A |
| 5735280 | Sherman et al. | Apr 1998 | A |
| 5740804 | Cerofolini | Apr 1998 | A |
| 5743863 | Chapelon | Apr 1998 | A |
| 5746005 | Steinberg | May 1998 | A |
| 5746762 | Bass | May 1998 | A |
| 5748767 | Raab | May 1998 | A |
| 5749364 | Sliwa et al. | May 1998 | A |
| 5755228 | Wilson et al. | May 1998 | A |
| 5755753 | Knowlton | May 1998 | A |
| 5762066 | Law | Jun 1998 | A |
| 5763886 | Schulte | Jun 1998 | A |
| 5769790 | Watkins | Jun 1998 | A |
| 5779644 | Eberle et al. | Jul 1998 | A |
| 5792058 | Lee | Aug 1998 | A |
| 5795297 | Daigle | Aug 1998 | A |
| 5795311 | Wess | Aug 1998 | A |
| 5810009 | Mine et al. | Sep 1998 | A |
| 5810888 | Fenn | Sep 1998 | A |
| 5814599 | Mitragotri et al. | Sep 1998 | A |
| 5817013 | Ginn et al. | Oct 1998 | A |
| 5817021 | Reichenberger | Oct 1998 | A |
| 5820564 | Slayton | Oct 1998 | A |
| 5823962 | Schaetzle | Oct 1998 | A |
| 5827204 | Grandia et al. | Oct 1998 | A |
| 5840032 | Hatfield et al. | Nov 1998 | A |
| 5844140 | Seale | Dec 1998 | A |
| 5853367 | Chalek et al. | Dec 1998 | A |
| 5866024 | de Villeneuve | Feb 1999 | A |
| 5869751 | Bonin | Feb 1999 | A |
| 5871524 | Knowlton | Feb 1999 | A |
| 5873902 | Sanghvi | Feb 1999 | A |
| 5876341 | Wang et al. | Mar 1999 | A |
| 5879303 | Averkiou et al. | Mar 1999 | A |
| 5882557 | Hayakawa | Mar 1999 | A |
| 5891034 | Bucholz | Apr 1999 | A |
| 5895356 | Andrus et al. | Apr 1999 | A |
| 5899861 | Friemel et al. | May 1999 | A |
| 5904659 | Duarte | May 1999 | A |
| 5919219 | Knowlton | Jul 1999 | A |
| 5923099 | Bilir | Jul 1999 | A |
| 5924989 | Polz | Jul 1999 | A |
| 5928169 | Schatzle et al. | Jul 1999 | A |
| 5931805 | Brisken | Aug 1999 | A |
| 5938606 | Bonnefous | Aug 1999 | A |
| 5938612 | Kline-Schoder | Aug 1999 | A |
| 5948011 | Knowlton | Sep 1999 | A |
| 5957844 | Dekel | Sep 1999 | A |
| 5957882 | Nita et al. | Sep 1999 | A |
| 5957941 | Ream | Sep 1999 | A |
| 5964707 | Fenster et al. | Oct 1999 | A |
| 5967980 | Ferre et al. | Oct 1999 | A |
| 5968034 | Fullmer | Oct 1999 | A |
| 5971949 | Levin | Oct 1999 | A |
| 5977538 | Unger et al. | Nov 1999 | A |
| 5984881 | Ishibashi et al. | Nov 1999 | A |
| 5984882 | Rosenchein | Nov 1999 | A |
| 5990598 | Sudol et al. | Nov 1999 | A |
| 5997471 | Gumb et al. | Dec 1999 | A |
| 5997497 | Nita et al. | Dec 1999 | A |
| 5999843 | Anbar | Dec 1999 | A |
| 6004262 | Putz et al. | Dec 1999 | A |
| 6007499 | Martin et al. | Dec 1999 | A |
| 6013032 | Savord | Jan 2000 | A |
| 6014473 | Hossack et al. | Jan 2000 | A |
| 6016255 | Bolan et al. | Jan 2000 | A |
| 6019724 | Gronningsaeter et al. | Feb 2000 | A |
| 6022308 | Williams | Feb 2000 | A |
| 6022317 | Cruanas et al. | Feb 2000 | A |
| 6022327 | Chang | Feb 2000 | A |
| 6030374 | McDaniel | Feb 2000 | A |
| 6036646 | Barthe | Mar 2000 | A |
| 6039048 | Silberg | Mar 2000 | A |
| 6039689 | Lizzi | Mar 2000 | A |
| 6042556 | Beach | Mar 2000 | A |
| 6049159 | Barthe | Apr 2000 | A |
| 6050943 | Slayton | Apr 2000 | A |
| 6059727 | Fowlkes | May 2000 | A |
| 6071239 | Cribbs | Jun 2000 | A |
| 6080108 | Dunham | Jun 2000 | A |
| 6083148 | Williams | Jul 2000 | A |
| 6086535 | Ishibashi | Jul 2000 | A |
| 6086580 | Mordon et al. | Jul 2000 | A |
| 6090054 | Tagishi | Jul 2000 | A |
| 6093148 | Fujimoto | Jul 2000 | A |
| 6093883 | Sanghvi | Jul 2000 | A |
| 6100626 | Frey et al. | Aug 2000 | A |
| 6101407 | Groezinger | Aug 2000 | A |
| 6106469 | Suzuki et al. | Aug 2000 | A |
| 6113558 | Rosenchein | Sep 2000 | A |
| 6113559 | Klopotek | Sep 2000 | A |
| 6120452 | Barthe | Sep 2000 | A |
| 6123081 | Durette | Sep 2000 | A |
| 6126619 | Peterson et al. | Oct 2000 | A |
| 6135971 | Hutchinson | Oct 2000 | A |
| 6139499 | Wilk | Oct 2000 | A |
| 6159150 | Yale et al. | Dec 2000 | A |
| 6171244 | Finger et al. | Jan 2001 | B1 |
| 6176840 | Nishimura | Jan 2001 | B1 |
| 6183426 | Akisada | Feb 2001 | B1 |
| 6183502 | Takeuchi | Feb 2001 | B1 |
| 6183773 | Anderson | Feb 2001 | B1 |
| 6190323 | Dias | Feb 2001 | B1 |
| 6190336 | Duarte | Feb 2001 | B1 |
| 6193658 | Wendelken | Feb 2001 | B1 |
| 6198956 | Dunne | Mar 2001 | B1 |
| 6210327 | Brackett et al. | Apr 2001 | B1 |
| 6213948 | Barthe | Apr 2001 | B1 |
| 6216029 | Paltieli | Apr 2001 | B1 |
| 6233476 | Strommer et al. | May 2001 | B1 |
| 6234990 | Rowe et al. | May 2001 | B1 |
| 6241753 | Knowlton | Jun 2001 | B1 |
| 6246898 | Vesely et al. | Jun 2001 | B1 |
| 6251074 | Averkiou et al. | Jun 2001 | B1 |
| 6251088 | Kaufman et al. | Jun 2001 | B1 |
| 6268405 | Yao | Jul 2001 | B1 |
| 6273864 | Duarte | Aug 2001 | B1 |
| 6280402 | Ishibashi et al. | Aug 2001 | B1 |
| 6287257 | Matichuk | Sep 2001 | B1 |
| 6287304 | Eggers et al. | Sep 2001 | B1 |
| 6296619 | Brisken | Oct 2001 | B1 |
| 6301989 | Brown et al. | Oct 2001 | B1 |
| 6307302 | Toda | Oct 2001 | B1 |
| 6309355 | Cain et al. | Oct 2001 | B1 |
| 6311090 | Knowlton | Oct 2001 | B1 |
| 6315741 | Martin | Nov 2001 | B1 |
| 6322509 | Pan et al. | Nov 2001 | B1 |
| 6322532 | D'Sa | Nov 2001 | B1 |
| 6325540 | Lounsberry et al. | Dec 2001 | B1 |
| 6325758 | Carol et al. | Dec 2001 | B1 |
| 6325769 | Klopotek | Dec 2001 | B1 |
| 6325798 | Edwards et al. | Dec 2001 | B1 |
| 6338716 | Hossack et al. | Jan 2002 | B1 |
| 6350276 | Knowlton | Feb 2002 | B1 |
| 6356780 | Licato et al. | Mar 2002 | B1 |
| 6361531 | Hissong | Mar 2002 | B1 |
| 6370411 | Osadchy et al. | Apr 2002 | B1 |
| 6375672 | Aksan | Apr 2002 | B1 |
| 6377854 | Knowlton | Apr 2002 | B1 |
| 6377855 | Knowlton | Apr 2002 | B1 |
| 6381497 | Knowlton | Apr 2002 | B1 |
| 6381498 | Knowlton | Apr 2002 | B1 |
| 6387380 | Knowlton | May 2002 | B1 |
| 6390982 | Bova et al. | May 2002 | B1 |
| 6405090 | Knowlton | Jun 2002 | B1 |
| 6409720 | Hissong | Jun 2002 | B1 |
| 6413216 | Cain et al. | Jul 2002 | B1 |
| 6413253 | Koop | Jul 2002 | B1 |
| 6413254 | Hissong | Jul 2002 | B1 |
| 6419648 | Vitek | Jul 2002 | B1 |
| 6423007 | Lizzi et al. | Jul 2002 | B2 |
| 6425865 | Salcudean | Jul 2002 | B1 |
| 6425867 | Vaezy | Jul 2002 | B1 |
| 6425912 | Knowlton | Jul 2002 | B1 |
| 6428477 | Mason | Aug 2002 | B1 |
| 6428532 | Doukas | Aug 2002 | B1 |
| 6430446 | Knowlton | Aug 2002 | B1 |
| 6432057 | Mazess et al. | Aug 2002 | B1 |
| 6432067 | Martin | Aug 2002 | B1 |
| 6432101 | Weber | Aug 2002 | B1 |
| 6436061 | Costantino | Aug 2002 | B1 |
| 6438424 | Knowlton | Aug 2002 | B1 |
| 6440071 | Slayton | Aug 2002 | B1 |
| 6440121 | Weber | Aug 2002 | B1 |
| 6443914 | Costantino | Sep 2002 | B1 |
| 6447443 | Keogh et al. | Sep 2002 | B1 |
| 6450979 | Miwa et al. | Sep 2002 | B1 |
| 6451013 | Bays et al. | Sep 2002 | B1 |
| 6453202 | Knowlton | Sep 2002 | B1 |
| 6461304 | Tanaka et al. | Oct 2002 | B1 |
| 6461378 | Knowlton | Oct 2002 | B1 |
| 6470216 | Knowlton | Oct 2002 | B1 |
| 6485420 | Bullis | Nov 2002 | B1 |
| 6488626 | Lizzi | Dec 2002 | B1 |
| 6491657 | Rowe | Dec 2002 | B2 |
| 6500121 | Slayton | Dec 2002 | B1 |
| 6500141 | Irion | Dec 2002 | B1 |
| 6506171 | Vitek et al. | Jan 2003 | B1 |
| 6508774 | Acker | Jan 2003 | B1 |
| 6511427 | Sliwa, Jr. et al. | Jan 2003 | B1 |
| 6511428 | Azuma | Jan 2003 | B1 |
| 6514244 | Pope | Feb 2003 | B2 |
| 6517484 | Wilk | Feb 2003 | B1 |
| 6524250 | Weber | Feb 2003 | B1 |
| 6666835 | Martin | Mar 2003 | B2 |
| 6540679 | Slayton | Apr 2003 | B2 |
| 6540685 | Rhoads et al. | Apr 2003 | B1 |
| 6540700 | Fujimoto et al. | Apr 2003 | B1 |
| 6547788 | Maguire et al. | Apr 2003 | B1 |
| 6554771 | Buil et al. | Apr 2003 | B1 |
| 6569099 | Babaev | May 2003 | B1 |
| 6569108 | Sarvazyan et al. | May 2003 | B2 |
| 6572552 | Fukukita | Jun 2003 | B2 |
| 6575956 | Brisken et al. | Jun 2003 | B1 |
| 6595934 | Hissong | Jul 2003 | B1 |
| 6599256 | Acker | Jul 2003 | B1 |
| 6605043 | Dreschel | Aug 2003 | B1 |
| 6605080 | Altshuler et al. | Aug 2003 | B1 |
| 6607498 | Eshel | Aug 2003 | B2 |
| 6618620 | Freundlich et al. | Sep 2003 | B1 |
| 6623430 | Slayton | Sep 2003 | B1 |
| 6626854 | Friedman | Sep 2003 | B2 |
| 6626855 | Weng | Sep 2003 | B1 |
| 6638226 | He et al. | Oct 2003 | B2 |
| 6645145 | Dreschel et al. | Nov 2003 | B1 |
| 6645150 | Angelsen et al. | Nov 2003 | B2 |
| 6645162 | Friedman | Nov 2003 | B2 |
| 6662054 | Kreindel | Dec 2003 | B2 |
| 6663627 | Francischelli | Dec 2003 | B2 |
| 6665806 | Shimizu | Dec 2003 | B1 |
| 6669638 | Miller | Dec 2003 | B1 |
| 6685639 | Wang et al. | Feb 2004 | B1 |
| 6685640 | Fry | Feb 2004 | B1 |
| 6692450 | Coleman | Feb 2004 | B1 |
| 6699237 | Weber | Mar 2004 | B2 |
| 6716184 | Vaezy et al. | Apr 2004 | B2 |
| 6719449 | Laughlin | Apr 2004 | B1 |
| 6719694 | Weng | Apr 2004 | B2 |
| 6726627 | Lizzi et al. | Apr 2004 | B1 |
| 6733449 | Krishnamurthy et al. | May 2004 | B1 |
| 6749624 | Knowlton | Jun 2004 | B2 |
| 6772490 | Toda | Aug 2004 | B2 |
| 6773409 | Truckai et al. | Aug 2004 | B2 |
| 6775404 | Pagoulatos et al. | Aug 2004 | B1 |
| 6790187 | Thompson et al. | Sep 2004 | B2 |
| 6824516 | Batten et al. | Nov 2004 | B2 |
| 6825176 | White et al. | Nov 2004 | B2 |
| 6835940 | Morikawa et al. | Dec 2004 | B2 |
| 6846290 | Lizzi et al. | Jan 2005 | B2 |
| 6875176 | Mourad et al. | Apr 2005 | B2 |
| 6882884 | Mosk et al. | Apr 2005 | B1 |
| 6887239 | Elstrom | May 2005 | B2 |
| 6887260 | McDaniel | May 2005 | B1 |
| 6889089 | Behl | May 2005 | B2 |
| 6896657 | Willis | May 2005 | B2 |
| 6902536 | Manna | Jun 2005 | B2 |
| 6905466 | Salgo | Jun 2005 | B2 |
| 6918907 | Kelly | Jul 2005 | B2 |
| 6920883 | Bessette | Jul 2005 | B2 |
| 6921371 | Wilson | Jul 2005 | B2 |
| 6932771 | Whitmore | Aug 2005 | B2 |
| 6932814 | Wood | Aug 2005 | B2 |
| 6936044 | McDaniel | Aug 2005 | B2 |
| 6936046 | Hissong | Aug 2005 | B2 |
| 6945937 | Culp et al. | Sep 2005 | B2 |
| 6948843 | Laugharn et al. | Sep 2005 | B2 |
| 6953941 | Nakano et al. | Oct 2005 | B2 |
| 6958043 | Hissong | Oct 2005 | B2 |
| 6971994 | Young et al. | Dec 2005 | B1 |
| 6974417 | Lockwood | Dec 2005 | B2 |
| 6976492 | Ingle | Dec 2005 | B2 |
| 6992305 | Maezawa et al. | Jan 2006 | B2 |
| 6997923 | Anderson | Feb 2006 | B2 |
| 7006874 | Knowlton | Feb 2006 | B2 |
| 7020528 | Neev | Mar 2006 | B2 |
| 7022089 | Ooba | Apr 2006 | B2 |
| 7058440 | Heuscher et al. | Jun 2006 | B2 |
| 7063666 | Weng | Jun 2006 | B2 |
| 7070565 | Vaezy et al. | Jul 2006 | B2 |
| 7074218 | Washington et al. | Jul 2006 | B2 |
| 7094252 | Koop | Aug 2006 | B2 |
| 7108663 | Talish et al. | Sep 2006 | B2 |
| 7115123 | Knowlton | Oct 2006 | B2 |
| 7122029 | Koop et al. | Oct 2006 | B2 |
| 7142905 | Slayton | Nov 2006 | B2 |
| 7165451 | Brooks et al. | Jan 2007 | B1 |
| 7179238 | Hissong | Feb 2007 | B2 |
| 7189230 | Knowlton | Mar 2007 | B2 |
| 7229411 | Slayton | Jun 2007 | B2 |
| 7235592 | Muratoglu | Jun 2007 | B2 |
| 7258674 | Cribbs | Aug 2007 | B2 |
| 7273459 | Desilets | Sep 2007 | B2 |
| 7294125 | Phalen et al. | Nov 2007 | B2 |
| 7297117 | Trucco | Nov 2007 | B2 |
| 7303555 | Makin et al. | Dec 2007 | B2 |
| 7311679 | Desilets et al. | Dec 2007 | B2 |
| 7327071 | Nishiyama et al. | Feb 2008 | B2 |
| 7331951 | Eshel et al. | Feb 2008 | B2 |
| 7332985 | Larson et al. | Feb 2008 | B2 |
| 7338434 | Haarstad et al. | Mar 2008 | B1 |
| 7347855 | Eshel | Mar 2008 | B2 |
| RE40403 | Cho et al. | Jun 2008 | E |
| 7393325 | Barthe | Jul 2008 | B2 |
| 7398116 | Edwards | Jul 2008 | B2 |
| 7399279 | Abend et al. | Jul 2008 | B2 |
| 7491171 | Barthe et al. | Feb 2009 | B2 |
| 7507235 | Keogh et al. | Mar 2009 | B2 |
| 7510536 | Foley et al. | Mar 2009 | B2 |
| 7517315 | Willis | Apr 2009 | B2 |
| 7530356 | Slayton | May 2009 | B2 |
| 7530958 | Slayton | May 2009 | B2 |
| 7532201 | Quistgaard et al. | May 2009 | B2 |
| 7571336 | Barthe | Aug 2009 | B2 |
| 7601120 | Moilanen et al. | Oct 2009 | B2 |
| 7615015 | Coleman | Nov 2009 | B2 |
| 7615016 | Barthe | Nov 2009 | B2 |
| 7652411 | Crunkilton et al. | Jan 2010 | B2 |
| 7662114 | Seip et al. | Feb 2010 | B2 |
| 7674257 | Pless et al. | Mar 2010 | B2 |
| 7686763 | Vaezy et al. | Mar 2010 | B2 |
| 7713203 | Lacoste et al. | Mar 2010 | B2 |
| 7694406 | Wildes et al. | Apr 2010 | B2 |
| 7695437 | Quistgaard et al. | Apr 2010 | B2 |
| 7727156 | Angelsen et al. | Jun 2010 | B2 |
| 7758524 | Barthe | Jul 2010 | B2 |
| 7766848 | Desilets et al. | Aug 2010 | B2 |
| 7789841 | Huckle et al. | Sep 2010 | B2 |
| 7806839 | Mast et al. | Oct 2010 | B2 |
| 7815570 | Eshel et al. | Oct 2010 | B2 |
| 7819826 | Diederich et al. | Oct 2010 | B2 |
| 7828734 | Azhari et al. | Oct 2010 | B2 |
| 7824348 | Barthe | Nov 2010 | B2 |
| 7833162 | Hasegawa et al. | Nov 2010 | B2 |
| 7841984 | Cribbs et al. | Nov 2010 | B2 |
| 7846096 | Mast et al. | Dec 2010 | B2 |
| 7857773 | Desilets et al. | Dec 2010 | B2 |
| 7875023 | Eshel et al. | Jan 2011 | B2 |
| 7901359 | Mandrusov et al. | Mar 2011 | B2 |
| 7905007 | Calisti et al. | Mar 2011 | B2 |
| 7905844 | Desilets et al. | Mar 2011 | B2 |
| 7914453 | Slayton et al. | Mar 2011 | B2 |
| 7914469 | Torbati | Mar 2011 | B2 |
| 7955281 | Pedersen et al. | Jun 2011 | B2 |
| 7967764 | Lidgren et al. | Jun 2011 | B2 |
| 7967839 | Flock et al. | Jun 2011 | B2 |
| 7955262 | Rosenberg | Jul 2011 | B2 |
| 7993289 | Quistgaard et al. | Aug 2011 | B2 |
| 8057465 | Sliwa, Jr. et al. | Sep 2011 | B2 |
| 8057389 | Barthe et al. | Nov 2011 | B2 |
| 8066641 | Barthe et al. | Nov 2011 | B2 |
| 8123707 | Huckle et al. | Feb 2012 | B2 |
| 8128618 | Gliklich et al. | Mar 2012 | B2 |
| 8133180 | Slayton et al. | Mar 2012 | B2 |
| 8133191 | Rosenberg et al. | Mar 2012 | B2 |
| 8142200 | Crunkilton et al. | Mar 2012 | B2 |
| 8152904 | Slobodzian et al. | Apr 2012 | B2 |
| 8162858 | Manna et al. | Apr 2012 | B2 |
| 8166332 | Barthe et al. | Apr 2012 | B2 |
| 8182428 | Angelsen et al. | May 2012 | B2 |
| 8197409 | Foley et al. | Jun 2012 | B2 |
| 8206299 | Foley et al. | Jun 2012 | B2 |
| 8208346 | Crunkilton | Jun 2012 | B2 |
| 8211017 | Foley et al. | Jul 2012 | B2 |
| 8262591 | Pedersen et al. | Sep 2012 | B2 |
| 8262650 | Zanelli et al. | Sep 2012 | B2 |
| 8264126 | Toda et al. | Sep 2012 | B2 |
| 8273037 | Kreindel et al. | Sep 2012 | B2 |
| 8282554 | Makin et al. | Oct 2012 | B2 |
| 8292835 | Cimino | Oct 2012 | B1 |
| 8298163 | Cimino | Oct 2012 | B1 |
| 8333700 | Barthe et al. | Dec 2012 | B1 |
| 8334637 | Crunkilton et al. | Dec 2012 | B2 |
| 8337407 | Quistgaard et al. | Dec 2012 | B2 |
| 8343051 | Desilets et al. | Jan 2013 | B2 |
| 8454540 | Eshel et al. | Jan 2013 | B2 |
| 8366622 | Slayton et al. | Feb 2013 | B2 |
| 8398549 | Palmeri et al. | Mar 2013 | B2 |
| 8409097 | Slayton et al. | Apr 2013 | B2 |
| 8425435 | Wing et al. | Apr 2013 | B2 |
| 8388535 | Weng et al. | May 2013 | B2 |
| 8444562 | Barthe et al. | May 2013 | B2 |
| 8460193 | Barthe et al. | Jun 2013 | B2 |
| 8480585 | Slayton et al. | Jul 2013 | B2 |
| 8486001 | Weyant | Jul 2013 | B2 |
| 8506486 | Slayton et al. | Aug 2013 | B2 |
| 8512250 | Quistgaard et al. | Aug 2013 | B2 |
| 8523775 | Barthe et al. | Sep 2013 | B2 |
| 8523849 | Liu et al. | Sep 2013 | B2 |
| 8535228 | Slayton et al. | Sep 2013 | B2 |
| 8570837 | Toda et al. | Oct 2013 | B2 |
| 8573392 | Bennett et al. | Nov 2013 | B2 |
| 8583211 | Salomir et al. | Nov 2013 | B2 |
| 8585618 | Hunziker et al. | Nov 2013 | B2 |
| 8604672 | Toda et al. | Dec 2013 | B2 |
| 8622937 | Weng et al. | Jan 2014 | B2 |
| 8636665 | Slayton et al. | Jan 2014 | B2 |
| 8641622 | Barthe et al. | Feb 2014 | B2 |
| 8663112 | Slayton et al. | Mar 2014 | B2 |
| 8672848 | Slayton et al. | Mar 2014 | B2 |
| 8690778 | Slayton et al. | Apr 2014 | B2 |
| 8690779 | Slayton et al. | Apr 2014 | B2 |
| 8690780 | Slayton et al. | Apr 2014 | B2 |
| 8708935 | Barthe et al. | Apr 2014 | B2 |
| 8715186 | Slayton et al. | May 2014 | B2 |
| 8726781 | Eckhoff et al. | May 2014 | B2 |
| 8728071 | Lischinsky et al. | May 2014 | B2 |
| 8753295 | Thierman | Jun 2014 | B2 |
| 8758253 | Sano et al. | Jun 2014 | B2 |
| 8836203 | Nobles et al. | Sep 2014 | B2 |
| 8857438 | Barthe et al. | Oct 2014 | B2 |
| 8858471 | Barthe et al. | Oct 2014 | B2 |
| 8915853 | Barthe et al. | Dec 2014 | B2 |
| 8915854 | Slayton et al. | Dec 2014 | B2 |
| 8915870 | Barthe et al. | Dec 2014 | B2 |
| 8920320 | Stecco et al. | Dec 2014 | B2 |
| 8920324 | Slayton et al. | Dec 2014 | B2 |
| 8926533 | Bockenstedt et al. | Jan 2015 | B2 |
| 8932224 | Barthe et al. | Jan 2015 | B2 |
| 8932238 | Wing et al. | Jan 2015 | B2 |
| 8968205 | Zeng et al. | Mar 2015 | B2 |
| 9011336 | Slayton et al. | Apr 2015 | B2 |
| 9039617 | Slayton et al. | May 2015 | B2 |
| 9039619 | Barthe et al. | May 2015 | B2 |
| 9050116 | Homer | Jun 2015 | B2 |
| 9095697 | Barthe et al. | Aug 2015 | B2 |
| 9107798 | Azhari et al. | Aug 2015 | B2 |
| 9114247 | Barthe et al. | Aug 2015 | B2 |
| 9180314 | Desilets et al. | Nov 2015 | B2 |
| 9216276 | Slayton et al. | Dec 2015 | B2 |
| 9220915 | Liu et al. | Dec 2015 | B2 |
| 9272162 | Slayton et al. | Mar 2016 | B2 |
| 9283409 | Slayton et al. | Mar 2016 | B2 |
| 9283410 | Slayton et al. | Mar 2016 | B2 |
| 9295607 | Rosenberg | Mar 2016 | B2 |
| 9308390 | Youngquist | Apr 2016 | B2 |
| 9308391 | Liu et al. | Apr 2016 | B2 |
| 9314650 | Rosenberg et al. | Apr 2016 | B2 |
| 9320537 | Slayton et al. | Apr 2016 | B2 |
| 9345910 | Slayton et al. | May 2016 | B2 |
| 9421029 | Barthe et al. | Aug 2016 | B2 |
| 9427600 | Barthe et al. | Aug 2016 | B2 |
| 9427601 | Barthe et al. | Aug 2016 | B2 |
| 9433803 | Lin et al. | Sep 2016 | B2 |
| 9440093 | Homer | Sep 2016 | B2 |
| 9440096 | Barthe et al. | Sep 2016 | B2 |
| 9492645 | Zhou et al. | Nov 2016 | B2 |
| 9492686 | Da Silva | Nov 2016 | B2 |
| 9498651 | Sapozhnikov et al. | Nov 2016 | B2 |
| 9510802 | Barthe et al. | Dec 2016 | B2 |
| 9522290 | Slayton et al. | Dec 2016 | B2 |
| 9532832 | Ron Edoute et al. | Jan 2017 | B2 |
| 9533174 | Barthe et al. | Jan 2017 | B2 |
| 9533175 | Slayton et al. | Jan 2017 | B2 |
| 9545529 | Britva et al. | Jan 2017 | B2 |
| 9566454 | Barthe et al. | Feb 2017 | B2 |
| 9623267 | Ulric et al. | Apr 2017 | B2 |
| 9694211 | Barthe et al. | Jul 2017 | B2 |
| 9694212 | Barthe et al. | Jul 2017 | B2 |
| 9700340 | Barthe et al. | Jul 2017 | B2 |
| 9707412 | Slayton et al. | Jul 2017 | B2 |
| 9710607 | Ramdas et al. | Jul 2017 | B2 |
| 9713731 | Slayton et al. | Jul 2017 | B2 |
| 9802063 | Barthe et al. | Oct 2017 | B2 |
| 9827449 | Barthe et al. | Nov 2017 | B2 |
| 9827450 | Slayton et al. | Nov 2017 | B2 |
| 9833639 | Slayton et al. | Dec 2017 | B2 |
| 9833640 | Barthe et al. | Dec 2017 | B2 |
| 9895560 | Barthe et al. | Feb 2018 | B2 |
| 9907535 | Barthe et al. | Mar 2018 | B2 |
| 9919167 | Domankevitz | Mar 2018 | B2 |
| 9974982 | Slayton et al. | May 2018 | B2 |
| 9993664 | Aviad et al. | Jun 2018 | B2 |
| 10010721 | Slayton et al. | Jul 2018 | B2 |
| 10010724 | Barthe et al. | Jul 2018 | B2 |
| 10010725 | Slayton et al. | Jul 2018 | B2 |
| 10010726 | Barthe et al. | Jul 2018 | B2 |
| 10016626 | Zovrin et al. | Jul 2018 | B2 |
| 10046181 | Barthe et al. | Aug 2018 | B2 |
| 10046182 | Barthe et al. | Aug 2018 | B2 |
| 10070883 | Barthe et al. | Sep 2018 | B2 |
| 10183183 | Burdette | Jan 2019 | B2 |
| 10226645 | Barthe | Mar 2019 | B2 |
| 10238894 | Slayton et al. | Mar 2019 | B2 |
| 10245450 | Slayton et al. | Apr 2019 | B2 |
| 10252086 | Barthe et al. | Apr 2019 | B2 |
| 10265550 | Barthe et al. | Apr 2019 | B2 |
| 10272272 | Lee et al. | Apr 2019 | B2 |
| 10300308 | Seip et al. | May 2019 | B2 |
| 10328289 | Barthe et al. | Jun 2019 | B2 |
| 10406383 | Luebcke | Sep 2019 | B2 |
| 10420960 | Emery | Sep 2019 | B2 |
| 10420961 | Lacoste | Sep 2019 | B2 |
| 10485573 | Clark, III et al. | Nov 2019 | B2 |
| 10492862 | Domankevitz | Dec 2019 | B2 |
| 10525288 | Slayton et al. | Jan 2020 | B2 |
| 10532230 | Barthe et al. | Jan 2020 | B2 |
| 10537304 | Barthe et al. | Jan 2020 | B2 |
| 10556123 | Altshuler et al. | Feb 2020 | B2 |
| 10583287 | Schwarz | Mar 2020 | B2 |
| 10603519 | Slayton et al. | Mar 2020 | B2 |
| 10603523 | Slayton et al. | Mar 2020 | B2 |
| 10610705 | Barthe et al. | Apr 2020 | B2 |
| 10610706 | Barthe et al. | Apr 2020 | B2 |
| 10639006 | Choi et al. | May 2020 | B2 |
| 10639504 | Kim | May 2020 | B2 |
| 10751246 | Kaila | Aug 2020 | B2 |
| 10772646 | Lu et al. | Sep 2020 | B2 |
| 10780298 | Cain et al. | Sep 2020 | B2 |
| 10888716 | Slayton et al. | Jan 2021 | B2 |
| 10888717 | Slayton et al. | Jan 2021 | B2 |
| 10888718 | Barthe et al. | Jan 2021 | B2 |
| 10960236 | Slayton et al. | Mar 2021 | B2 |
| 20010009997 | Pope | Jul 2001 | A1 |
| 20010009999 | Kaufman et al. | Jul 2001 | A1 |
| 20010014780 | Martin | Aug 2001 | A1 |
| 20010014819 | Ingle | Aug 2001 | A1 |
| 20010031922 | Weng | Oct 2001 | A1 |
| 20010039380 | Larson et al. | Nov 2001 | A1 |
| 20010041880 | Brisken | Nov 2001 | A1 |
| 20020000763 | Jones | Jan 2002 | A1 |
| 20020002345 | Marlinghaus | Jan 2002 | A1 |
| 20020040199 | Klopotek | Apr 2002 | A1 |
| 20020040442 | Ishidera | Apr 2002 | A1 |
| 20020055702 | Atala | May 2002 | A1 |
| 20020062077 | Emmenegger | May 2002 | A1 |
| 20020062142 | Knowlton | May 2002 | A1 |
| 20020072691 | Thompson et al. | Jun 2002 | A1 |
| 20020082528 | Friedman | Jun 2002 | A1 |
| 20020082529 | Suorsa et al. | Jun 2002 | A1 |
| 20020082589 | Friedman | Jun 2002 | A1 |
| 20020087080 | Slayton | Jul 2002 | A1 |
| 20020095143 | Key | Jul 2002 | A1 |
| 20020099094 | Anderson | Jul 2002 | A1 |
| 20020111569 | Rosenschien et al. | Aug 2002 | A1 |
| 20020115917 | Honda et al. | Aug 2002 | A1 |
| 20020128639 | Pless et al. | Aug 2002 | A1 |
| 20020128648 | Weber | Sep 2002 | A1 |
| 20020143252 | Dunne et al. | Oct 2002 | A1 |
| 20020156400 | Babaev | Oct 2002 | A1 |
| 20020161357 | Anderson | Oct 2002 | A1 |
| 20020165529 | Danek | Nov 2002 | A1 |
| 20020168049 | Schriever | Nov 2002 | A1 |
| 20020169394 | Eppstein et al. | Nov 2002 | A1 |
| 20020169442 | Neev | Nov 2002 | A1 |
| 20020173721 | Grunwald et al. | Nov 2002 | A1 |
| 20020193784 | McHale et al. | Dec 2002 | A1 |
| 20020193831 | Smith | Dec 2002 | A1 |
| 20030009153 | Brisken et al. | Jan 2003 | A1 |
| 20030014039 | Barzell et al. | Jan 2003 | A1 |
| 20030018255 | Martin | Jan 2003 | A1 |
| 20030018270 | Makin et al. | Jan 2003 | A1 |
| 20030023283 | McDaniel | Jan 2003 | A1 |
| 20030028111 | Vaezy et al. | Feb 2003 | A1 |
| 20030028113 | Gilbert et al. | Feb 2003 | A1 |
| 20030032900 | Ella | Feb 2003 | A1 |
| 20030036706 | Slayton et al. | Feb 2003 | A1 |
| 20030040739 | Koop | Feb 2003 | A1 |
| 20030050678 | Sierra | Mar 2003 | A1 |
| 20030055308 | Friemel et al. | Mar 2003 | A1 |
| 20030055417 | Truckai et al. | Mar 2003 | A1 |
| 20030060736 | Martin et al. | Mar 2003 | A1 |
| 20030065313 | Koop | Apr 2003 | A1 |
| 20030066708 | Allison et al. | Apr 2003 | A1 |
| 20030073907 | Taylor | Apr 2003 | A1 |
| 20030074023 | Kaplan | Apr 2003 | A1 |
| 20030083536 | Eshel | May 2003 | A1 |
| 20030092988 | Makin | May 2003 | A1 |
| 20030097071 | Halmann et al. | May 2003 | A1 |
| 20030099383 | Lefebvre | May 2003 | A1 |
| 20030125629 | Ustuner | Jul 2003 | A1 |
| 20030135135 | Miwa et al. | Jul 2003 | A1 |
| 20030139790 | Ingle et al. | Jul 2003 | A1 |
| 20030149366 | Stringer et al. | Aug 2003 | A1 |
| 20030153961 | Babaev | Aug 2003 | A1 |
| 20030171678 | Batten et al. | Sep 2003 | A1 |
| 20030171701 | Babaev | Sep 2003 | A1 |
| 20030176790 | Slayton | Sep 2003 | A1 |
| 20030191396 | Sanghvi | Oct 2003 | A1 |
| 20030199794 | Sakurai et al. | Oct 2003 | A1 |
| 20030200481 | Stanley | Oct 2003 | A1 |
| 20030212129 | Liu et al. | Nov 2003 | A1 |
| 20030212351 | Hissong | Nov 2003 | A1 |
| 20030212393 | Knowlton | Nov 2003 | A1 |
| 20030216648 | Lizzi et al. | Nov 2003 | A1 |
| 20030216795 | Harth | Nov 2003 | A1 |
| 20030220536 | Hissong | Nov 2003 | A1 |
| 20030220585 | Hissong | Nov 2003 | A1 |
| 20030229331 | Brisken et al. | Dec 2003 | A1 |
| 20030233085 | Giammarusti | Dec 2003 | A1 |
| 20030236487 | Knowlton | Dec 2003 | A1 |
| 20040000316 | Knowlton | Jan 2004 | A1 |
| 20040001809 | Brisken | Jan 2004 | A1 |
| 20040002658 | Marian, Jr. | Jan 2004 | A1 |
| 20040002705 | Knowlton | Jan 2004 | A1 |
| 20040010222 | Nunomura et al. | Jan 2004 | A1 |
| 20040015079 | Berger et al. | Jan 2004 | A1 |
| 20040015106 | Coleman | Jan 2004 | A1 |
| 20040030227 | Littrup | Feb 2004 | A1 |
| 20040030268 | Weng et al. | Feb 2004 | A1 |
| 20040039312 | Hillstead | Feb 2004 | A1 |
| 20040039418 | Elstrom | Feb 2004 | A1 |
| 20040041563 | Lewin et al. | Mar 2004 | A1 |
| 20040041880 | Ikeda et al. | Mar 2004 | A1 |
| 20040042168 | Yang et al. | Mar 2004 | A1 |
| 20040044375 | Diederich et al. | Mar 2004 | A1 |
| 20040049134 | Tosaya et al. | Mar 2004 | A1 |
| 20040049734 | Tosaya et al. | Mar 2004 | A1 |
| 20040059266 | Fry | Mar 2004 | A1 |
| 20040068186 | Ishida et al. | Apr 2004 | A1 |
| 20040073079 | Altshuler et al. | Apr 2004 | A1 |
| 20040073113 | Salgo | Apr 2004 | A1 |
| 20040073115 | Horzewski et al. | Apr 2004 | A1 |
| 20040073116 | Smith | Apr 2004 | A1 |
| 20040073204 | Ryan et al. | Apr 2004 | A1 |
| 20040077977 | Ella et al. | Apr 2004 | A1 |
| 20040082857 | Schonenberger | Apr 2004 | A1 |
| 20040082859 | Schaer | Apr 2004 | A1 |
| 20040102697 | Evron | May 2004 | A1 |
| 20040105559 | Aylward et al. | Jun 2004 | A1 |
| 20040106867 | Eshel et al. | Jun 2004 | A1 |
| 20040122323 | Vortman et al. | Jun 2004 | A1 |
| 20040122493 | Ishibashi et al. | Jun 2004 | A1 |
| 20040143297 | Ramsey | Jul 2004 | A1 |
| 20040152982 | Hwang et al. | Aug 2004 | A1 |
| 20040158150 | Rabiner et al. | Aug 2004 | A1 |
| 20040186535 | Knowlton | Sep 2004 | A1 |
| 20040189155 | Funakubo | Sep 2004 | A1 |
| 20040206365 | Knowlton | Oct 2004 | A1 |
| 20040210214 | Knowlton | Oct 2004 | A1 |
| 20040217675 | Desilets | Nov 2004 | A1 |
| 20040249318 | Tanaka | Dec 2004 | A1 |
| 20040254620 | Lacoste | Dec 2004 | A1 |
| 20040267252 | Washington et al. | Dec 2004 | A1 |
| 20050007879 | Nishida | Jan 2005 | A1 |
| 20050033201 | Takahashi | Feb 2005 | A1 |
| 20050033316 | Kertz | Feb 2005 | A1 |
| 20050038340 | Vaezy et al. | Feb 2005 | A1 |
| 20050055018 | Kreindel | Mar 2005 | A1 |
| 20050055073 | Weber | Mar 2005 | A1 |
| 20050061834 | Garcia et al. | Mar 2005 | A1 |
| 20050070961 | Maki | Mar 2005 | A1 |
| 20050074407 | Smith | Apr 2005 | A1 |
| 20050080469 | Larson | Apr 2005 | A1 |
| 20050085731 | Miller et al. | Apr 2005 | A1 |
| 20050091770 | Mourad et al. | May 2005 | A1 |
| 20050096542 | Weng et al. | May 2005 | A1 |
| 20050104690 | Larson et al. | May 2005 | A1 |
| 20050113689 | Gritzky | May 2005 | A1 |
| 20050131302 | Poland | Jun 2005 | A1 |
| 20050137656 | Malak | Jun 2005 | A1 |
| 20050143677 | Young et al. | Jun 2005 | A1 |
| 20050154313 | Desilets | Jul 2005 | A1 |
| 20050154314 | Quistgaard | Jul 2005 | A1 |
| 20050154332 | Zanelli | Jul 2005 | A1 |
| 20050154431 | Quistgaard | Jul 2005 | A1 |
| 20050187495 | Quistgaard | Aug 2005 | A1 |
| 20050191252 | Mitsui | Sep 2005 | A1 |
| 20050193451 | Quistgaard | Sep 2005 | A1 |
| 20050193820 | Sheljaskow et al. | Sep 2005 | A1 |
| 20050197681 | Barolet et al. | Sep 2005 | A1 |
| 20050203399 | Vaezy | Sep 2005 | A1 |
| 20050228281 | Nefos | Oct 2005 | A1 |
| 20050240127 | Seip et al. | Oct 2005 | A1 |
| 20050240170 | Zhang et al. | Oct 2005 | A1 |
| 20050251120 | Anderson et al. | Nov 2005 | A1 |
| 20050251125 | Pless et al. | Nov 2005 | A1 |
| 20050256406 | Barthe | Nov 2005 | A1 |
| 20050261584 | Eshel | Nov 2005 | A1 |
| 20050261585 | Makin et al. | Nov 2005 | A1 |
| 20050267454 | Hissong | Dec 2005 | A1 |
| 20050288748 | Li et al. | Dec 2005 | A1 |
| 20060004306 | Altshuler | Jan 2006 | A1 |
| 20060020260 | Dover et al. | Jan 2006 | A1 |
| 20060025756 | Francischelli | Feb 2006 | A1 |
| 20060042201 | Curry | Mar 2006 | A1 |
| 20060058664 | Barthe | Mar 2006 | A1 |
| 20060058671 | Vitek et al. | Mar 2006 | A1 |
| 20060058707 | Barthe | Mar 2006 | A1 |
| 20060058712 | Altshuler et al. | Mar 2006 | A1 |
| 20060074309 | Bonnefous | Apr 2006 | A1 |
| 20060074313 | Slayton et al. | Apr 2006 | A1 |
| 20060074314 | Slayton | Apr 2006 | A1 |
| 20060074355 | Slayton | Apr 2006 | A1 |
| 20060079816 | Barthe | Apr 2006 | A1 |
| 20060079868 | Makin | Apr 2006 | A1 |
| 20060084891 | Barthe | Apr 2006 | A1 |
| 20060089632 | Barthe | Apr 2006 | A1 |
| 20060089688 | Panescu | Apr 2006 | A1 |
| 20060094988 | Tosaya | May 2006 | A1 |
| 20060106325 | Perrier | May 2006 | A1 |
| 20060111744 | Makin | May 2006 | A1 |
| 20060116583 | Ogasawara et al. | Jun 2006 | A1 |
| 20060116671 | Slayton | Jun 2006 | A1 |
| 20060122508 | Slayton | Jun 2006 | A1 |
| 20060122509 | Desilets | Jun 2006 | A1 |
| 20060161062 | Arditi et al. | Jul 2006 | A1 |
| 20060184069 | Vaitekunas | Aug 2006 | A1 |
| 20060184071 | Klopotek | Aug 2006 | A1 |
| 20060189972 | Grossman | Aug 2006 | A1 |
| 20060206105 | Chopra | Sep 2006 | A1 |
| 20060224090 | Ostrovsky et al. | Oct 2006 | A1 |
| 20060229514 | Wiener | Oct 2006 | A1 |
| 20060238068 | May et al. | Oct 2006 | A1 |
| 20060241440 | Eshel | Oct 2006 | A1 |
| 20060241442 | Barthe | Oct 2006 | A1 |
| 20060241470 | Novak et al. | Oct 2006 | A1 |
| 20060241576 | Diederich et al. | Oct 2006 | A1 |
| 20060250046 | Koizumi et al. | Nov 2006 | A1 |
| 20060282691 | Barthe | Dec 2006 | A1 |
| 20060291710 | Wang et al. | Dec 2006 | A1 |
| 20070016039 | Vortman et al. | Jan 2007 | A1 |
| 20070032784 | Gilklich et al. | Feb 2007 | A1 |
| 20070035201 | Desilets | Feb 2007 | A1 |
| 20070055154 | Torbati | Mar 2007 | A1 |
| 20070055155 | Owen et al. | Mar 2007 | A1 |
| 20070055156 | Desilets et al. | Mar 2007 | A1 |
| 20070065420 | Johnson | Mar 2007 | A1 |
| 20070083120 | Cain et al. | Apr 2007 | A1 |
| 20070087060 | Dietrich | Apr 2007 | A1 |
| 20070088245 | Babaev et al. | Apr 2007 | A1 |
| 20070088346 | Mirizzi et al. | Apr 2007 | A1 |
| 20070161902 | Dan | Jul 2007 | A1 |
| 20070166357 | Shaffer et al. | Jul 2007 | A1 |
| 20070167709 | Slayton | Jul 2007 | A1 |
| 20070018553 | Kennedy | Aug 2007 | A1 |
| 20070208253 | Slayton | Sep 2007 | A1 |
| 20070219448 | Seip | Sep 2007 | A1 |
| 20070219604 | Yaroslavsky et al. | Sep 2007 | A1 |
| 20070219605 | Yaroslavsky et al. | Sep 2007 | A1 |
| 20070238994 | Stecco et al. | Oct 2007 | A1 |
| 20070239075 | Rosenberg | Oct 2007 | A1 |
| 20070239077 | Azhari et al. | Oct 2007 | A1 |
| 20070239079 | Manstein et al. | Oct 2007 | A1 |
| 20070239142 | Altshuler | Oct 2007 | A1 |
| 20080015435 | Cribbs et al. | Jan 2008 | A1 |
| 20080027328 | Klopotek | Jan 2008 | A1 |
| 20080033458 | McLean et al. | Feb 2008 | A1 |
| 20080039724 | Seip et al. | Feb 2008 | A1 |
| 20080071255 | Barthe | Mar 2008 | A1 |
| 20080086054 | Slayton | Apr 2008 | A1 |
| 20080086056 | Chang et al. | Apr 2008 | A1 |
| 20080097214 | Meyers et al. | Apr 2008 | A1 |
| 20080097253 | Pedersen et al. | Apr 2008 | A1 |
| 20080114251 | Weymer | May 2008 | A1 |
| 20080139943 | Deng et al. | Jun 2008 | A1 |
| 20080139974 | Da Silva | Jun 2008 | A1 |
| 20080146970 | Litman et al. | Jun 2008 | A1 |
| 20080167556 | Thompson | Jul 2008 | A1 |
| 20080183077 | Moreau-Gobard et al. | Jul 2008 | A1 |
| 20080183110 | Davenport et al. | Jul 2008 | A1 |
| 20080188745 | Chen et al. | Aug 2008 | A1 |
| 20080194964 | Randall et al. | Aug 2008 | A1 |
| 20080195000 | Spooner et al. | Aug 2008 | A1 |
| 20080200810 | Buchalter | Aug 2008 | A1 |
| 20080200813 | Quistgaard | Aug 2008 | A1 |
| 20080214966 | Slayton | Sep 2008 | A1 |
| 20080214988 | Altshuler et al. | Sep 2008 | A1 |
| 20080221491 | Slayton | Sep 2008 | A1 |
| 20080223379 | Stuker et al. | Sep 2008 | A1 |
| 20080242991 | Moon et al. | Oct 2008 | A1 |
| 20080243035 | Crunkilton | Oct 2008 | A1 |
| 20080269608 | Anderson et al. | Oct 2008 | A1 |
| 20080275342 | Barthe | Nov 2008 | A1 |
| 20080281206 | Bartlett et al. | Nov 2008 | A1 |
| 20080281236 | Eshel et al. | Nov 2008 | A1 |
| 20080281237 | Slayton | Nov 2008 | A1 |
| 20080281255 | Slayton | Nov 2008 | A1 |
| 20080294072 | Crutchfield, III | Nov 2008 | A1 |
| 20080294073 | Barthe | Nov 2008 | A1 |
| 20080319356 | Cain | Dec 2008 | A1 |
| 20090005680 | Jones et al. | Jan 2009 | A1 |
| 20090012394 | Hobelsberger et al. | Jan 2009 | A1 |
| 20090043198 | Milner et al. | Feb 2009 | A1 |
| 20090043293 | Pankratov et al. | Feb 2009 | A1 |
| 20090048514 | Azhari et al. | Feb 2009 | A1 |
| 20090069677 | Chen et al. | Mar 2009 | A1 |
| 20090093737 | Chomas et al. | Apr 2009 | A1 |
| 20090156969 | Santangelo | Jun 2009 | A1 |
| 20090163807 | Sliwa | Jun 2009 | A1 |
| 20090171252 | Bockenstedt et al. | Jul 2009 | A1 |
| 20090171266 | Harris | Jul 2009 | A1 |
| 20090177122 | Peterson | Jul 2009 | A1 |
| 20090177123 | Peterson | Jul 2009 | A1 |
| 20090182231 | Barthe et al. | Jul 2009 | A1 |
| 20090198157 | Babaev et al. | Aug 2009 | A1 |
| 20090216159 | Slayton et al. | Aug 2009 | A1 |
| 20090226424 | Hsu | Sep 2009 | A1 |
| 20090227910 | Pedersen et al. | Sep 2009 | A1 |
| 20090230823 | Kushculey et al. | Sep 2009 | A1 |
| 20090253988 | Slayton et al. | Oct 2009 | A1 |
| 20090281463 | Chapelon et al. | Nov 2009 | A1 |
| 20090312693 | Thapliyal et al. | Dec 2009 | A1 |
| 20090318909 | Debenedictis et al. | Dec 2009 | A1 |
| 20090326420 | Moonen et al. | Dec 2009 | A1 |
| 20100011236 | Barthe et al. | Jan 2010 | A1 |
| 20100022919 | Peterson | Jan 2010 | A1 |
| 20100022921 | Seip et al. | Jan 2010 | A1 |
| 20100022922 | Barthe et al. | Jan 2010 | A1 |
| 20100030076 | Vortman et al. | Feb 2010 | A1 |
| 20100042020 | Ben-Ezra | Feb 2010 | A1 |
| 20100049178 | Deem et al. | Feb 2010 | A1 |
| 20100056925 | Zhang et al. | Mar 2010 | A1 |
| 20100056962 | Vortman et al. | Mar 2010 | A1 |
| 20100100014 | Eshel et al. | Apr 2010 | A1 |
| 20100113983 | Heckerman et al. | May 2010 | A1 |
| 20100130891 | Taggart et al. | May 2010 | A1 |
| 20100160782 | Slayton et al. | Jun 2010 | A1 |
| 20100160837 | Hunziker et al. | Jun 2010 | A1 |
| 20100168576 | Poland et al. | Jul 2010 | A1 |
| 20100191120 | Kraus et al. | Jul 2010 | A1 |
| 20100241035 | Barthe et al. | Sep 2010 | A1 |
| 20100249602 | Buckley et al. | Sep 2010 | A1 |
| 20100249669 | Ulric et al. | Sep 2010 | A1 |
| 20100256489 | Pedersen et al. | Oct 2010 | A1 |
| 20100274161 | Azhari et al. | Oct 2010 | A1 |
| 20100280420 | Barthe et al. | Nov 2010 | A1 |
| 20100286518 | Lee et al. | Nov 2010 | A1 |
| 20100312150 | Douglas et al. | Dec 2010 | A1 |
| 20110040171 | Foley et al. | Feb 2011 | A1 |
| 20110040190 | Jahnke et al. | Feb 2011 | A1 |
| 20110040213 | Dietz et al. | Feb 2011 | A1 |
| 20110040214 | Foley et al. | Feb 2011 | A1 |
| 20110066084 | Desilets et al. | Mar 2011 | A1 |
| 20110072970 | Slobodzian et al. | Mar 2011 | A1 |
| 20110077514 | Ulric et al. | Mar 2011 | A1 |
| 20110079083 | Yoo | Apr 2011 | A1 |
| 20110087099 | Eshel et al. | Apr 2011 | A1 |
| 20110087255 | McCormack et al. | Apr 2011 | A1 |
| 20110112405 | Barthe et al. | May 2011 | A1 |
| 20110144490 | Davis et al. | Jun 2011 | A1 |
| 20110178444 | Slayton et al. | Jul 2011 | A1 |
| 20110178541 | Azhari | Jul 2011 | A1 |
| 20110190745 | Uebelhoer et al. | Aug 2011 | A1 |
| 20110201976 | Sanghvi et al. | Aug 2011 | A1 |
| 20110251524 | Azhari et al. | Oct 2011 | A1 |
| 20110251527 | Kushculey et al. | Oct 2011 | A1 |
| 20110270137 | Goren et al. | Nov 2011 | A1 |
| 20110319793 | Henrik et al. | Dec 2011 | A1 |
| 20110319794 | Gertner | Dec 2011 | A1 |
| 20120004549 | Barthe et al. | Jan 2012 | A1 |
| 20120016239 | Barthe et al. | Jan 2012 | A1 |
| 20120029353 | Slayton et al. | Feb 2012 | A1 |
| 20120035473 | Sanghvi et al. | Feb 2012 | A1 |
| 20120035475 | Barthe et al. | Feb 2012 | A1 |
| 20120035476 | Barthe et al. | Feb 2012 | A1 |
| 20120046547 | Barthe et al. | Feb 2012 | A1 |
| 20120053458 | Barthe et al. | Mar 2012 | A1 |
| 20120059288 | Barthe et al. | Mar 2012 | A1 |
| 20120111339 | Barthe et al. | May 2012 | A1 |
| 20120123304 | Rybyanets et al. | May 2012 | A1 |
| 20120136280 | Rosenberg et al. | May 2012 | A1 |
| 20120136282 | Rosenberg et al. | May 2012 | A1 |
| 20120143056 | Slayton et al. | Jun 2012 | A1 |
| 20120143100 | Jeong et al. | Jun 2012 | A1 |
| 20120165668 | Slayton et al. | Jun 2012 | A1 |
| 20120165848 | Slayton et al. | Jun 2012 | A1 |
| 20120191019 | Desilets et al. | Jul 2012 | A1 |
| 20120191020 | Vitek et al. | Jul 2012 | A1 |
| 20120197120 | Makin et al. | Aug 2012 | A1 |
| 20120197121 | Slayton et al. | Aug 2012 | A1 |
| 20120209150 | Zeng et al. | Aug 2012 | A1 |
| 20120215105 | Slayton et al. | Aug 2012 | A1 |
| 20120271202 | Wisdom | Oct 2012 | A1 |
| 20120271294 | Barthe | Oct 2012 | A1 |
| 20120277639 | Pollock et al. | Nov 2012 | A1 |
| 20120296240 | Azhari et al. | Nov 2012 | A1 |
| 20120302883 | Kong et al. | Nov 2012 | A1 |
| 20120316426 | Foley et al. | Dec 2012 | A1 |
| 20120330197 | Makin et al. | Dec 2012 | A1 |
| 20120330222 | Makin et al. | Dec 2012 | A1 |
| 20120330223 | Makin et al. | Dec 2012 | A1 |
| 20120330283 | Hyde et al. | Dec 2012 | A1 |
| 20120330284 | Hyde et al. | Dec 2012 | A1 |
| 20130012755 | Slayton | Jan 2013 | A1 |
| 20130012816 | Slayton et al. | Jan 2013 | A1 |
| 20130012838 | Jaeger et al. | Jan 2013 | A1 |
| 20130012842 | Barthe | Jan 2013 | A1 |
| 20130018285 | Park et al. | Jan 2013 | A1 |
| 20130018286 | Slayton et al. | Jan 2013 | A1 |
| 20130046209 | Slayton et al. | Feb 2013 | A1 |
| 20130051178 | Rybyanets | Feb 2013 | A1 |
| 20130060170 | Lee et al. | Mar 2013 | A1 |
| 20130066208 | Barthe et al. | Mar 2013 | A1 |
| 20130066237 | Smotrich et al. | Mar 2013 | A1 |
| 20130072826 | Slayton et al. | Mar 2013 | A1 |
| 20130073001 | Campbell | Mar 2013 | A1 |
| 20130096471 | Slayton et al. | Apr 2013 | A1 |
| 20130096596 | Schafer | Apr 2013 | A1 |
| 20130190659 | Slayton et al. | Jul 2013 | A1 |
| 20130211293 | Auboiroux et al. | Aug 2013 | A1 |
| 20130225994 | Hsu et al. | Aug 2013 | A1 |
| 20130268032 | Neev | Oct 2013 | A1 |
| 20130274603 | Barthe et al. | Oct 2013 | A1 |
| 20130278111 | Sammoura | Oct 2013 | A1 |
| 20130281853 | Slayton et al. | Oct 2013 | A1 |
| 20130281891 | Slayton et al. | Oct 2013 | A1 |
| 20130296697 | Slayton et al. | Nov 2013 | A1 |
| 20130296700 | Slayton et al. | Nov 2013 | A1 |
| 20130296743 | Lee et al. | Nov 2013 | A1 |
| 20130303904 | Barthe et al. | Nov 2013 | A1 |
| 20130303905 | Barthe et al. | Nov 2013 | A1 |
| 20130310714 | Eshel et al. | Nov 2013 | A1 |
| 20130310863 | Makin et al. | Nov 2013 | A1 |
| 20130345562 | Barthe et al. | Dec 2013 | A1 |
| 20140024974 | Slayton et al. | Jan 2014 | A1 |
| 20140050054 | Toda et al. | Feb 2014 | A1 |
| 20140081300 | Melodelima et al. | Mar 2014 | A1 |
| 20140082907 | Barthe et al. | Mar 2014 | A1 |
| 20140117814 | Toda et al. | May 2014 | A1 |
| 20140142430 | Slayton et al. | May 2014 | A1 |
| 20140148834 | Barthe et al. | May 2014 | A1 |
| 20140155747 | Bennett | Jun 2014 | A1 |
| 20140180174 | Slayton et al. | Jun 2014 | A1 |
| 20140187944 | Slayton et al. | Jul 2014 | A1 |
| 20140188015 | Slayton et al. | Jul 2014 | A1 |
| 20140188145 | Slayton et al. | Jul 2014 | A1 |
| 20140194723 | Herzog et al. | Jul 2014 | A1 |
| 20140208856 | Schmid | Jul 2014 | A1 |
| 20140221823 | Keogh et al. | Aug 2014 | A1 |
| 20140236049 | Barthe et al. | Aug 2014 | A1 |
| 20140236061 | Lee et al. | Aug 2014 | A1 |
| 20140243713 | Slayton et al. | Aug 2014 | A1 |
| 20140257145 | Emery | Sep 2014 | A1 |
| 20140276055 | Barthe et al. | Sep 2014 | A1 |
| 20140330124 | Carol | Nov 2014 | A1 |
| 20150000674 | Barthe et al. | Jan 2015 | A1 |
| 20150025420 | Slayton et al. | Jan 2015 | A1 |
| 20150064165 | Perry et al. | Mar 2015 | A1 |
| 20150080723 | Barthe et al. | Mar 2015 | A1 |
| 20150080771 | Barthe et al. | Mar 2015 | A1 |
| 20150080874 | Slayton et al. | Mar 2015 | A1 |
| 20150088182 | Slayton et al. | Mar 2015 | A1 |
| 20150141734 | Chapelon et al. | May 2015 | A1 |
| 20150164734 | Slayton et al. | Jun 2015 | A1 |
| 20150165238 | Slayton et al. | Jun 2015 | A1 |
| 20150165243 | Slayton et al. | Jun 2015 | A1 |
| 20150174388 | Slayton | Jun 2015 | A1 |
| 20150202468 | Slayton et al. | Jul 2015 | A1 |
| 20150217141 | Barthe et al. | Aug 2015 | A1 |
| 20150224347 | Barthe | Aug 2015 | A1 |
| 20150238258 | Palero et al. | Aug 2015 | A1 |
| 20150297188 | Konofagou | Oct 2015 | A1 |
| 20150321026 | Branson et al. | Nov 2015 | A1 |
| 20150360058 | Barthe et al. | Dec 2015 | A1 |
| 20150374333 | Barthe et al. | Dec 2015 | A1 |
| 20150375014 | Slayton et al. | Dec 2015 | A1 |
| 20160001097 | Cho et al. | Jan 2016 | A1 |
| 20160016015 | Slayton et al. | Jan 2016 | A1 |
| 20160027994 | Toda et al. | Jan 2016 | A1 |
| 20160151618 | Powers et al. | Jun 2016 | A1 |
| 20160158580 | Slayton et al. | Jun 2016 | A1 |
| 20160175619 | Lee et al. | Jun 2016 | A1 |
| 20160206335 | Slayton | Jul 2016 | A1 |
| 20160206341 | Slayton | Jul 2016 | A1 |
| 20160256675 | Slayton | Sep 2016 | A1 |
| 20160296769 | Barthe et al. | Oct 2016 | A1 |
| 20160310444 | Dobak, III | Oct 2016 | A1 |
| 20160361571 | Bernabei | Dec 2016 | A1 |
| 20160361572 | Slayton | Dec 2016 | A1 |
| 20170028227 | Emery et al. | Feb 2017 | A1 |
| 20170043190 | Barthe et al. | Feb 2017 | A1 |
| 20170050019 | Ron Edoute et al. | Feb 2017 | A1 |
| 20170080257 | Paunescu et al. | Mar 2017 | A1 |
| 20170100585 | Hall et al. | Apr 2017 | A1 |
| 20170119345 | Levien | May 2017 | A1 |
| 20170136263 | Reil | May 2017 | A1 |
| 20170209201 | Slayton et al. | Jul 2017 | A1 |
| 20170209202 | Friedrichs et al. | Jul 2017 | A1 |
| 20170304654 | Blanche et al. | Oct 2017 | A1 |
| 20170368574 | Sammoura | Dec 2017 | A1 |
| 20180001113 | Streeter | Jan 2018 | A1 |
| 20180015308 | Reed et al. | Jan 2018 | A1 |
| 20180043147 | Slayton | Feb 2018 | A1 |
| 20180099162 | Bernabei | Apr 2018 | A1 |
| 20180099163 | Bernabei | Apr 2018 | A1 |
| 20180126190 | Aviad et al. | May 2018 | A1 |
| 20180154184 | Kong et al. | Jun 2018 | A1 |
| 20180207450 | Sanchez et al. | Jul 2018 | A1 |
| 20180272156 | Slayton et al. | Sep 2018 | A1 |
| 20180272157 | Barthe et al. | Sep 2018 | A1 |
| 20180272158 | Barthe et al. | Sep 2018 | A1 |
| 20180272159 | Slayton et al. | Sep 2018 | A1 |
| 20180317884 | Chapelon et al. | Nov 2018 | A1 |
| 20180333595 | Barthe et al. | Nov 2018 | A1 |
| 20180360420 | Vortman et al. | Dec 2018 | A1 |
| 20190000498 | Barthe et al. | Jan 2019 | A1 |
| 20190009110 | Gross et al. | Jan 2019 | A1 |
| 20190009111 | Myhr et al. | Jan 2019 | A1 |
| 20190022405 | Greenbaum et al. | Jan 2019 | A1 |
| 20190038921 | Domankevitz | Feb 2019 | A1 |
| 20190060675 | Krone et al. | Feb 2019 | A1 |
| 20190091490 | Alexander et al. | Mar 2019 | A1 |
| 20190142380 | Emery et al. | May 2019 | A1 |
| 20190143148 | Slayton | May 2019 | A1 |
| 20190184202 | Zereshkian et al. | Jun 2019 | A1 |
| 20190184203 | Slayton et al. | Jun 2019 | A1 |
| 20190184205 | Slayton et al. | Jun 2019 | A1 |
| 20190184207 | Barthe et al. | Jun 2019 | A1 |
| 20190184208 | Barthe et al. | Jun 2019 | A1 |
| 20190224501 | Burdette | Jul 2019 | A1 |
| 20190262634 | Barthe et al. | Aug 2019 | A1 |
| 20190282834 | Zawada et al. | Sep 2019 | A1 |
| 20190290939 | Watson | Sep 2019 | A1 |
| 20190350562 | Slayton et al. | Nov 2019 | A1 |
| 20190366126 | Pahk et al. | Dec 2019 | A1 |
| 20190366127 | Emery | Dec 2019 | A1 |
| 20190366128 | Slayton et al. | Dec 2019 | A1 |
| 20200094083 | Slayton et al. | Mar 2020 | A1 |
| 20200100762 | Barthe et al. | Apr 2020 | A1 |
| 20200129759 | Schwarz | Apr 2020 | A1 |
| 20200171330 | Barthe et al. | Jun 2020 | A1 |
| 20200179727 | Slayton et al. | Jun 2020 | A1 |
| 20200179729 | Slayton et al. | Jun 2020 | A1 |
| 20200188703 | Barthe et al. | Jun 2020 | A1 |
| 20200188704 | Barthe et al. | Jun 2020 | A1 |
| 20200206072 | Capelli et al. | Jul 2020 | A1 |
| 20200222728 | Khokhlova et al. | Jul 2020 | A1 |
| 20210038925 | Emery | Feb 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2460061 | Nov 2001 | CN |
| 1734284 | Dec 2009 | CN |
| 104027893 | Sep 2014 | CN |
| 4029175 | Mar 1992 | DE |
| 10140064 | Mar 2003 | DE |
| 10219297 | Nov 2003 | DE |
| 10219217 | Dec 2004 | DE |
| 20314479 | Dec 2004 | DE |
| 0142215 | May 1984 | EP |
| 0344773 | Dec 1989 | EP |
| 1479412 | Nov 1991 | EP |
| 0473553 | Apr 1992 | EP |
| 670147 | Feb 1995 | EP |
| 0661029 | Jul 1995 | EP |
| 724894 | Feb 1996 | EP |
| 763371 | Nov 1996 | EP |
| 1044038 | Oct 2000 | EP |
| 1050322 | Nov 2000 | EP |
| 1234566 | Aug 2002 | EP |
| 1262160 | Dec 2002 | EP |
| 0659387 | Apr 2003 | EP |
| 1374944 | Jan 2004 | EP |
| 1028660 | Jan 2008 | EP |
| 1874241 | Jan 2008 | EP |
| 1362223 | May 2008 | EP |
| 1750804 | Jul 2008 | EP |
| 1283690 | Nov 2008 | EP |
| 1811901 | Apr 2009 | EP |
| 1785164 | Aug 2009 | EP |
| 2230904 | Sep 2010 | EP |
| 1501331 | Jun 2011 | EP |
| 2066405 | Nov 2011 | EP |
| 2474050 | Jul 2012 | EP |
| 2709726 | Nov 2015 | EP |
| 1538980 | Jan 2017 | EP |
| 3124047 | Jan 2017 | EP |
| 2897547 | Nov 2017 | EP |
| 2173261 | Aug 2018 | EP |
| 3417911 | Dec 2018 | EP |
| 2532851 | Sep 1983 | FR |
| 2685872 | Jan 1992 | FR |
| 2672486 | Aug 1992 | FR |
| 2703254 | Mar 1994 | FR |
| 2113099 | Aug 1983 | GB |
| 102516 | Jan 1996 | IL |
| 112369 | Aug 1999 | IL |
| 120079 | Mar 2001 | IL |
| 63036171 | Feb 1988 | JP |
| 03048299 | Mar 1991 | JP |
| 3123559 | May 1991 | JP |
| 03136642 | Jun 1991 | JP |
| 4089058 | Mar 1992 | JP |
| 04150847 | May 1992 | JP |
| 7080087 | Mar 1995 | JP |
| 07505793 | Jun 1995 | JP |
| 7184907 | Jul 1995 | JP |
| 7222782 | Aug 1995 | JP |
| 09047458 | Feb 1997 | JP |
| 9108288 | Apr 1997 | JP |
| 9503926 | Apr 1997 | JP |
| 3053069 | Oct 1998 | JP |
| 11123226 | May 1999 | JP |
| 11505440 | May 1999 | JP |
| 11506636 | Jun 1999 | JP |
| 10248850 | Sep 1999 | JP |
| 2000126310 | May 2000 | JP |
| 2000166940 | Jun 2000 | JP |
| 2000233009 | Aug 2000 | JP |
| 2001-46387 | Feb 2001 | JP |
| 2001136599 | May 2001 | JP |
| 2001170068 | Jun 2001 | JP |
| 2002505596 | Feb 2002 | JP |
| 2002078764 | Mar 2002 | JP |
| 2002515786 | May 2002 | JP |
| 2002537013 | May 2002 | JP |
| 2002521118 | Jul 2002 | JP |
| 2002537939 | Nov 2002 | JP |
| 2003050298 | Jul 2003 | JP |
| 2003204982 | Jul 2003 | JP |
| 2004-504898 | Feb 2004 | JP |
| 2004-507280 | Mar 2004 | JP |
| 2004154256 | Mar 2004 | JP |
| 2004-509671 | Apr 2004 | JP |
| 2004-512856 | Apr 2004 | JP |
| 2004147719 | May 2004 | JP |
| 2005503388 | Feb 2005 | JP |
| 2005527336 | Sep 2005 | JP |
| 2005323213 | Nov 2005 | JP |
| 2006520247 | Sep 2006 | JP |
| 2008515559 | May 2008 | JP |
| 2009518126 | May 2009 | JP |
| 2010517695 | May 2010 | JP |
| 2001-0019317 | Mar 2001 | KR |
| 1020010024871 | Mar 2001 | KR |
| 2002-0038547 | May 2002 | KR |
| 100400870 | Oct 2003 | KR |
| 20060121267 | Nov 2006 | KR |
| 1020060113930 | Nov 2006 | KR |
| 1020070065332 | Jun 2007 | KR |
| 1020070070161 | Jul 2007 | KR |
| 1020070098856 | Oct 2007 | KR |
| 1020070104878 | Oct 2007 | KR |
| 1020070114105 | Nov 2007 | KR |
| 1020000059516 | Apr 2012 | KR |
| 10-2013-0124598 | Nov 2013 | KR |
| 10-1365946 | Feb 2014 | KR |
| 386883 | Sep 2000 | TW |
| 201208734 | Mar 2012 | TW |
| WO9312742 | Jul 1993 | WO |
| WO9524159 | Sep 1995 | WO |
| WO9625888 | Aug 1996 | WO |
| WO9634568 | Nov 1996 | WO |
| WO9639079 | Dec 1996 | WO |
| WO9735518 | Oct 1997 | WO |
| WO9832379 | Jul 1998 | WO |
| WO9852465 | Nov 1998 | WO |
| WO9933520 | Jul 1999 | WO |
| WO9939677 | Aug 1999 | WO |
| WO9949788 | Oct 1999 | WO |
| WO200006032 | Feb 2000 | WO |
| WO0015300 | Mar 2000 | WO |
| WO0021612 | Apr 2000 | WO |
| WO0048518 | Aug 2000 | WO |
| WO0053113 | Sep 2000 | WO |
| WO200071021 | Nov 2000 | WO |
| WO0128623 | Apr 2001 | WO |
| WO01045550 | Jun 2001 | WO |
| WO0182777 | Nov 2001 | WO |
| WO0182778 | Nov 2001 | WO |
| WO0187161 | Nov 2001 | WO |
| WO01080709 | Nov 2001 | WO |
| WO0209812 | Feb 2002 | WO |
| WO0209813 | Feb 2002 | WO |
| WO02015768 | Feb 2002 | WO |
| WO0224050 | Mar 2002 | WO |
| WO2002054018 | Jul 2002 | WO |
| WO02092168 | Nov 2002 | WO |
| WO03053266 | Jul 2003 | WO |
| WO03065347 | Aug 2003 | WO |
| WO03070105 | Aug 2003 | WO |
| WO03077833 | Sep 2003 | WO |
| WO03086215 | Oct 2003 | WO |
| WO03096883 | Nov 2003 | WO |
| WO03099177 | Dec 2003 | WO |
| WO03099382 | Dec 2003 | WO |
| WO03101530 | Dec 2003 | WO |
| WO2004000116 | Dec 2003 | WO |
| WO2004080147 | Sep 2004 | WO |
| WO2004110558 | Dec 2004 | WO |
| WO2005011804 | Feb 2005 | WO |
| WO2005065408 | Jul 2005 | WO |
| WO2005065409 | Jul 2005 | WO |
| WO2005090978 | Sep 2005 | WO |
| WO2005113068 | Dec 2005 | WO |
| WO2006042163 | Apr 2006 | WO |
| WO2006036870 | Apr 2006 | WO |
| WO2006042168 | Apr 2006 | WO |
| WO2006042201 | Apr 2006 | WO |
| WO2006065671 | Jun 2006 | WO |
| WO2006082573 | Aug 2006 | WO |
| WO2006104568 | Oct 2006 | WO |
| WO2007067563 | Jun 2007 | WO |
| WO2008036479 | Mar 2008 | WO |
| WO2008036622 | Mar 2008 | WO |
| WO2008144274 | Nov 2008 | WO |
| WO2009013729 | Jan 2009 | WO |
| WO2009149390 | Oct 2009 | WO |
| WO2012134645 | Oct 2012 | WO |
| WO2013048912 | Apr 2013 | WO |
| WO2013178830 | Dec 2013 | WO |
| WO2014045216 | Mar 2014 | WO |
| WO2014055708 | Apr 2014 | WO |
| WO2014057388 | Apr 2014 | WO |
| WO2014127091 | Aug 2014 | WO |
| WO2015160708 | Oct 2015 | WO |
| WO2016054155 | Apr 2016 | WO |
| WO2016115363 | Jul 2016 | WO |
| WO2017127328 | Jul 2017 | WO |
| WO2017149506 | Sep 2017 | WO |
| WO2017165595 | Sep 2017 | WO |
| WO 2017212489 | Dec 2017 | WO |
| WO2017212489 | Dec 2017 | WO |
| WO2018035012 | Feb 2018 | WO |
| WO2018158355 | Sep 2018 | WO |
| WO2019008573 | Jan 2019 | WO |
| WO 2019147596 | Aug 2019 | WO |
| WO2019147596 | Aug 2019 | WO |
| WO2019164836 | Aug 2019 | WO |
| WO2020009324 | Jan 2020 | WO |
| WO2020075906 | Apr 2020 | WO |
| WO2020080730 | Apr 2020 | WO |
| WO2020121307 | Jun 2020 | WO |
| Entry |
|---|
| US 10,398,895 B2, 09/2019, Schwarz (withdrawn) |
| PCT/US2017/46703 International Search Report dated Jan. 12, 2018, 32 pages. |
| Agren, Magnus S. et al., Collagenase in Wound Healing: Effect of Wound Age and Type. The Journal of Investigative Dermatology, vol. 99/No. 6, (Dec. 1992). |
| Alam, M., “The future of noninvasive procedural dermatology”. Semin Cutan Med Surg. Mar. 2013; 32(1):59-61. |
| Alam, M., et al., “Ultrasound tightening of facial and neck skin: a rater-blinded prospective cohort study”. J Am Acad Dermatol, 2010. 62(2): p. 262-9. |
| Alexiades-Armenakas, M., “Ultrasound Technologies for Dermatologic Techniques”. J Drugs Derm. 2014. 12 (11): p. 1305. |
| Alster, T.S., et. al., “Noninvasive lifting of arm, thigh, and knee skin with transcutaneousintense focused ultrasound”. Dermatol Surg, 2012. 38(5): p. 754-9. |
| Alster, Tinas S., Tanzi, Elizabeth L., “Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85. |
| Arosarena, O., “Options and Challenges for Facial Rejuvenation in Patients With Higher Fitzpatrick Skin Phototypes”. JAMA Facial Plastic Surgery, 2015. |
| Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600. |
| Barthe et al., “Ultrasound therapy system and ablation results utilizing miniature imaging/therapy arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3. |
| Bozec, Laurent et al., Thermal Denaturation Studies of Collagen by Microthermal Analysis and Atomic Force Microscopy, Biophysical Journal, vol. 101, pp. 228-236. (Jul. 2001). |
| Brobst, R.W., et al., “Noninvasive Treatment of the Neck”. Facial Plast Surg Clin North Am, 2014. 22(2): p. 191-202. |
| Brobst, R.W., et., al., “Ulthera: initial and six month results”. Facial Plast Surg Clin North Am, 2012. 20(2): p. 163-76. |
| Calderhead et al., “One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell” Laser Therapy 17.3: 141-148 (2008). |
| Casabona, G., et al., “Microfocused Ultrasound With Visualization and Fillers for Increased Neocollagenesis: Clinical and Histological Evaluation”. Dermatol Surg 2014;40:S194-S198. |
| Casabona, G., et al., “Microfocused Ultrasound with Visualization and Calcium Hydroxylapatite for Improving Skin Laxity and Cellulite Appearance”; Plast Reconstr Surg Glob Open. Jul. 25, 2017;5(7):e1388, 8 pages. |
| Chan, N.P., et al., “Safety study of transcutaneous focused ultrasound for non-invasive skin tightening in Asians”. Lasers Surg Med, 2011. 43(5): p. 366-75. |
| Chapelon et al., “Effects of Cavitation In The High Intensity Therapeutic Ultrasound”, Ultrasonics Symposium—1357 (1991). |
| Chapelon, et al., “Thresholds for Tissue Ablation by Focused Ultrasound” (1990). |
| Chen, L. et al., “Effect of Blood Perfusion on the ablation of liver parenchyma with high intensity focused ultrasound,” Phys. Med. Biol; 38:1661-1673; 1993b. |
| Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectrometry” Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468. |
| Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444, 456. |
| Damianou et al., “Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery,” 1993 IEEE Ultrasound Symposium, pp. 1199-1202. |
| Daum et al., Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438. |
| Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 Ultrasonics Symposium, pp. 921-924. |
| Dayan, S.H., et al., “Prospective, Multi-Center, Pivotal Trial Evaluating the Safety and Effectiveness of Micro-Focused Ultrasound with Visualization (MFU-V) for Improvement in Lines and Wrinkles of the Décolletage”. Plast Reconstr Surg. Oct. 2014; 134(4 Suppl 1):123-4. |
| Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on pp. 1-4 of the Information Disclosure Statement herein (English translation, English translation certification, and Korean decision included). |
| Delon Martin, C., et al, “Venous Thrombosis Generation By Means of High-Intensity Focused Ultrasound” Ultrasound in Med. & Biol., vol. 21, No. 1, pp. 113-119 (1995). |
| Dierickx, Christine C., “The Role of Deep Heating for Noninvasive Skin Rejuvenation” Lasers in Surgery and Medicine 38:799-807 (2006). |
| Dobke, M.K., et al., “Tissue restructuring by energy-based surgical tools”. Clin Plast Surg, 2012. 39(4): p. 399-408. |
| Dong, Yuan-Lin et al., “Effect of Ibuprofen on the Inflammatory Response To Surgical Wounds” The Journal of Trauma, vol. 35, No. 3. (1993). |
| Dvivedi, Sanjay, et al. “Effect of Ibuprofen and diclofenac sodium on experimental wound healing” Indian Journal of Experimental Biology, vol. 35, pp. 1243-1245. (Nov. 1997). |
| Fabi, S.G., “Microfocused Ultrasound With Visualization for Skin Tightening and Lifting: My Experience and a Review of the Literature”. Dermatol Surg. Dec. 2014; 40 Suppl 12:S164-7. |
| Fabi, S.G., “Noninvasive skin tightening: focus on new ultrasound techniques”. Clin Cosmet Investig Dermatol. Feb. 5, 2015; 8:47-52. |
| Fabi, S.G., et. al., “A prospective multicenter pilot study of the safety and efficacy of microfocused ultrasound with visualization for improving lines and wrinkles of the décolleté”. Dermatol Surg. Mar. 2015; 41(3):327-35. |
| Fabi, S.G., et. al., “Evaluation of microfocused ultrasound with visualization for lifting, tightening, and wrinkle reduction of the decolletage”. J Am Acad Dermatol, 2013. 69(6): p. 965-71. |
| Fabi, S.G., et. al., “Future directions in cutaneous laser surgery”. Dermatol Clin, 2014. 32(1): p. 61-9. |
| Fabi, S.G., et. al., “Retrospective Evaluation of Micro-focused Ultrasound for Lifting and Tightening the Face and Neck”. Dermatol Surg, 2014. |
| Friedmann D.P., “Comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face”. Aesthet Surg J. Mar. 2015;35(3):NP81-2. |
| Friedmann, D.P., et. al., “Combination of intense pulsed light, Sculptra, and Ultherapy for treatment of the aging face”. J Cosmet Dermatol, 2014. 13(2): p. 109-18. |
| Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” J. Neurosurg., 11:471-478; 1954. |
| Fujimoto, et al., “A New Cavitation Suppression Technique for Local Ablation Using High-Intensity Focused Ultrasound” Ultrasonics Symposium—1629 (1995). |
| Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9, No. 1. |
| Gold, M.H., et. al., “Use of Micro-Focused Ultrasound with Visualization to Lift and Tighten Lax Knee Skin”. J Cosmet Laser Ther, 2014: p. 1-15. |
| Goldberg, D.J., et. al., “Safety and Efficacy of Microfocused Ultrasound to Lift, Tighten, and Smooth the Buttocks”. Dermatol Surg 2014; 40:1113-1117. |
| Greene, R.M., et al., “Skin tightening technologies”. Facial Plast Surg. Feb. 2014; 30(1):62-7. |
| Greenhalgh, David G., “Wound healing and diabetes mellitus” Clinics in Plastic Surgery 30; 37-45. (2003). |
| Guo, S. et al., “Factors Affecting Wound Healing” Critical Reviews in Oral Biology & Medicine, J Dent Res 89(3), pp. 219-229. (2010). |
| Haar, G.R et al., “Tissue Destruction with Focused Ultrasound in Vivo,” Eur. Urol. 23 (suppl. 1):8-11; 1993. |
| Hantash, Basil M. et al., “Bipolar Fractional Radiofrequency Treatment Induces Neoelastogenesis and Neocollagenesis” Lasers in Surgery and Medicine 41:1-9 (2009). |
| Hantash, Basil M. et al., “In Vivo Histological Evaluation of a Novel Ablative Fractional Resurfacing Device” Lasers in Surgery and Medicine 39:96-107 (2007). |
| Harris, M.O., “Safety of Microfocused Ultrasound With Visualization in Patients With Fitzpatrick Skin Phototypes III to VI”. JAMA Facial Plast. Surg, 2015. |
| Hart, et. al., “Current Concepts in the Use of PLLA:Clinical Synergy Noted with Combined Use of Microfocused Ultrasound and Poly-I-Lactic Acid on the Face, Neck, and Décolletage”. Amer. Soc. Plast. Surg. 2015. 136; 180-187S. |
| Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” advanced in Polymer Science, 2000, pp. 37-65, vol. 153. |
| Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7. |
| Hexsel et al., “A Validated Photonumeric Cellulite Severity Scale”; J Eur Acad Dermatol Venereol. May 2009; 23(5):523-8, 6 pages. |
| Hitchcock, T.M. et. al., “Review of the safety profile for microfocused ultrasound with Visualization”. Journal of Cosmetic Dermatology, 13, 329-335. (2014). |
| Husseini et al, “The Role of Cavitation in Acoustically Activated Drug Delivery,” J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2). |
| Husseini et al. “Investigating the mechanism of acoustically activated uptake of drugs from Plutonic micelles,” BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6. |
| Hynynen et al., Temperature Distributions During Local Ultrasound Induced Hyperthermia In Vivo, Ultrasonics Symposium—745 (1982). |
| Jeffers et al., “Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms,” 1993 IEEE Ultrasonics Symposium, pp. 925-928. |
| Jenne, J., et al., “Temperature Mapping for High Energy US-Therapy”, 1994 Ultrasonics Symposium, pp. 1879-1882. |
| Jeong, K.H., et al., “Neurologic complication associated with intense focused ultrasound”. J Cosmet Laser Ther, 2013. |
| Johnson, S.A., et al., “Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic Temperature Tomography”, Ultrasonics Symposium Proceedings, pp. 977-982. (1977). |
| Kim, H.J., et al., “Coagulation and ablation patterns of high-intensity focused ultrasound on a tissue mimicking phantom and cadaveric skin”. Laser Med Sci. Sep. 4, 2015. |
| Kornstein, A.N., “Ulthera for silicone lip correction”. Plast Reconstr Surg, 2012. 129(6): p. 1014e-1015e. |
| Kornstein, A.N., “Ultherapy shrinks nasal skin after rhinoplasty following failure of conservative measures”. Plast Reconstr Surg, 2013. 131(4): p. 664e-6e. |
| Krischak, G.D., et al., “The effects of non-steroidal anti-inflammatory drug application on incisional wound healing in rats” Journal of Wound Care, vol. 6, No. 2, (Feb. 2007). |
| Laubach, H.J., et. al., “Confined Thermal Damage with Intense Ultrasound (IUS)” [abstr.] American Society for Laser Medicine and Surgery Abstracts, p. 15 #43 (Apr. 2006). |
| Laubach, H.J., et. al., “Intense focused ultrasound: evaluation of a new treatment modality for precise microcoagulation within the skin”. Dermatol Surg, 2008. 34(5): p. 727-34. |
| Lee, H.J., et. al., “The efficacy and safety of intense focused ultrasound in the treatment of enlarged facial pores in Asian skin”. J Dermatolog Treat, 2014. |
| Lee, H.S., et. al., “Multiple Pass Ultrasound Tightening of Skin Laxity of the Lower Face and Neck”. Dermatol Surg, 2011. |
| Lin, Sung-Jan, et al., “Monitoring the thermally induced structural transitions of collagen by use of second-harmonic generation microscopy” Optics Letters, vol. 30, No. 6, (Mar. 15, 2005). |
| Macgregor J.L., et. al., “Microfocused Ultrasound for Skin Tightening”. Semin Cutan Med Surg 32:18-25. (2013). |
| Madersbacher, S. et al., “Tissue Ablation in Benign Prostatic Hyperplasia with High Intensity Focused Ultrasound,” Dur. Urol., 23 (suppl. 1):39-43; 1993. |
| Makin et al, “B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3. |
| Makin et al, “Confirmed Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays,” 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004. |
| Makin et al., “Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging,” UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11). |
| Manohar et al, “Photoacoustic mammography laboratory prototype: imaging of breast tissue phantoms,” Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6. |
| Mast et al, “Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling and Experiments,” J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4). |
| Meshkinpour, Azin, et al., “Treatment of Hypertrophic Scars and Keloids With a Radiofrequency Device: A Study of Collagen Effects” Lasers in Surgery and Medicine 37:343-349 (2005). |
| Minkis, K., et. al., “Ultrasound skin tightening”. Dermatol Clin, 2014. 32(1): p. 71-7. |
| Mitragotri, S., “Healing sound: the use of ultrasound in drug delivery and other therapeutic applications,” Nature Reviews; Drug Delivery, pp. 255-260, vol. 4 (Mar. 2005). |
| Mosser, David M. et al., “Exploring the full spectrum of macrophage activation” Nat Rev Immunol; 8(12): 958-969. (Dec. 2008). |
| Murota, Sei-Itsu, et al., “Stimulatory Effect of Prostaglandins on the Production of Hexosamine-Containing Substances by Cultured Fibroblasts (3) Induction of Hyaluronic Acid Synthetase by Prostaglandin” Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan. (Nov. 1977, vol. 14, No. 5). |
| Murota, Sei-Itsu, et al., “The Stimulatory Effect of Prostaglandins on Production of Hexosamine-Containing Substances by Cultured Fibroblasts” Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan. (Aug. 1976, vol. 12, No. 2). |
| Nestor, M.S. et. al., “Safety and Efficacy of Micro-focused Ultrasound Plus Visualization for the Treatment of Axillary Hyperhidrosis”. J Clin Aesthet Dermatol, 2014. 7(4): p. 14-21. |
| Oni, G., et. al. “Response to ‘comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face’”. Aesthet Surg J. Mar. 2015;35(3):NP83-4. |
| Oni, G., et. al., “Evaluation of a Microfocused Ultrasound System for Improving Skin Laxity and Tightening in the Lower Face”. Aesthet Surg J, 2014. 38:861-868. |
| Pak, C.S., et. al., “Safety and Efficacy of Ulthera in the Rejuvenation of Aging Lower Eyelids: A Pivotal Clinical Trial”. Aesthetic Plast Surg, 2014. |
| Paradossi et al., “Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications,” Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14. |
| Pritzker, R.N., et. al, “Updates in noninvasive and minimally invasive skin tightening”. Semin Cutan Med Surg. Dec. 2014;33(4):182-7. |
| Pritzker, R.N., et. al., “Comparison of different technologies for noninvasive skin tightening”. Journal of Cosmetic Dermatology, 13, 315-323. (2014). |
| Rappolee, Daniel A., et al., “Wound Macrophages Express TGF and Other Growth Factors in Vivo: Analysis by mRNA Phenotyping” Science, vol. 241, No. 4866 (Aug. 1988). |
| Reid, Gavin, et al., “Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions,” Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583. |
| Righetti et al, “Elastographic Characterization of HIFU-lnduced Lesions in Canine Livers,” 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113. |
| Rokhsar, C., et. al., “Safety and efficacy of microfocused ultrasound in tightening of lax elbow skin”. Dermatol Surg. 2015; 41(7):821-6. |
| Rosenberg, Carol S. “Wound Healing in the Patient with Diabetes Mellitus” Nursing Clinics of North America, vol. 25, No. 1, (Mar. 1990). |
| Saad et al., “Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors,” Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992). |
| Sabet-Peyman, E.J. et. al., “Complications Using Intense Ultrasound Therapy to TreatDeep Dermal Facial Skin and Subcutaneous Tissues”. Dermatol Surg 2014; 40:1108-1112. |
| Sandulache, Vlad C. et al., “Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-B1-induced collagen synthesis” Wound Rep Reg 15 122-133, 2007. (2007). |
| Sanghvi, N.T., et al., “Transrectal Ablation of Prostate Tissue Using Focused Ultrasound,” 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210. |
| Sasaki, G.H. et. al., “Clinical Efficacy and Safety of Focused-lmage Ultrasonography: A 2-Year Experience”. Aesthet Surg J, 2012. |
| Sasaki, G.H. et. al., “Microfocused Ultrasound for Nonablative Skin and Subdermal Tightening to the Periorbitum and Body Sites: Preliminary Report on Eighty-Two Patients”. Journal of Cosmetics, Dermatological Sciences and Applications, 2012, 2, 108-116. |
| Sassen, Sander, “ATI's R520 architecture, the new king of the hill?” http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages. |
| Seip, Ralf, et al., “Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fields,” IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993. |
| Seip, Ralf, et al., “Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound,” IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839. |
| Simon et al., “Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy,” Ultrasound in Med. & Biol. vol. 19, No. 2, pp. 123-125 (1993). |
| Sklar, L.R., et. al., “Use of transcutaneous ultrasound for lipolysis and skin tightening: a review”. Aesthetic Plast Surg, 2014. 38(2): p. 429-41. |
| Smith, Nadine Barrie, et al., “Non-invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques”, 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3. |
| Suh, D.H., et. al., “A intense-focused ultrasound tightening for the treatment of infraorbital laxity”. J Cosmet Laser Ther, 2012. 14(6): p. 290-5. |
| Suh, D.H., et. al., “Comparative histometric analysis of the effects of high-intensity focused ultrasound and radiofrequency on skin”. J Cosmet Laser Ther. Mar. 24, 2015:1-7. |
| Suh, D.H., et. al., “Intense Focused Ultrasound Tightening in Asian Skin: Clinical and Pathologic Results” American Society for Dermatologic Surgery, Inc.; 37:1595-1602. (2011). |
| Surry et al., “Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging,” Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49. |
| Syka J. E. P. et al., “Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry,” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533. |
| Talbert, D. G., “An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays,” UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67. |
| Tata et al., “Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions,” American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555. |
| Ueno, S., et al., “Ultrasound Thermometry in Hyperthermia”, 1990 Ultrasonic Symposium, pp. 1645-1652. |
| Verhofstad, Michiel H.J. et al., “Collagen Synthesis in rat skin and ileum fibroblasts is affected differently by diabetes-related factors” Int. J. Exp. Path. (1998), 79, 321-328. |
| Wang, H., et al., “Limits on Focused Ultrasound for Deep Hyperthermia”, 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3. |
| Wasson, Scott, “NVIDIA's GeForce 7800 GTX graphics processor Power MADD,” http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages. |
| Weiss, M., “Commentary: noninvasive skin tightening: ultrasound and other technologies: where are we in 2011?” Dermatol Surg, 2012. 38(1): p. 28-30. |
| White et al. “Selective Creating of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy,” Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1 (pp. 22-29). |
| White, W. M., et al., “Selective Transcutaneous Delivery of Energy to Facial Subdermal Tissues Using the Ultrasound Therapy System” [abstr]. American Society for Laser Medicine and Surgery Abstracts, p. 37 #113 (Apr. 2006). |
| White, W. Matthew, et al., “Selective Transcutaneous Delivery of Energy to Porcine Soft Tissues Using Intense Ultrasound (IUS)” Lasers in Surgery and Medicine 40:67-75 (2008). |
| Woodward, J.A., et. al. “Safety and Efficacy of Combining Microfocused Ultrasound With Fractional CO2 Laser Resurfacing for Lifting and Tightening the Face and Neck”. Dermatol Surg, Dec. 2014 40:S190-S193. |
| Zelickson, Brian D. et al., “Histological and Ultrastructural Evaluation of the Effects of a Radiofrequency-Based Nonablative Dermal Remodeling Device, A Pilot Study” Arch Dermatol, vol. 140, (Feb. 2004). |
| Ulthera, Inc., Petition for Inter Partes Review filed Jul. 19, 2016 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 63 pages (Filed Jul. 19, 2016). |
| ULTHERA Exhibit 1001, U.S. Pat. No. 6,113,559 to Klopotek, filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1002, Patent file history of U.S. Pat. No. 6,113,559 Klopotek filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1003, Declaration of Expert Witness Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1004, Curriculum Vitae of Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1005, International PCT Publication WO96/34568 Knowlton filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1006, French Patent No. 2,672,486, Technomed patent filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1007, English translation of French Patent No. 2,672,486, Technomed filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1008, International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1009, English translation of International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1010, U.S. Pat. No. 5,601,526, which claims priority to Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1011, Patent file history for European Patent Application No. 98964890.2, Klopotek filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1012, Translator Declaration filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1013, U.S. Pat. No. 5,230,334 to Klopotek filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1014, U.S. Pat. No. 5,755,753 to Knowlton filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1015, Excerpts from The American Medical Association Encyclopedia of Medicine (1989) filed Jul. 19, 2016 in re IPR2016-01459. |
| ULTHERA Exhibit 1016, The Simultaneous Study of Light Emissions and Shock Waves Produced by Cavitation Bubbles, G. Gimenez, J. Acoust. Soc. Am. 71(4), Apr. 1982, pp. 839-847 (filed Jul. 19, 2016 in re IPR2016-01459). |
| ULTHERA Exhibit 1017, Excerpts from Gray's Anatomy (1995) (filed Jul. 19, 2016 in re IPR2016-01459). |
| ULTHERA Exhibit 1018, Anatomy of the Superficial Venous System, Comjen G.M., Dermatol. Surg., 1995; 21:35-45 (filed Jul. 19, 2016 in re IPR2016-01459). |
| ULTHERA Exhibit 1019, Section 2.6 from Ultrasonics Theory and Application, by G.L. Gooberman (Hart Publishing Co., 1969) (filed Jul. 19, 2016 in re IPR2016-01459). |
| ULTHERA Exhibit 1020, Deep Local Hyperthermia for Cancer Therapy: External Electromagnetic and Ultrasound Techniques, A.Y. Cheung and A. Neyzari, Cancer Research (Suppl.), vol. 44, pp. 4736-4744 (1984) (filed Jul. 19, 2016 in re IPR2016-01459). |
| Decision on Institution of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 20 pages [011] (Dated Jan. 23, 2017). |
| DERMAFOCUS Response to Institution of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 73 pages [018] (Dated Apr. 26, 2017). |
| DERMAFOCUS Exhibit List in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 5 pages [019] (Dated Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2002, Declaration of Mark Palmeri, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 136 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2003, Deposition of Dr. Mark Schafer, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 327 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2004, Amendment No. 4 to Ulthera Form S-1, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 308 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2005, Excerpt from Churchill Livingstone, Gray's Anatomy (38th ed. 1995), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2006, Bo Eklof et al., “Revision of the CEAP Classification for Chronic Venous Disorders: Consensus Statement,” ACTA FAC MED NAISS, vol. 25, No. 1 (2008), 3-10 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2007, WebMD, “Varicose Veins and Spider Veins” downloaded from http://www.webmd.com/skin-problems-andtreatments/guide/varicose-spider-veins#1 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 3 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2008, John M. Porter et al, “Reporting Standards in Venous Disease: An Update,” Journal of Vascular Surgery, vol. 21, No. 4 (1995), 635-645 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 11 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2009, Kullervo Hynynen, “Review of Ultrasound Therapy,” 1997 Ultrasonics Symposium (1997), 1305-1313, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 9 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2010, A.G. Visioli et al, “Prelimiary Results of a Phase I Dose Escalation Clinical Trial Using Focused Ultrasound in the Treatment of Localised Tumours,” European Journal of Ultrasound, vol. 9 (1999), 11-18, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 8 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2011, U.S. Pat. No. 5,143,063, issued on Sep. 1, 1992, Fellner, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2012, Hugh G. Beebe et al, “Consensus Statement: Classification and Grading of Chronic Venous Disease in the Lower Limbs,” European Journal of Vascular and Endovascular Surgery, vol. 12 (1996), 487-492, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2013, Excerpt from Mosby's Medical Dictionary (3rd ed. 1990), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2014, Excerpt from Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health (5th ed. 1992), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2015, David J. Tibbs et al, Varicose Veins, Venous Disorders, and Lymphatic Problems in the Lower Limbs (1997), Chapter 4: Clinical Patterns of Venous Disorder I, 47-67, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 24 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2016, Mitchel P. Goldman et al, Varicose Veins and Telangiectasias (2nd ed. 1999), Chapter 22: Treatment of Leg Telangiectasias with Laser and High-Intensity Pulsed Light, 470-497, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 31 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2017, Email from Anderson to Klopotek dated May 25, 2004, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 1 page (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2018, List of Klopotek Patents, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 411 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2019, Declaration of Peter Klopotek Civil Action 15-cv-654-SLR, dated Nov. 2, 2016, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 1 page (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2020, “Our Technology,” downloaded from http://jobs.ulthera.com/about on Apr. 10, 2017, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2021, C. Damianou and K. Hynynen, “Focal Spacing and Near-Field Heating During Pulsed High Temperature Ultrasound Therapy,” Ultrasound in Medicine & Biology, vol. 19, No. 9 (1993), 777-787, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 11 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2022, Excerpt from Mosby's Medical Dictionary (5th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 5 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2023, Excerpt from Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health (6th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2024, Excerpt from Stedman's Concise Medical Dictionary (3 rd ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2025, Excerpt from Taber's Cyclopedic Medical Dictionary (18th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 9 pages (Filed Apr. 26, 2017). |
| DERMAFOCUS Exhibit 2026, Bo Eklof et al, “Revision of the CEAP Classification for Chronic Venous Disorders: Consensus Statement,” Journal ofVascular Surgery, vol. 40, No. 6 (2004), 1248-1252.el, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017). |
| Ulthera, Inc., Reply in Support of Petition for Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 33 pages (Filed Aug. 2, 2017). |
| ULTHERA Exhibit 1022, Use of the Argon and Carbon Dioxide Lasers for Treatment of Superficial Venous Varicosities of the Lower Extremity, D. Apfelberg et al., Lasers in Surgery and Medicine, vol. 4.3, pp. 221-231 (1984) (filed Aug. 2, 2017 in re IPR2016-01459). |
| ULTHERA Exhibit 1023, 532-Nanometer Green Laser Beam Treatment of Superficial Varicosities of the Lower Extremities, T. Smith et al., Lasers in Surgery and Medicine, vol. 8.2, pp. 130-134 (1988) (filed Aug. 2, 2017 in re IPR2016-01459). |
| ULTHERA Exhibit 1024, Deposition Transcript of Dr. Mark Palmeri on Jul. 11, 2017 (filed Aug. 2, 2017 in re IPR2016-01459). |
| ULTHERA Exhibit 1025, Ulthera Oral Proceeding Demonstrative Slides (filed Oct. 2, 2017 in re IPR2016-01459). |
| DERMAFOCUS Exhibit 2027, DermaFocus Oral Proceeding Demonstrative Slides (filed Oct. 2, 2017 in re IPR2016-01459). |
| PTAB Record of Oral Hearing held Oct. 4, 2017 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 67 pages (PTAB Document sent to Ulthera on Nov. 1, 2017). |
| Final Written Decision of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 37 pages [030] (Entered Jan. 19, 2018). |
| Adams et al., “High Intensity Focused Ultrasound Ablation of Rabbit Kidney Tumors” Sonablate High-Intensity Focused Ultrasound device; Journal of Endourology vol. 10, No. 1, (Feb. 1996). |
| Brown J A et al: “Fabrication and performance of 40-60 MHz annular arrays”, 2003 IEEE Ultrasonics Symposium Proceedings. Honolulu, Hawaii, Oct. 5-8, 2003; [IEEE Ultrasonics Symposium Proceedings], New York, NY : IEEE, US, vol. 1, Oct. 5, 2003 (Oct. 5, 2003), pp. 869-872. |
| Carruthers et al., “Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers,and Energy-Based Devices” Dermatol Surg 2016 (pp. 1-12). |
| Driller et al., “Therapeutic Applications of Ultrasound: A Review” IEEE Engineering in Medicine and Biology; (Dec. 1987) pp. 33-40. |
| Ketterling J. A. et al.: “Design and fabrication of a 40-MHz annular array transducer”, IEEE Transactions On Ultrasonics, Ferroelectrics And Frequency Control, IEEE, US, vol. 52, No. 4, Apr. 1, 2005 (Apr. 1, 2005), pp. 672-681. |
| MICROCHIP microID 125 kHz EFID System Design Guide, Microchip Technology Inc. (2004). |
| Sonocare, Inc. Therapeutic Ultrasound System Model CST-100 Instruction Manual (1985). |
| Webster et al. “The role of ultrasound-induced cavitation in the ‘in vitro’ stimulation of collagen synthesis in human fibroblasts”; Ultrasonics pp. 33-37(Jan. 1980). |
| Ulthera, Inc., Petitioner Notice of Appeal to Federal Circuit 2018-1542 re: IPR2016-01459; 4 pages from [001] (no appendices) (Filed Feb. 9, 2018). |
| Federal Circuit Order Granting Ulthera Motion to Remand, re: 2018-1542; 4 pages [022] (Dated May 25, 2018). |
| Ulthera Brief (Corrected), Fed. Cir. Appeal Case 19-1006 from re: IPR2016-01459; 136 pages [030] (Dated Apr. 3, 2019). |
| DermaFocus Brief (Corrected), Fed. Cir. Appeal Case 19-1006 from re: IPR2016-01459; 73 pages [032] (Dated Apr. 4, 2019). |
| Number | Date | Country | |
|---|---|---|---|
| 20190142380 A1 | May 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62375607 | Aug 2016 | US | |
| 62482440 | Apr 2017 | US | |
| 62482476 | Apr 2017 | US | |
| 62520055 | Jun 2017 | US |
